0001477932-23-001798.txt : 20230328 0001477932-23-001798.hdr.sgml : 20230328 20230328135819 ACCESSION NUMBER: 0001477932-23-001798 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20230328 DATE AS OF CHANGE: 20230328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Genvor Inc CENTRAL INDEX KEY: 0001792941 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE PRODUCTION - CROPS [0100] IRS NUMBER: 832054746 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-234815 FILM NUMBER: 23768463 BUSINESS ADDRESS: STREET 1: 13155 NOEL ROAD, SUITE 900 CITY: DALLAS STATE: TX ZIP: 75240 BUSINESS PHONE: 214-427-1921 MAIL ADDRESS: STREET 1: 13155 NOEL ROAD, SUITE 900 CITY: DALLAS STATE: TX ZIP: 75240 FORMER COMPANY: FORMER CONFORMED NAME: Allure Worldwide, Inc. DATE OF NAME CHANGE: 20191031 10-K 1 genvor_10k.htm FORM 10-K genvor_10k.htm

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

Mark One

 

     ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended: September 30, 2022

 

     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to _________

 

Commission File No. 333-234815

 

GENVOR INCORPORATED

(Exact name of registrant as specified in its charter)

 

Nevada

 

83-2054746

(State or Other Jurisdiction of

Incorporation or Organization)

 

(IRS Employer

Identification Number)

 

13155 Noel Road, Suite 900,

Dallas, Texas 75240

(214) 427-1921

 (Address and telephone number of principal executive offices)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Not applicable.

 

 

 

 

 

Securities registered under Section 12(g) of the Act:

Not applicable.

(Title of class)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☒ No ☐

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No

 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

On March 31, 2022, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant had an undetermined value as the registrant’s common stock was not trading on any exchange, nor was it quoted for trading on the OTC Link ATS or any other over-the-counter market or alternative trading system.

 

The number of the registrant’s shares of common stock outstanding was 18,122,821 as of March 24, 2023.

 

 

 

 

TABLE OF CONTENTS

 

Page

PART I.

 

Item 1.

Business

3

Item 1A.

Risk Factors

5

Item 1B.

Unresolved Staff Comments

5

Item 2.

Properties

5

Item 3.

Legal Proceedings

5

Item 4.

Mine Safety Disclosures

5

PART II.

 

Item 5.

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

6

Item 6.

Selected Financial Data

7

Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operation

7

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

11

Item 8.

Financial Statements and Supplementary Data

12

Item 9.

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

13

Item 9A.

Controls and Procedures

13

Item 9B.

Other Information

14

PART III.

 

Item 10.

Directors, Executive Officers and Corporate Governance

15

Item 11.

Executive Compensation

19

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

19

Item 13.

Certain Relationships and Related Transactions, and Director Independence

21

Item 14.

Principal Accounting Fees and Services

21

PART IV.

 

Item 15.

Exhibits, Financial Statement Schedules

22

Signatures

23

Exhibits

 

 
2

Table of Contents

 

FORWARD LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Rule 175 of the Securities Act of 1933, as amended, and Rule 3b-6 of the Securities Act of 1934, as amended, that involve substantial risks and uncertainties. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs and our assumptions. Words such as "anticipate," "expects," "intends," "plans," "believes," "seeks" and "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Form 10-K. Investors should carefully consider all of such risks before making an investment decision with respect to the Company's stock. The following discussion and analysis should be read in conjunction with our financial statements for Genvor Incorporated Such discussion represents only the best present assessment from our Management.

 

PART I

 

Item 1: Description of Business

 

Genvor Incorporated (the “Company” or “Genvor”) was incorporated in Florida on September 26, 2018, as “Allure Worldwide, Inc.,” and as of November 18, 2019, redomiciled to Nevada. On June 24, 2022, the Company changed its name to from “Allure Worldwide, Inc.” to “Genvor Incorporated.”

 

The Company was originally formed with the intention of seeking to acquire the assets or shares of an entity actively engaged in business which generates revenues, in exchange for its securities. On January 11, 2021, the Company entered into an Exchange Agreement (the “Purchase Agreement”) with Genvor Inc., a Delaware corporation (“Genvor”) to acquire (the “Acquisition”) Genvor. On March 2, 2022, the Company and Genvor entered into a merger agreement (the “Merger Agreement”) to consummate the Acquisition, and pursuant to which a wholly-owned subsidiary of the Company, Genvor Acquisition Corp., a Delaware corporation, would merge (the “Merger”) with and into Genvor, with each share of Genvor common stock issued immediately prior to the time of the merger automatically converted into the right to receive one share of common stock of the Company.

 

On May 27, 2022, the Acquisition closed, Merger Subsidiary merged with and into Genvor, each share of Genvor was exchanged for the right to receive one share of Company common stock, 35,261,871 shares of Company common stock were issued to Genvor’s pre-merger shareholders (the “Merger Shares”), constituting a change of control of the Company, and Genvor became a wholly owned subsidiary of the Company. As a result of these transactions, the Company had 55,261,871 issued and outstanding common shares upon the closing of the share exchange with Genvor, and subsequently the Company’s original founding shareholders cancelled 18,144,112 shares of Company common stock in connection with the Acquisition.

 

As a result of the Acquisition, the Company’s business plan is that of Genvor, and the Company is developing plant-based defense technology designed to help farmers achieve global food security.

 

Genvor History

 

The Company’s subsidiary, Genvor Inc. was incorporated under the laws of the State of Delaware on April 4, 2019, as “Nexion Biosciences Inc.,” and on January 22, 2020, its name was changed to “Genvor Inc.” Genvor Inc. develops plant-based defense technology designed to help farmers achieve global food security.

 

During May 2019, Genvor Inc. acquired Nexion Biosciences LLC (“NBLLC”) from a founder for nominal consideration. NBLLC was formed in the State of Delaware on December 28, 2018.

 

 
3

Table of Contents

 

Genvor’s technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike. Genvor’s technology is currently being advanced by the USDA in corn seed varieties and with U.S. Sugar in citrus trees.

 

Genvor’s headquarters is located at 13155 Noel Road, Suite 900, Dallas, Texas, 75240.

 

Genvor’s Plan of Operation

 

The United States Food and Agriculture Organization reports that annual global crop losses due to plant pathogens and viruses are now estimated to exceed $100 billion. Alarming to the FDA are the fungi “Aspergillus Flavus,” which produce Aflatoxins, a toxic and carcinogenic compound known to cause liver cancer in humans and animals. Aspergillus Flavus is also the second leading cause of “aspergillosis” in humans. Patients infected with Aspergillus flavus often have reduced or compromised immune systems.

 

The U.S. Food and Drug Administration estimates the annual cost of Aflatoxin contamination in the United States at approximately $500 million through two categories of loss: market rejection and animal health impacts. As a result, the United States Department of Agriculture (USDA) has imposed strict guidelines for crop inspection and discovery of diseased crops caused by Aflatoxins. Both planted fields and harvested crops that are found to be contaminated beyond permitted testing levels must be destroyed. As a result, farmers and growers can be exposed to catastrophic economic losses. This Aflatoxin problem has created a significant opportunity for agricultural companies who can develop the technology needed to defend against Aflatoxins.

 

Genvor’s Solution

 

Genvor’s technology is the only known solution that Genvor is aware of, which Genvor believes provides broad spectrum effectiveness against Aspergillus Flavus and Aflatoxins. This technology is deliverable by both bioengineered seed trait, as well as through biopesticide application.

 

Dr. Jaynes, one of Genvor’s founders, has been on a 30+ year quest to find a global crop solution for defense against Aflatoxins. As a result of successful testing and collaboration between Dr. Jaynes and the United States Department of Agriculture, Agriculture Research Service (USDA-ARS), the USDA-ARS awarded Genvor with a Cooperative Research & Development Agreement in August of 2018. The stated goal of this agreement is to develop and commercialize disease resistant and nutritionally enhanced corn seed varieties using Genvor’s seed trait technology.

 

Seed Traits

 

In the United States, the adoption of crop seeds with enhanced traits has been staggering. Currently, over 90 percent of U.S. corn, cotton and soybeans are produced using seeds with enhanced traits. Trait fees for these three crops alone represent over $2 billion annually based on an average trait fee of $13 per acre on approximately 170 million acres. U.S. corn crops alone account for roughly $1.2 billion of the estimated $2 billion.

 

Biopesticides

 

Biopesticides are one of the fastest-growing crop protection market sectors, increasing at twice the compound annual growth rate of the crop protection market as a whole. Primary drivers of this growth include a rising global demand for organic foods, the trend in the reduction of chemical residues, stricter import and supermarket standards, shorter pre-harvest intervals, a push for sustainability, and the demand for additional modes of action for managing resistance. The biopesticide market in north America alone is currently estimated to be over $4.8 billion annually.

 

Genvor’s technology is effective with corn seed and is believed by Genvor to be effective with many known crop types, and the technology may be delivered as a topical spray in the form of a biopesticide.

 

Genvor Incorporated (“Genvor” or the “Company”) was incorporated in the State of Florida on September 26, 2018,

 

 
4

Table of Contents

 

Reports to Security Holders

 

We intend to furnish our shareholders annual reports containing financial statements audited by our independent registered public accounting firm and to make available quarterly reports containing unaudited financial statements for each of the first three quarters of each year. We file Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K with the Securities and Exchange Commission voluntarily in order to disclose material information regarding the Company to the public. We may also file additional documents with the Commission if they become necessary in the course of our company's operations.

 

The public may read and copy any materials that we file with the SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is www.sec.gov.

 

Government Regulations

 

We believe that we are and will continue to be in compliance in all material respects with applicable statutes and the regulations passed in the United States. There are no current orders or directions relating to our company with respect to the foregoing laws and regulations.

 

Environmental Regulations

 

While our products and business activities do not currently violate any laws, any regulatory changes that impose additional restrictions or requirements on us or on our products or potential customers could adversely affect us by increasing our operating costs or decreasing demand for our products or services, which could have a material adverse effect on our results of operations.

 

Employees

 

As of September 30, 2022, we had no full-time employees.

 

Property

 

The Company does not own or rent property. The Company’s corporate headquarters is provided by the Company’s CEO and Director, Bradley White, at no charge.

 

Item 1A. Risk Factors

 

As a smaller reporting company, we are not required to provide the information required by this item.

 

Item 1B. Unresolved Staff Comments.

 

None.

 

Item 2. Properties

 

We do not own any real estate or other properties.

 

Item 3. Legal Proceedings

 

Management is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As of the date of this Annual Report, no director, officer, or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been threatened against us or our properties.

 

Item 4. Mine Safety Disclosures

 

Not applicable to our Company.

 

 
5

Table of Contents

 

PART II

 

Item 5. Market for Common Equity and Related Stockholder Matters

 

Market Information

 

There has been no market for our securities. Our common stock is not traded on any exchange or on the over-the-counter market. We hope to have a market maker file an application with the Financial Industry Regulatory Authority, FINRA for our common stock to be eligible for trading on OTC Markets. We are in the process of having OTC Markets Group, Inc. do so, but there is no assurance that any such application will ever be approved or that a trading market will develop, or, if developed, that it will be sustained.

 

The Company's transfer agent is Securities Transfer Corporation, Securities Transfer Corporation 2901 N. Dallas Parkway, Suite 380, Plano, Texas, 75093, Telephone: (469) 633-0088.

 

Dividend Distributions

 

We have not paid any cash dividends on our common stock and have no present intention of paying any dividends on the shares of our common stock. Our current policy is to retain earnings, if any, for use in our operations and in the development of our business. Our future dividend policy will be determined from time to time by our board of directors.

 

Securities authorized for issuance under equity compensation plans

 

The Company does not have a stock option plan.

 

Penny Stock

 

Our common stock is considered "penny stock" under the rules the Securities and Exchange Commission (the "SEC") under the Securities Exchange Act of 1934. The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ Stock Market System, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or quotation system. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the Commission, that:

 

 

·

contains a description of the nature and level of risks in the market for penny stocks in both public offerings and secondary trading;

 

·

contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of Securities' laws; contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price;

 

·

contains a toll-free telephone number for inquiries on disciplinary actions;

 

·

defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and

 

·

contains such other information and is in such form, including language, type, size and format, as the Commission shall require by rule or regulation.

 

 
6

Table of Contents

 

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with:

 

 

·

bid and offer quotations for the penny stock;

 

·

the compensation of the broker-dealer and its salesperson in the transaction;

 

·

the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the marker for such stock; and

 

·

monthly account statements showing the market value of each penny stock held in the customer's account.

 

In addition, the penny stock rules that require that prior to a transaction in a penny stock not otherwise exempt from those rules; the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgement of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitably statement.

 

These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock.

 

Related Stockholder Matters

 

None.

 

Purchase of Equity Securities

 

None.

 

Item 6. Selected Financial Data

 

As the Company is a "smaller reporting company," this item is inapplicable.

 

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Rule 175 of the Securities Act of 1933, as amended, and Rule 3b-6 of the Securities Act of 1934, as amended, that involve substantial risks and uncertainties. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs, and our assumptions. Words such as “anticipate,” “expects,” “intends,” “plans,” “believes,” “seeks” and “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Form 10-K. Investors should carefully consider all of such risks before making an investment decision with respect to the Company’s stock. The following discussion and analysis should be read in conjunction with our financial statements and summary of selected financial data for the Company. Such discussion represents only the best present assessment from our Management.

 

DESCRIPTION OF COMPANY

 

Genvor Incorporated (the “Company”) was incorporated in Florida on September 26, 2018, as Allure Worldwide, Inc., and as of November 18, 2019, redomiciled to Nevada. On June 24, 2022, the Company changed its name to from Allure Worldwide, Inc. to Genvor Incorporated.

 

 
7

Table of Contents

 

The Company was originally formed with the intention of seeking to acquire the assets or shares of an entity actively engaged in business which generates revenues, in exchange for its securities. On January 11, 2021, the Company entered into an Exchange Agreement (the “Purchase Agreement”) with Genvor Inc., a Delaware corporation (“Genvor”) to acquire (the “Acquisition”) Genvor. On March 2, 2022, the Company and Genvor entered into a merger agreement (the “Merger Agreement”) to consummate the Acquisition, and pursuant to which a wholly-owned subsidiary of the Company, Genvor Acquisition Corp., a Delaware corporation, would merge (the “Merger”) with and into Genvor, with each share of Genvor common stock issued immediately prior to the time of the merger automatically converted into the right to receive one share of common stock of the Company.

  

On May 27, 2022, the Acquisition closed, Merger Subsidiary merged with and into Genvor, each share of Genvor was exchanged for the right to receive one share of Company common stock, 35,261,871 shares of Company common stock were issued to Genvor’s pre-merger shareholders (the “Merger Shares”), constituting a change of control of the Company, and Genvor became a wholly owned subsidiary of the Company. As a result of these transactions, the Company had 55,261,871 issued and outstanding common shares upon the closing of the share exchange with Genvor, and subsequently the Company’s original founding shareholders cancelled 18,144,112 shares of Company common stock in connection with the Acquisition.

 

As a result of the Acquisition, the Company’s business plan is that of Genvor, and the Company is developing plant-based defense technology designed to help farmers achieve global food security.

 

The Company’s technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike. The Company’s technology is currently being advanced by the USDA in corn seed varieties and with U.S. Sugar in citrus trees.

 

The following Management Discussion and Analysis should be read in conjunction with the financial statements and accompanying notes included in this Form 10-K.

 

COMPARISON OF THE NINE MONTHS ENDED SEPTEMBER 30, 2022, TO THE YEAR ENDED DECEMBER 31, 2021

 

Results of Operations

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial statements and notes thereto for the nine months ended September 30, 2022 and the year ended December 31, 2021, and related management discussion herein.

 

Our financial statements are stated in U.S. Dollars and are prepared in accordance with generally accepted accounting principles of the United States (“GAAP”).

 

Going Concern Qualification

 

Several conditions and events cast substantial doubt about the Company’s ability to continue as a going concern. At September 30, 2022, the Company had an accumulated deficit of $16,288,417, incurred a net loss of $4,486,589 for the nine months ended September 30, 2022, requires capital for contemplated operational activities to take place. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans with respect to operations include raising additional capital through sales of equity or debt securities as may be necessary to pursue such business plans and sustain operations until such time as the Company can merge with or be acquired by another entity. However, there can be no assurance that management will be successful in obtaining additional funding or in attaining profitable operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern.

 

 
8

Table of Contents

 

Our operating results for the nine months ended September 30, 2022, and year ended December 31, 2021, and the changes between those periods for the respective items, are summarized as follows:

 

 

 

Nine Months Ended

September 30,

2022

 

 

Year Ended December 31,

2021

 

Operating loss

 

$(4,310,361)

 

$(3,101,904)

Total other income (expense)

 

 

(176,228)

 

 

(337,620)

Net loss

 

$(4,486,589)

 

$(3,439,524)

 

Revenues

 

We did not earn any revenues during the nine months ended September 30, 2022, or the year ended December 31, 2021.

 

Operating Loss

 

Our loss from operations increased to $4,310,361 during the nine months ended September 30, 2022, from an operating loss of $3,101,904 in the year ended December 31, 2021. The following table presents operating expenses for the nine months ended September 30, 2022, and the year ended December 31, 2021:

 

 

 

Nine Months Ended

September 30,

2022

 

 

Year Ended December 31,

2021

 

Professional fees

 

$233,153

 

 

$89,640

 

Payroll related expenses

 

 

120,725

 

 

 

390,000

 

Research and development

 

 

246,480

 

 

 

226,448

 

Stock-based compensation

 

 

3,512,500

 

 

 

2,222,961

 

Depreciation expense

 

 

1,374

 

 

 

1,832

 

General and administrative expenses

 

$196,129

 

 

$171,023

 

Total Operating Expenses

 

$4,310,361

 

 

$3,101,904

 

 

We realized an increase in professional fees during the nine months ended September 30, 2022 as compared to the year ended December 31, 2021 primarily as a result of increased accounting, audit, and legal expenses incurred during 2022. Stock-based compensation expenses increased during the nine months ended September 30, 2022 as compared to the year ended December 31, 2021 primarily as a result of the issuance of shares of common stock.

 

Net Loss

 

The Company incurred a net loss of $4,486,589 during the nine months ended September 30, 2022, as compared to a net loss of $3,439,524 during the year ended December 31, 2021, as a result of the increased operating expenses during 2022 described above.

 

Liquidity and Capital Resources

 

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

 

 
9

Table of Contents

 

Working Capital

 

The following table presents our working capital position as of September 30, 2022, and December 31, 2021:

 

 

 

September 30,

2022

 

 

December 31,

2021

 

Cash

 

$296,385

 

 

$384,621

 

Current Assets

 

 

298,385

 

 

 

535,952

 

Current Liabilities

 

 

1,867,654

 

 

 

2,449,808

 

Working Capital (Deficiency)

 

$(1,569,269)

 

$(1,913,856)

 

The decrease in working capital deficiency as of September 30, 2022, as compared to December 31, 2021, was primarily due to notes payable decreasing from $1,632,250 as of December 31, 2021, to $1,100,750 as of September 30, 2022, partially offset by the decrease current assets as of September 30, 2022, as compared to December 31, 2021.

 

Cash Flow

 

We fund our operations with cash received from issuances of promissory notes and equity as described below.

 

Cash Flows from Operating Activities

 

We did not generate cash flows from operating activities for the nine months ended September 30, 2022, or the year ended December 31, 2021. For the nine months ended September 30, 2022, and the year ended December 31, 2021, net cash used in operating activities were $553,236 and $663,203, respectively.

 

Cash Flows from Investing Activities

 

For the nine months ended September 30, 2022, and the year ended December 31, 2021, no cash flows were provided by or used in investing activities.

 

Cash Flows from Financing Activities

 

For the nine months ended September 30, 2022, and the year ended December 31, 2021, $465,000 and $889,851, respectively, in net cash was provided by financing activities. For the nine months ended September 30, 2022, and year ended December 31, 2021, $300,000 and $365,000, respectively, in cash was provided by notes payable, and $165,000 and $570,005, respectively, in net cash was provided by sales of common stock.

 

 
10

Table of Contents

 

Off-Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

Critical Accounting Policies

 

Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include the amortization period for intangible assets, valuation and impairment valuation of intangible assets, depreciable lives of the web site and property and equipment, valuation of warrant and beneficial conversion feature debt discounts, valuation of share-based payments and the valuation allowance on deferred tax assets.

 

Investments in Equity

 

We measure all equity investments that do not result in consolidation and are not accounted for under the equity method at fair value with the change in fair value included in net income. We use quoted market prices to determine the fair value of equity securities with readily determinable fair values. For equity securities without readily determinable fair values, we have elected the measurement alternative under which we measure these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Management assesses each of these investments on an individual basis.

 

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

 

As the Company is a "smaller reporting company," this item is inapplicable.

 

 
11

Table of Contents

 

Item 8. Financial Statements and Supplementary Data

 

Genvor Incorporated

 

Table of Contents

 

 

 

Page

 

 

 

 

 

Report of Independent Registered Public Accounting Firm (PCAOB ID: 76)

 

 

F-1

 

 

 

 

 

 

Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021

 

 

F-3

 

 

 

 

 

 

Consolidated Statements of Operations for the nine months ended September 30, 2022 and for the year ended December 31, 2021

 

 

F-4

 

 

 

 

 

 

Consolidated Statements of Changes in Shareholders' Deficit for the nine months ended September 30, 2022 and for the year ended December 31, 2021

 

 

F-5

 

 

 

 

 

 

Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and for the year ended December 31, 2021

 

 

F-6

 

 

 

 

 

 

Notes to the Consolidated Financial Statements

 

 

F-7

 

 

 
12

Table of Contents

 

 

Your Vision Our Focus

 

genvor_10kimg1.jpg

 

Report of Independent Registered Public Accounting Firm

 

Board of Directors and Stockholders

Genvor Incorporated

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Genvor Incorporated as of September 30, 2022 and December 31, 2021, and the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for the nine months ended September 30, 2022 and year ended December 31, 2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of Genvor Incorporated as of September 30, 2022 and December 31, 2021, and the results of its operations and its cash flows for the nine months ended September 30, 2022 and year ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note 1 to the financial statements, the entity has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the entity’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to Genvor Incorporated in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Genvor Incorporated is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ Turner, Stone & Company, L.L.P.

 

 

 

 

 

We have served as Genvor Incorporated’s auditor since 2020.

 

 

 

 

 

Dallas, Texas

March 28, 2023

 

 

 

Turner, Stone & Company, L.L.P.

Accountants and Consultants

12700 Park Central Drive, Suite 1400

Dallas, Texas 75251

Telephone: 972-239-1660 ⁄ Facsimile: 972-239-1665

Toll Free: 877-853-4195

Website turnerstone.com

 

 

 

genvor_10kimg3.jpg

 

 
F-1

Table of Contents

 

Genvor Incorporated

(f/k/a Allure Worldwide, Inc.)

Consolidated Balance Sheets

 

 

 

 September 30,

 

 

 December 31,

 

 

 

 2022

 

 

 2021

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash

 

$296,385

 

 

$384,621

 

Prepaid expenses

 

 

-

 

 

 

1,331

 

Prepaid costs for reverse capitalization

 

 

-

 

 

 

150,000

 

Other current assets

 

 

2,000

 

 

 

-

 

Total current assets

 

 

298,385

 

 

 

535,952

 

 

 

 

 

 

 

 

 

 

Fixed assets, net

 

 

17,565

 

 

 

18,939

 

Receivables from related parties

 

 

-

 

 

 

2,053

 

 

 

 

 

 

 

 

 

 

Total assets

 

$315,951

 

 

$556,944

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Notes payable

 

$1,052,000

 

 

$1,632,250

 

Accounts payable and accrued expenses

 

 

516,658

 

 

 

571,158

 

Due to related party

 

 

3,846

 

 

 

-

 

     SBA loan

 

 

 48,750

 

 

 

 -

 

USDA CRADA liability

 

 

246,400

 

 

 

246,400

 

Total current liabilities

 

 

1,867,654

 

 

 

2,449,808

 

Non-current liabilities:

 

 

 

 

 

 

 

 

Convertible notes payable, net of discounts

 

 

89,221

 

 

 

-

 

Notes payable, net of discounts

 

 

-

 

 

 

344,167

 

Total non-current liabilities

 

 

89,221

 

 

 

344,167

 

Total liabilities

 

 

1,956,875

 

 

 

2,793,975

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies (Note 6)

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Stockholders' deficit:

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, 20,000,000 shares authorized, 9 and 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively

 

 

-

 

 

 

-

 

Common stock, $0.001 par value, 300,000,000 shares authorized, 38,678,155 and 26,025,020 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively

 

 

38,678

 

 

 

26,025

 

Additional paid-in capital

 

 

14,608,815

 

 

 

9,538,772

 

Accumulated deficit

 

 

(16,288,417)

 

 

(11,801,828)

Total stockholders' deficit

 

 

(1,640,924)

 

 

(2,237,031)

 

 

 

 

 

 

 

 

 

Total liabilities and stockholders' deficit

 

$315,951

 

 

$556,944

 

 

The accompanying notes are an integral part of these consolidated financial statements. 

 

 
F-2

Table of Contents

 

Genvor Incorporated

(f/k/a Allure Worldwide, Inc.)

Consolidated Statements of Operations

 

 

 

For the

 

 

For the

 

 

 

Nine Months

 

 

Year

 

 

 

 Ended

 

 

 Ended

 

 

 

 September 30,

 

 

 December 31,

 

 

 

 2022

 

 

 2021

 

 

 

 

 

 

 

 

Revenue

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

Professional fees

 

 

233,153

 

 

 

89,640

 

Payroll related expenses

 

 

120,725

 

 

 

390,000

 

Research and development

 

 

246,480

 

 

 

226,448

 

Stock-based compensation

 

 

3,512,500

 

 

 

2,222,961

 

Depreciation expense

 

 

1,374

 

 

 

1,832

 

Other general and administrative expenses

 

 

196,129

 

 

 

171,023

 

Total operating expenses

 

 

4,310,361

 

 

 

3,101,904

 

 

 

 

 

 

 

 

 

 

Operating loss

 

 

(4,310,361)

 

 

(3,101,904)

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

Interest expense

 

 

(51,117)

 

 

(102,792)

Penalties

 

 

(90,000)

 

 

(120,000)

Beneficial conversion feature

 

 

(30,111)

 

 

-

 

Loss on Agromed acuisition failure

 

 

-

 

 

 

(114,828)

Loss on settlement of liabilities

 

 

(5,000)

 

 

-

 

Total other income (expense)

 

 

(176,228)

 

 

(337,620)

 

 

 

 

 

 

 

 

 

Net loss

 

$(4,486,589)

 

$(3,439,524)

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per common share

 

$(0.14)

 

$(0.15)

Basic and diluted weighted average common shares outstanding

 

 

32,437,505

 

 

 

22,493,382

 

 

The accompanying notes are an integral part of these consolidated financial statements. 

  

 
F-3

Table of Contents

 

Genvor Incorporated

(f/k/a Allure Worldwide, Inc.)

Consolidated Statements of Changes in Stockholders' Deficit

For the Nine Months Ended September 30, 2022 and the Year Ended December 31, 2021

 

 

 

 Series A

 

 

 

 

 

 

 Additional

 

 

 Accumu-

 

 

 

 

 

 Preferred Stock

 

 

 Common Stock

 

 

 Paid-in

 

 

 lated

 

 

 

 

 

 Shares

 

 

 Amount

 

 

 Shares

 

 

 Amount

 

 

 Capital

 

 

 Deficit

 

 

 Total

 

Allure balance, December 31, 2020

 

 

 -

 

 

 -

 

 

 

20,000,000

 

 

$

2,000

 

 

$

6,773,677

 

 

(8,333,278

)

 

$

(1,557,601

)

Recapitalization / RTO impact

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

18,000

 

 

 

(21,846

)

 

 

(29,026

)

 

 

(32,872

)

Balance, December 31, 2020

 

 

-

 

 

$-

 

 

 

20,000,000

 

 

$20,000

 

 

$6,751,831

 

 

$(8,362,304)

 

$(1,590,473)

Common stock issued for services

 

 

-

 

 

 

-

 

 

 

3,150,000

 

 

 

3,150

 

 

 

1,519,863

 

 

 

-

 

 

 

1,523,012

 

Exercise of options

 

 

-

 

 

 

-

 

 

 

1,400,000

 

 

 

1,400

 

 

 

(1,400 )

 

 

 

 

 

 

-

 

Common stock issued for cash

 

 

-

 

 

 

-

 

 

 

1,475,020

 

 

 

1,475

 

 

 

568,530

 

 

 

 

 

 

 

570,005

 

Common stock options issued for services

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

699,948

 

 

 

-

 

 

 

699,948

 

Net loss for the period ended December 31, 2021

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(3,439,524)

 

 

(3,439,524)

Balance, December 31, 2021

 

 

-

 

 

$-

 

 

 

26,025,020

 

 

$26,025

 

 

$9,538,772

 

 

$(11,801,828 )

 

 

(2,237,031 )

Common stock issued for services

 

 

-

 

 

 

-

 

 

 

6,525,000

 

 

 

6,525

 

 

 

3,505,975

 

 

 

-

 

 

 

3,512,500

 

Common stock issued for cash

 

 

-

 

 

 

-

 

 

 

305,000

 

 

 

305

 

 

 

164,970

 

 

 

-

 

 

 

165,275

 

Common stock issued for debt conversion

 

 

-

 

 

 

-

 

 

 

2,622,647

 

 

 

2,622

 

 

 

1,232,933

 

 

 

-

 

 

 

1,235,555

 

Founder shares issued

 

 

-

 

 

 

-

 

 

 

1,855,888

 

 

 

1,856

 

 

 

(1,856 )

 

 

-

 

 

 

-

 

Payment for reverse capitalization

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(150,000 )

 

 

-

 

 

 

(150,000 )

Issuance of common stock to prior S-1 investors

 

 

-

 

 

 

-

 

 

 

975,000

 

 

 

975

 

 

 

48,750

 

 

 

-

 

 

 

49,725

 

Issuance of common stock for note receivable

 

 

-

 

 

 

-

 

 

 

99,600

 

 

 

100

 

 

 

(100)

 

 

-

 

 

 

-

 

Issuance of common stock for 2021 SPA

 

 

-

 

 

 

-

 

 

 

50,000

 

 

 

50

 

 

 

(50 )

 

 

-

 

 

 

-

 

Issuance of common stock for settlements

 

 

-

 

 

 

-

 

 

 

50,000

 

 

 

50

 

 

 

(50 )

 

 

-

 

 

 

-

 

Beneficial conversion feature

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

269,916

 

 

 

-

 

 

 

269,916

 

419 fund raising services

 

 

-

 

 

 

-

 

 

 

170,000

 

 

 

170

 

 

 

(170 )

 

 

-

 

 

 

-

 

Issuance of preferred stock

 

 

9

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss for the period ended September 30, 2022

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(4,486,589 )

 

 

(4,486,589 )

Balance, September 30, 2022

 

 

9

 

 

$-

 

 

 

38,678,155

 

 

$38,678

 

 

$14,608,815

 

 

$(16,288,417 )

 

$(1,640,924 )

                                                          

The accompanying notes are an integral part of these consolidated financial statements. 

    

 
F-4

Table of Contents

 

Genvor Incorporated

(f/k/a Allure Worldwide, Inc.)

Consolidated Statements of Cash Flow

 

 

 

For the

 

 

For the

 

 

 

Nine

Months

 

 

Year

 

 

 

Ended

 

 

Ended

 

 

 

 September 30,

 

 

 December 31,

 

 

 

 2022

 

 

 2021

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$(4,486,589 )

 

$(3,439,524 )

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation expense

 

 

1,374

 

 

 

1,832

 

Interest expense capitalized into notes payable

 

 

-

 

 

 

10,000

 

Late fee capitalized into notes payable

 

 

90,000

 

 

 

120,000

 

Loss on Agromed acquisition failure

 

 

-

 

 

 

114,828

 

Stock-based compensation

 

 

3,512,500

 

 

 

2,222,961

 

Beneficial conversion feature amortization

 

 

30,111

 

 

 

-

 

Amortization of debt discount

 

 

-

 

 

 

11,667

 

Loss on settlement of liabilities

 

 

5,000

 

 

 

-

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses

 

 

1,331

 

 

 

(1,331 )

Prepaid costs for reverse capitalization

 

 

150,000

 

 

 

(100,000 )

Other current assets

 

 

(2,000 )

 

 

-

 

Receivables from related parties

 

 

2,053

 

 

 

-

 

Accounts payable and accrued expenses

 

 

139,138

 

 

 

323,564

 

Due to related party

 

 

3,846

 

 

 

-

 

USDA CRADA liability

 

 

-

 

 

 

72,800

 

Net cash used in operating activities

 

 

(553,236 )

 

 

(663,203 )

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from notes payable

 

 

300,000

 

 

 

365,000

 

Payments of notes payable

 

 

-

 

 

(6,000 )

Payments of receivable from related parties

 

 

-

 

 

 

(25,579 )

Proceeds from sale of common stock

 

 

165,000

 

 

 

570,005

 

Repayments of advances payable from related parties

 

 

-

 

 

 

(3,575 )

Net cash provided by financing activities

 

 

465,000

 

 

 

899,851

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash

 

 

(88,236 )

 

 

236,648

 

 

 

 

 

 

 

 

 

 

Cash at beginning of period

 

 

384,621

 

 

 

147,973

 

 

 

 

 

 

 

 

 

 

Cash at end of period

 

$296,385

 

 

$384,621

 

 

 

 

 

 

 

 

 

 

Cash paid for interest

 

$-

 

 

$-

 

Cash paid for taxes

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

Non-cash investing and financing activities:

 

 

 

 

 

 

 

 

Discount on notes payable

 

$269,916

 

 

$35,000

 

Right of use, lease asset and liability

 

$-

 

 

$13,480

 

Issuance of common stock for debt conversion

 

$1,235,555

 

 

$-

 

Issuance of common stock for debt settlement

 

$49,725

 

 

$-

 

Fundraising services

 

$

170,000

 

 

$

-

 

Prepaid costs for reverse capitalization recognized in additional paid-in capital

 

$150,000

 

 

$-

 

 

The accompanying notes are an integral part of these consolidated financial statements. 

    

 
F-5

Table of Contents

 

Genvor Incorporated

Notes to Consolidated Financial Statements

September 30, 2022

 

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

 

Company Background

 

On May 27, 2022, Genvor Incorporated, formerly known as Allure Worldwide, Inc. (the “Company” or “Genvor” or “we”), a Nevada corporation, Genvor Acquisition, Corp., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Genvor Inc., a Delaware corporation (“Old Genvor”), completed their previously announced merger transaction pursuant to which the Company acquired Old Genvor (the “Acquisition”), and Old Genvor became a wholly-owned subsidiary of the Company. The Acquisition was completed pursuant to an Exchange Agreement, dated as of January 11, 2021 (the “Acquisition Agreement”), pursuant to which Old Genvor was to be acquired by the Company as its wholly owned subsidiary and each share of Old Genvor common stock would be exchanged for a share of the Company’s common stock, and a merger agreement, dated March 2, 2022 (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger, and each share of Old Genvor being converted into the right to receive a share of the Company (the “Merger”). After closing of the Merger, the Company was renamed “Genvor Incorporated”. Genvor develops plant-based defense technology designed to help farmers achieve global food security.

 

During May 2019, Old Genvor acquired Nexion Biosciences LLC (“NBLLC”) from a founder for nominal consideration as a wholly owned subsidiary. NBLLC was formed in the state of Delaware on December 28, 2018. The consolidated financial statements of the Company include the accounts of Genvor Incorporated, Old Genvor, and its wholly owned subsidiary NBLLC. Intercompany accounts and transactions have been eliminated upon consolidation.

 

Nature of Operations

 

The Company’s business plan is developing plant-based defense technology designed to help farmers achieve global food security. The Company’s technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike.

 

Basis of Presentation

 

The Company follows the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and has a year-end of September 30. The wholly owned subsidiary has a year-end of December 31. 

 

Due to the different fiscal year-ends, the consolidated financial statements will reflect the balance sheets and the statements of changes in stockholders’ deficit dates of September 30, 2022, and December 31, 2021, whereas the statements of operations and statements of cash flows are for the nine months ended September 30, 2022, and the year ended December 31, 2021.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in the consolidation. The consolidated financial statements included herein, presented in accordance with United States generally accepted accounting principles (“GAAP”) and stated in United States dollars, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission.

 

 
F-6

Table of Contents

 

Liquidity and Going Concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At September 30, 2022, the Company had an accumulated deficit of $16,288,417. For the nine months ended September 30, 2022, the Company recognized a net loss of $4,486,589 and had net cash used in operating activities of $553,236, with no revenues earned, and limited operational history. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

While the Company is currently developing its products and technologies, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of additional public and/or private offerings of its stock. Management believes that the actions presently being taken to further implement its business plan, develop its products and technologies, and generate revenues should provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds in the future, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate cash flows from financing activities or operating activities. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash Flow Reporting

 

The Company follows Accounting Standards Codification (“ASC 230”), Statement of Cash Flows, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“indirect method”) as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.

 

Cash

 

Cash is comprised of cash balances. Cash is held at major financial institutions and is subject to credit risk to the extent that those balances exceed applicable Federal Deposit Insurance Corporation (“FDIC”) insurance amounts of $250,000. From time to time, the Company has certain cash balances, including restricted cash, that may exceed insured limits. The Company utilizes large banking institutions that are reputable therefore mitigating the risks.

 

The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. At September 30, 2022, $46,385 of the Company’s cash balances were in excess of federally insured limits.

 

Fixed Assets

 

Furniture and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately seven years. Expenditures for minor enhancements and maintenance are expensed as incurred.

 

 
F-7

Table of Contents

 

Stock-Based Compensation

 

The Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, Compensation – Stock Compensation, and Certain Redeemable Financial Instruments. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.

 

Fair Value of Financial Instruments

 

The book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature of these instruments. The fair value hierarchy under GAAP distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).

 

The hierarchy consists of three levels

 

 

Level one — Quoted market prices in active markets for identical assets or liabilities;

 

Level two — Inputs other than level one inputs that are either directly or indirectly observable; and

 

Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

 

Determining which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures each quarter.

 

Long-lived Assets

 

The Company’s long-lived assets and other assets (consisting of furniture, equipment and a patent) are reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company had not experienced impairment losses on its long-lived assets.

 

Research and Development

 

The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional service costs associated with the development of the plant-based defense technology products.  For the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company had $246,480 and $226,448 in research and development expenses, respectively.

 

Patents

 

Any patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative expenses in the statement of operations.

 

Purchased patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements.

 

 
F-8

Table of Contents

 

Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases.

 

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled.

 

The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of September 30, 2022. Interest and penalties in any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the nine months ended September 30, 2022.

 

Stock-Based Compensation

 

The Company measures compensation cost for all employee stock-based awards at their fair values on the date of grant. Stock-based awards issued to non-employees are measured at their fair values on the date of grant and are re-measured at each reporting period through their vesting dates, as applicable. The fair value of stock-based awards is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method.

 

Loss Per Share of Common Stock

 

Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (“EPS”) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. The Company had total potential additional dilutive securities outstanding at September 30, 2022 and December 31, 2021 of $300,000 and $0, respectively.

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options, which simplifies accounting for convertible instruments. The new guidance eliminates two of the three models in ASC 470-20 that require separating embedded conversion features from convertible instruments. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share calculation. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.

 

Recently Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

 

 
F-9

Table of Contents

 

NOTE 3 – BORROWINGS

 

Commercial Loan

 

On April 9, 2020, the Company received a loan from the Small Business Administration pursuant to the Paycheck Protection Program (PPP) in the principal amount of $48,750. The note bears interest at a variable rate of approximately 1% and matured in April 2022; and it is currently in default. Forgiveness for the loan was applied for and is pending. The principal amount of the loan was based on the consulting agreement salary between Nexion Biosciences, Inc., organized in the state of Florida (NBFL) (a related party) and the CEO.

 

Payable for Patent

 

On August 22, 2020, the Company’s subsidiary, Genvor Inc., completed an acquisition of Agromed LLC (“Agromed”) in a transaction accounted for under the asset purchase method of accounting, whereby the assets acquired and the liabilities, if any assumed, are to be valued at fair value, and compared to the fair value of the consideration given to identify if there are any identifiable intangible assets to be recognized as a result of the transaction. Based on ASC 805, the Company first performed a screen test; determining that substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset. Agromed only held one patent and two applications for patents and had no sales, employees, or customers as of the acquisition date. Accordingly, the assets acquired are not considered a business and the recorded cost of the acquisition was based upon the fair value of the assets acquired. As consideration for Agromed, the Company was to pay $150,000 by March 31, 2021, and issue 230,000 shares of the Company’s common stock, which shares were issued and valued at $114,828. Accordingly, the patent was recorded at $264,828 on the date of acquisition. Subsequently, it was discovered that the patent had been transferred to another party prior to August 2020. Such transfer had not been recorded with the United States Patent and Trademark Office and therefore neither the Company nor the seller were aware of the seller at the time of the acquisition. As a result, the Company is no longer honoring the agreement to pay $150,000 but decided to let the seller retain the shares. The $150,000 note payable was written off along with the patent during the year ended December 31, 2021, resulting in a loss on the failed acquisition of $114,828 for the year ended December 31, 2021.

 

Notes Payable

 

From time to time, the Company’s subsidiary, Genvor Inc., enters into unsecured notes payable with individual investors. Only Noteholder E (below) has security in the form of a personal guarantee by the CEO and prior consultant (Note 6). The terms of these notes are listed below. Several of the notes are convertible into shares of the Company’s common stock as detailed in the following schedule.

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible

 

 

 

 

 

 

 

Interest

 

 

 Loan

 

 

into

 

Noteholder

 

Origination

 

Maturity

 

Rate

 

 

 Balance

 

 

Shares (c)

 

Noteholder A (a)

 

2019

 

12/31/2021

 

 

0%

 

$217,000

 

 

 

N/A

 

Noteholder B (a)

 

3/19/2019

 

4/29/2019

 

 

0%

 

 

450,000

 

 

 

N/A

 

Noteholder C (a)

 

3/1/2019

 

2/29/2020

 

 

18%

 

 

32,500

 

 

 

N/A

 

Noteholder D (d)

 

4/29/2019

 

unspecified

 

 

0%

 

 

300,000

 

 

 

30,000

 

Noteholder E (a)

 

8/1/2019

 

8/31/2019

 

 

0%

 

 

37,500

 

 

 

N/A

 

Noteholder F (a)(b)

 

2/27/2020

 

4/30/2020

 

 

0%

 

 

2,500

 

 

 

5,000

 

Noteholder G

 

8/3/2021

 

8/3/2023

 

 

10%

 

 

12,500

 

 

 

25,000

 

Noteholder H (e)

 

6/27/2022

 

6/27/2024

 

 

5%

 

 

300,000

 

 

 

1,000,000

 

 

 

 

 

 

 

 

 

 

 

 

1,352,000

 

 

 

1,060,000

 

(d) Debt discount

 

 

 

 

 

 

 

 

 

 

(210,779)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$1,141,221

 

 

 

 

 

(a) Past due at September 30, 2022

(b) Note is payable in a combination of $2,500 to $6,000 in cash and 5,000 to 15,000 share of common stock

(c) Convertible into common stock of the subsidiary, Genvor Inc.

(d) Debt discount

(e) Noteholder is a shareholder of the Company.

 

The notes do not have default provisions except Noteholder B receives a default penalty of $10,000 each month the note goes unpaid.

 

 
F-10

Table of Contents

 

During the nine months ended September 30, 2022, $989,000 principal and $146,946 interest was converted into 2,316,147 common stock shares of the Company. One note holder had a change in settlement terms, resulting in the recognition of $5,000 loss on debt settlement in the accompanying statement of operations for the nine months ended September 30, 2022.

 

Future maturities of the notes payable are as follows:

 

2023

 

$12,500

 

 

 

 

 

 

2024

 

$300,000

 

 

Interest expense totaled $141,117 and $222,792, respectively, for the nine months ended September 30, 2022, and the year ended December 31, 2021, including default penalties. Late fees totaled $90,000 and $120,000, respectively, for the nine months ended September 30, 2022, and the year ended December 31, 2021.

 

NOTE 4 – STOCKHOLDERS’ DEFICIT

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 20,000,000 shares with a $0.001 par value.

 

On August 10, 2022, the Company designated 10 shares of its preferred stock as Series A Preferred Stock (“Series A”). Each share of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation. When and as any dividend or distribution is declared or paid by the Company on the common stock, the Series A holders are entitled to participate in such dividend or distribution. Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock. Upon any liquidation, dissolution, or winding-up of the Company, the Series A holders are entitled to receive out the assets of the Company, for each share of Series A, an amount equal to par value before any distribution or payment shall be made to the holder of any junior securities (including common stock and all other equity or equity equivalent securities of the Company).  

 

As of September 30, 2022, and December 31, 2021, there were 9 and 0 shares of preferred stock issued and outstanding, respectively.  The preferred stock was issued on August 16, 2022, as follows: Bradley White (Chief Executive Officer), 3 shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 7.

 

On October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B Preferred Stock (“Series B”).  The designation authorized 2,500,000 shares of Series B.  Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company. See Note 10.

 

Common Stock

 

The authorized common stock of the Company consists of 300,000,000 shares with a $0.001 par value. All common stock shares are non-assessable and have one vote per share.

 

On April 21, 2022, the Company issued 569 shares of common stock to an individual under a transfer and exchange agreement for a note receivable held in NBFL (see Note 3). At the transfer date, the latest sale of common stock was at $0.50, accordingly the shares were valued at $285, and the note was written off since NBFL has since dissolved.

 

In connection with the Merger (see Notes 1 and 8), the founding shareholders of the Company cancelled 18,144,112 shares of common stock, retaining 5%, or 1,855,888 shares of common stock, as of June 30, 2022. The cancellation is presented in the accompanying statements of changes in stockholders’ deficit within the line item “Retroactive application of recapitalization.”

 

 
F-11

Table of Contents

 

During July 2022, the Company entered into a transfer and exchange agreement with an individual to issue 99,600 shares of common stock for the note receivable held in NBFL. Since NBFL has minimal assets and was dissolved during the year ended December 31, 2019, the note receivable was immediately written-off. Based on the latest SPA price per share, the stock was valued at $1.00 per share, or $99,600.

 

On September 8, 2022, the Company issued 100,000 shares of common stock to a prior Nexion contractor.  This was in regard to a claim against the predecessor management and the Company opted as a settlement to issue the common stock.

 

Shares Issued for Services

 

During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company issued 751,500 and 2,650,000 shares of common stock, respectively, for business advisory services received, valued at $325,750 and $1,325,323, respectively.

 

On February 18, 2022, the Company issued 20,000 shares of common stock, valued at $10,000 (based on the latest third-party sale of common stock) to an investor for stock compensation. Additionally, 5,000 shares were issued to a debt holder as incentive, valued at $2,500 (based on the latest third-party sale of common stock), recorded in interest expense in the accompanying consolidated statement of operations for the nine months ended September 30, 2022.

 

On March 8, 2022, the Company issued 2,000,000 shares of common stock to each of its three directors, for a total of 6,000,000 shares issued valued at $3,000,000 (based on the latest third-party sale of common stock). The issuances are recorded in stock compensation in the accompanying consolidated statement of operations.

 

During April 2022, the Company issued 5,000 shares of common stock to a consultant valued at $2,500 and recorded in stock compensation in the accompanying consolidated statement of operations.

 

On May 27, 2022, the Company issued 500,000 shares of common stock for consulting services. Based on the latest third-party sale of common stock, this resulted in $500,000 stock-based compensation.

 

On September 13, 2022, the Company issued 170,000 shares of common stock to Scott Gann for services.

 

Stock Issued for Cash

 

From October through December 2021, the Company entered into fourteen stock purchase agreements (“SPA”) for the issuance of a total of 1,475,020 shares of common stock at prices ranging from $0.40-$0.50. The proceeds received under these SPAs totaled $570,005.

 

During January and February 2022, the Company entered into six SPAs for the issuance of a total of 280,000 shares of common stock at $0.50. The proceeds received under these SPAs totaled $140,000.

 

On May 12, 2022, the Company entered into an SPA for the issuance of 25,000 shares of common stock for $25,000, or $1.00 per share.

 

During July 2022, the Company issued 975,000 common stock shares to the prior S-1 investors pursuant to their subscription agreements.

 

During July 2022, the Company issued 50,000 shares of common stock to a shareholder pursuant to a December 2021 SPA.

 

 
F-12

Table of Contents

 

Stock Options and Warrants

 

During 2019, as an inducement for debt, the Company issued a stock option to Noteholder E for 10,000 shares of common stock at the time of the Company’s initial public offering (“IPO”). The cost of the option was $1.00 and provides for a 50% discount to the initial opening stock price. Since the IPO has yet to take place and the Company had minimal assets at the time of issuance, the option was valued at $0.

 

On January 4, 2021, the Company entered into a consulting agreement for product development and marketing services. As part of the agreement, 600,000 option shares were issued at signing. An additional 100,000 option shares are earned monthly through August 2021. Although the IPO is still pending, since the Company sold warrants at $.50 during 2020, these options were valued at $.50. On December 20, 2021, the consultant elected to convert all 1,400,000 option shares into 1,400,000 shares of common stock.

 

The Company estimated the fair value of the 2021 options based on weighted probabilities of assumptions used in the Black Scholes pricing model. At issuance, the fair value of the options was estimated using the following weighted-average inputs: the price of the Company’s common stock of $0.50; a risk-free interest rate of 0.10% and expected volatility of the Company’s common stock of 500%, an exercise price of $.0001, and terms under one year.

 

NOTE 5 – FEDERAL INCOME TAX

 

As of September 30, 2022, and December 31, 2021, the Company has net operating loss carry forwards of $2,572,885 and $2,343,000, respectively, which may be available to reduce future years’ taxable income through 2042. The Company’s net operating loss carry forwards may be subject to annual limitations, which could reduce or defer the utilization of the losses as a result of an ownership change as defined in Section 382 of the Internal Revenue Code.

 

The Company’s tax expense differs from the “expected” tax expense for Federal income tax purposes (computed by applying the United States Federal tax rate of 21% to loss before taxes for fiscal year 2022 and 2021), as follows:

 

 

 

 September 30,

 

 

 December 31,

 

 

 

 2022

 

 

 2021

 

Tax expense (benefit) at the statutory rate

 

$(204,559 )

 

$(255,478 )

State income taxes, net of federal income tax benefit

 

 

(25,326 )

 

 

(31,631 )

Change in valuation allowance

 

 

229,885

 

 

 

287,109

 

Total

 

$-

 

 

$-

 

 

The tax effects of the temporary differences between reportable financial statement income and taxable income are recognized as deferred tax assets and liabilities.

 

The tax years 2022 and 2021 remains open for examination by federal agencies and other jurisdictions in which it operates.

 

The tax effect of significant components of the Company’s deferred tax assets and liabilities at September 30, 2022 and December 31, 2021, are as follows:

 

 

 

 September 30,

 

 

 December 31,

 

 

 

 2022

 

 

 2021

 

Net operating loss carryforward

 

$2,572,885

 

 

$2,343,000

 

Total gross deferred tax assets

 

 

2,572,885

 

 

 

2,343,000

 

Less: Deferred tax asset valuation allowance

 

 

(2,572,885 )

 

 

(2,343,000 )

Total net deferred taxes

 

$-

 

 

$-

 

 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

 

Because of the historical earnings history of the Company, the net deferred tax assets for 2022 and 2021 were fully offset by a 100% valuation allowance. The valuation allowance for the remaining net deferred tax assets was $2,572,885 and $2,343,000 as of December 31, 2022, and 2021, respectively.

 

 
F-13

Table of Contents

  

NOTE 6 – COMMITMENTS AND CONTINGENCIES

 

From time to time, the Company may be involved in litigation in the ordinary course of business. The Company is not currently involved in any litigation that we believe could have a material adverse effect on its financial condition or results of operations.

 

Subscription Agreement and Cash Held in Escrow

 

On February 20, 2019, the Company entered into a subscription escrow agreement (the “Trust Agreement”) with Branch Banking and Trust Company (“BB&T”). This Trust Agreement was established for the subscription agreement proceeds raised and escrowed pursuant to the Company’s prior Rule 419 S-1 offering. The balance held in trust at September 30, 2022 and December 31, 2021, totaled $19,705.

 

Upon completion of the Merger (see Notes 1 and 8), the Company issued 975,000 common stock shares to the investors in that prior S-1 offering during July 2022 and were released to the Company.

 

Consulting Agreements

 

During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company paid the CEO $103,605 and $39,966, respectively, pursuant to a consulting agreement carried over from related party NBFL. The agreement provides for an annual salary of $150,000 which increases based on certain capital raise thresholds. At September 30, 2022 and December 31, 2021, accrued payroll owed to the CEO totaled $188,484 and $186,034, respectively, as presented in the accompanying consolidated balance sheets.

 

On July 24, 2020, the Company entered into a consulting agreement for business development activities, networking, negotiations, and strategic planning. The compensation pursuant to the agreement was $20,000 monthly. During the nine months ended September 30, 2022, and the year ended December 31, 2021, $144,975 and $47,500, respectively, was paid to the consultant. Additionally, during the year ended December 31, 2021, the Company issued 500,000 shares of common stock to the consultant, valued at $250,000. During the nine months ended September 30, 2022, the Company issued 751,500 shares of common stock, valued at $325,750, to settle the amounts owed to the consultant (Note 4).  Accordingly, at September 30, 2022 and December 31, 2021, $0 and $202,500, respectively, accrued payroll remained outstanding which is presented in the accompanying consolidated balance sheets.

 

On January 14, 2021, the Company entered into two consulting agreements for strategic advisory services to be provided through December 31, 2021. The compensation per the two agreements provided for the issuance of 1,700,000 and 450,000 shares of common stock. The stock compensation to these two advisors totaled $1,073,388.

 

Office Lease

 

The Company entered into a sublease agreement with the above consultant (providing business development assistance from 2019-2020) effective August 1, 2019, subject to the terms and conditions of the office lease held by the consultant at 15540 Quorum Drive #2624, Addison, Texas. On January 1, 2019, the Company adopted ASC 842 requiring this lease to be recorded as an asset and corresponding liability on its balance sheet. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms of the underlying lease. A discount rate was not used in the determination of the right of use asset and liability since its effect would not be significant. The lease moved to a month-to-month basis beginning in September 2021 at $2,810 per month in addition to common area maintenance charges. During the nine months ended September 30, 2022, and the year ended December 31, 2021, we incurred $30,240 and $20,094, respectively, in office rental expense.

 

Research and Development Agreement

 

During September 2020, the Company assumed a Cooperative Research And Development Agreement (CRADA) with the United States Department of Agriculture (USDA), Agricultural Research Service (ARS). Under this agreement, the Company committed to funding the remaining amount due. As of September 30, 2022, and December 31, 2021, $246,400 and $243,400, respectively, remained outstanding and is presented in the accompanying consolidated balance sheets as USDA CRADA liability.

 

 
F-14

Table of Contents

  

NOTE 7 – RELATED PARTY TRANSACTIONS

 

Share Issuances to the Board of Directors

 

During December 2020, the Board of Directors allocated 11,137,833 shares of common stock among the three founders. These issuances were valued at $.50 per share based on a third-party sale of common stock (see Note 4), totaling $5,560,567.

 

On March 8, 2022, the Company issued 2,000,000 shares of common stock to each of its three directors, for a total of 6,000,000 shares issued valued at $3,000,000 (based on the latest third-party sale of common stock). The issuances are recorded in stock compensation in the accompanying consolidated statement of operations.

 

The Company issued Series B preferred stock on August 16, 2022, as follows: Bradley White (Chief Executive Officer), 3 shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 4.

 

Services from Related Parties

 

The daughter of the CEO and Board member was paid $21,900 and $16,925, respectively, for clerical services provided during the nine months ended September 30, 2022 and the year ended December 31, 2021.

 

Advance payable from CEO and Director

 

During the year ended December 31, 2019, the Company’s CEO advanced $5,000 to the Company. During the year ended December 31, 2021, the CEO was advanced $991 and was repaid the full amount by December 31, 2021. The advance was non-interest bearing and due upon demand.

 

Receivables from Related Parties

 

During the year ended December 31, 2020, one of the Company’s directors advanced the Company $3,000. Later that year, $5,000 was repaid leaving a total $2,000 receivable from the director at September 30, 2022 and 2021, respectively.

 

During 2018, Robert Bubeck, former CEO, paid $3,846 of expenses on behalf of the Company. The amount due to related party at both September 30, 2022 and 2021 is $3,846 and is due on demand and non-interest bearing.

 

During the nine months ended September 30, 2021, Robert Bubeck, former CEO, paid $13,500 of accrued expenses on behalf of the Company. Since the amount due to the shareholder is not expected to be repaid, it has been accounted for as additional paid-in capital in the accompanying consolidated financial statements.

 

During January 2021, in connection with the acquisition (see Note 8), Robert Bubeck resigned as CEO and Bradley White was appointed to serve as CEO.

 

 
F-15

Table of Contents

 

NOTE 8 – MERGER WITH OLD GENVOR

 

On May 27, 2022, the Company, formerly known as Allure Worldwide, Inc., Merger Sub, and Old Genvor completed the Acquisition and Merger transaction (Note 1). The transaction was completed pursuant to the Merger Agreement, pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation in the Merger. Immediately upon completion of the Merger, the former stockholders of Old Genvor stockholders held a majority of the common stock and voting interest of the combined company.

 

In the Merger, the Company issued shares of its common stock to Old Genvor stockholders at an exchange ratio of 1:1 (with each share of Old Genvor common stock automatically converted in the merger into the right to receive a share of Company common stock, and a total of 35,261,871 shares of Company common stock issued to Old Genvor’s pre-merger stockholders). Pursuant to the original Acquisition agreement and Merger, the Company’s founding shareholders retained 5% of the Company’s outstanding shares of common stock, or 1,855,888 shares (Note 4). After closing the Acquisition and for a period of two years following commencement of trading of the Company’s common stock, the Company and Old Genvor agreed that the Company will make additional issuances of the Company’s common stock to the founding shareholders to ensure that in the aggregate they maintain their 5% ownership of the Company’s outstanding common stock.

 

Pursuant to business combination accounting for reverse acquisitions, the Company accounted for the Merger as a capital transaction (reverse recapitalization) rather than a business combination (or asset acquisition). Since the Company was formerly a special purpose acquisition company (SPAC) with no assets and only expenses related to maintaining its public shell company status, and Old Genvor has cash, other assets, a contract with the USDA (Note 6), and has raised funds from investors, Old Genvor was determined to be the accounting acquirer. Because a reverse recapitalization is equivalent to the issuance of shares by the private operating company for the net monetary assets of the public shell company, the transaction costs incurred by Old Genvor to effect the recapitalization were recognized as a reduction in additional paid-in capital rather than expensed as incurred. The assets and liabilities of Old Genvor were consolidated with the Company at their book value, the equity accounts were retroactively adjusted to reflect the equity of the Company, with a balancing adjustment through the additional paid-in capital account.

 

During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company paid $140,000 and $10,000, respectively, in anticipation of closing the Acquisition. The total $150,000 was recognized in additional paid-in capital as of the date of the Merger.

 

NOTE 9 – INTELLECTUAL PROPERTIES

 

The Company was granted a patent (#11083775) on August 10, 2021 by the United States Patent and Trademark Office. The patent was assigned by the inventors to the Company and The United States of America, as represented by the Secretary of Agriculture.

 

NOTE 10 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from the balance sheet through the date of this filing and determined there were no events to disclose except the following.

 

On October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B.  The designation authorized 2,500,000 shares of Series B.  Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company. See Note 4.

 

On October 19, 2022, the following shareholders converted shares of common stock of the Company into shares of Series B, as follows:

 

Name

 

Common Shares Exchanged

 

 

Series B

Issued

 

Jaynes Investment LLC

 

 

2,000,000

 

 

 

200,000

 

ACT Holdings LLC

 

 

7,312,612

 

 

 

731,262

 

LASB Family Trust

 

 

3,800,112

 

 

 

380,012

 

Jesse Michael Jaynes

 

 

4,767,611

 

 

 

476,762

 

Bradley White

 

 

1,225,000

 

 

 

122,500

 

 PJ Advisory Group 

 

 

1,500,000

 

 

 

150,000

 

 Total   

 

 

20,605,334

 

 

 

2,060,536

 

 

 
F-16

Table of Contents

 

Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

 

We have had no disagreements with our accountants required to be disclosed pursuant to Item 304 of Regulation S-K. 

 

Item 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

The Company's Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the nine months ended September 30, 2022. Based upon such evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company's disclosure controls and procedures were not effective as required under Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

 

Management's Annual Report on Internal Control over Financial Reporting

 

The management of the Company is responsible for the preparation of the financial statements and related financial information appearing in this Annual Report on Form 10-K. The financial statements and notes have been prepared in conformity with accounting principles generally accepted in the United States of America. The management of the Company is also responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. A company's internal control over financial reporting is defined as a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:

 

 

·

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;

 

 

 

 

·

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management and the board of directors of the Company; and

 

 

 

 

·

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.

 

Management, including the Chief Executive Officer and Chief Financial officer, does not expect that the Company's disclosure controls and internal controls will prevent all error and all fraud. Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable, not absolute, assurance that the objectives of the control system are met and may not prevent or detect misstatements. Further, over time, control may become inadequate because of changes in conditions or the degree of compliance with the policies or procedures may deteriorate.

 

With the participation of the Chief Executive Officer and Chief Financial Officer, our management evaluated the effectiveness of the Company's internal control over financial reporting as of September 30, 2021, based upon the framework in Internal Control –Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013. Based on that evaluation, our management has concluded that, as of September 30, 2022, the Company had material weaknesses in its internal control over financial reporting and the Company’s internal control over financial reporting were not effective. Specifically, management identified the following material weaknesses at September 30, 2022:

 

 

1.

Lack of oversight by independent directors in the establishment and monitoring of required internal controls and procedures;

 

 
13

Table of Contents

 

 

2.

Lack of functioning audit committee, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures;

 

3.

Insufficient personnel resources within the accounting function to segregate the duties over financial transaction processing and reporting and to allow for proper monitoring controls over accounting;

 

4.

Insufficient written policies and procedures over accounting transaction processing and period end financial disclosure and reporting processes.

 

To remediate our internal control weaknesses, management intends to implement the following measures:

 

·          

The Company will add sufficient number of independent directors to the board and appoint an audit committee.

 

·          

The Company will add sufficient knowledgeable accounting personnel to properly segregate duties and to effect a timely, accurate preparation of the financial statements.

 

·

Upon the hiring of additional accounting personnel, the Company will develop and maintain adequate written accounting policies and procedures.

 

The additional hiring is contingent upon the Company's efforts to obtain additional funding through equity or debt for its continued operational activities and corporate expenses. Management provides no assurances that it will be able to do so.

 

We understand that remediation of material weaknesses and deficiencies in internal controls are a continuing work in progress due to the issuance of new standards and promulgations. However, remediation of any known deficiency is among our highest priorities. Our management will periodically assess the progress and sufficiency of our ongoing initiatives and make adjustments as and when necessary.

 

As a smaller reporting company, we are not required to provide, and this annual report does not include, an attestation report of our registered public accounting firm regarding internal control over financial reporting.

 

Changes in Internal Control over Financial Reporting

 

Except as set forth above, there were no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Limitations on the Effectiveness of Controls

 

The Company's management, including the CEO and CFO, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Further, the design of the control system must reflect that there are resource constraints and that the benefits must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

 

Item 9B. Other Information.

 

None.

 

 
14

Table of Contents

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance.

 

The following table sets forth information with respect to persons who are serving as directors and officers of the Company. Each director holds office until the next annual meeting of shareholders or until his successor has been elected and qualified.

 

Name

Age

Position

Bradley White

58

Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer, Director (1)

Clayton Yates

 

46

 

Chief Scientific Officer, Director (1)

Jesse Jaynes

 

71

 

Chief Research Officer, Director (1)

__________

(1) Appointed on January 12, 2021.

 

Biographies of Directors and Officers

 

The following is a brief account of the education and business experience during at least the past five years of each director, executive officer and key employee of our company, indicating the person's principal occupation during that period, and the name and principal business of the organization in which such occupation and employment were carried out.

 

Bradley White brings over 28 years of experience in the field of business development with a passion for moving business concepts and technology to commercial application. Mr. White has extensive expertise in seed business start-up and growth, strategic planning, and research management. He is a proven driver of company revenue and in negotiating game changing deals with major institutions globally. Mr. White has traveled to and transacted business on every continent, and he has a deep understanding of the business processes and cultural etiquette within and across key countries. Prior to joining Genvor in 2018, Mr. White was a founding Partner of Alpha Financial Technologies (AFT) where he co-created the world’s first publicly traded suite of commodity indexes. While acting as Global Head of Business Development during his 13-year tenure with AFT, his company reached peak index assets (AUM) of over $13 billion. Mr. White holds his Bachelor of Business Administration from The University of Texas and Master of Arts, Legal Studies from Arizona State University.

 

Dr. Clayton Yates, Ph.D., co-founded Genvor and is Chairman of the Board of Genvor. His research is currently funded by the National Cancer Institute (NCI) and Department of Defense (DOD) Congressionally Medical Directed Research Programs. Dr. Yates is also scientist at Tuskegee University, focused on identifying molecular targets for therapeutic intervention in prostate, breast, and pancreatic cancers. Dr. Yates received his initial training at the University of Pittsburgh School of Medicine in the Department of Cellular and Molecular Pathology. He completed additional training in Tissue Engineering and Regenerative Medicine jointly from the McGowan Institute for Regenerative Medicine and Massachusetts Institute of Technology (MIT). Dr. Yates completed his post-doctoral training at Emory University School of Medicine in the Department of Molecular Urology.

 

Dr. Jesse Jaynes, Ph.D., co-founded Genvor as well, and he leads the research for Genvor and manages ongoing, critical communication with our outside research and development partners and associations. Dr. Jaynes is one of the world's leading authorities on therapeutic peptide design and has vast experience in drug development for various applications, including agriculture, animal health, wound healing, and oncology. Dr. Jaynes’ research is funded by USDA, NSF, and NIH. He has more than 60 United States and foreign patents and has authored over 100 scientific journal articles. Over the past 15 years, Dr. Jaynes has served on the board of numerous life science companies and is currently the Chief Technology Officer for the National Cancer Coalition. Dr. Jaynes is a Professor of Biochemistry at Tuskegee University. Dr. Jaynes completed his doctoral training at Brigham Young University, Utah.

 

 
15

Table of Contents

 

There are no family relationships among any of our directors and executive officers.

 

Our directors are elected at the annual meeting of the shareholders, with vacancies filled by the Board of Directors, and serve until their successors are elected and qualified, or their earlier resignation or removal. Officers are appointed by the board of directors and serve at the discretion of the board of directors or until their earlier resignation or removal. Any action required can be taken at any annual or special meeting of stockholders of the corporation which may be taken without a meeting, without prior notice and without a vote, if consent of consents in writing setting forth the action so taken, shall be signed by the holders of the outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the corporation by delivery to its registered office, its principle place of business, or an officer or agent of the corporation having custody of the book in which the proceedings of meetings are recorded.

 

As we have recently devoted efforts to exploring the intersection of technology and wholistic technology-based health treatments for a variety of mental health conditions, from autism to dementia and Alzheimer’s, we have also retained Board of Advisors composed of advisors we believe are competent to advise us regarding technology, sports health issues and treatments, and PTSD. 

 

Indemnification of Directors and Officers

 

Section 78.138 of the Nevada Revised Statutes ("NRS") provides that a director or officer will not be individually liable unless it is proven that (i) the director's or officer's acts or omissions constituted a breach of his or her fiduciary duties, and (ii) such breach involved intentional misconduct, fraud or a knowing violation of the law. Section 78.7502 of NRS permits a company to indemnify its directors and officers against expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with a threatened, pending or completed action, suit or proceeding if the officer or director (i) is not liable pursuant to NRS 78.138 or (ii) acted in good faith and in a manner the officer or director reasonably believed to be in or not opposed to the best interests of the corporation and, if a criminal action or proceeding, had no reasonable cause to believe the conduct of the officer or director was unlawful. Section 78.751 of NRS permits a Nevada company to indemnify its officers and directors against expenses incurred by them in defending a civil or criminal action, suit or proceeding as they are incurred and in advance of final disposition thereof, upon receipt of an undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court of competent jurisdiction that such officer or director is not entitled to be indemnified by the company. Section 78.751 of NRS further permits the company to grant its directors and officers additional rights of indemnification under its articles of incorporation or bylaws or otherwise. Section 78.752 of NRS provides that a Nevada company may purchase and maintain insurance or make other financial arrangements on behalf of any person who is or was a director, officer, employee or agent of the company, or is or was serving at the request of the company as a director, officer, employee or agent of another company, partnership, joint venture, trust or other enterprise, for any liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee or agent, or arising out of his status as such, whether or not the company has the authority to indemnify him against such liability and expenses.

 

Our Articles of Incorporation provide that no director or officer of the Company will be personally liable to the Company or any of its stockholders for damages for breach of fiduciary duty as a director or officer; provided, however, that the foregoing provision shall not eliminate or limit the liability of a director or officer (i) for acts or omissions which involve intentional misconduct, fraud or knowing violation of law, or (ii) the payment of dividends in violation of Section 78.300 of NRS. In addition, our Bylaws implement the indemnification and insurance provisions permitted by Chapter 78 of the NRS by providing that the Company shall indemnify its directors to the fullest extent permitted by the NRS and may, if and to the extent authorized by the board of directors, so indemnify its officers and any other person whom it has the power to indemnify against liability, reasonable expense or other matter whatsoever; and the Company may at the discretion of the board of directors purchase and maintain insurance on behalf of any person who holds or who has held any position identified in the paragraph above against any and all liability incurred by such person in any such position or arising out of his status as such.

 

 
16

Table of Contents

 

Insofar as indemnification by us for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling the company pursuant to provisions of our articles of incorporation and bylaws, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification by such director, officer or controlling person of us in the successful defense of any action, suit or proceeding is asserted by such director, officer or controlling person in connection with the securities being offered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

Director Compensation

 

During the nine months ended September 30, 2022 and the year ended December 31, 2021, we did not have an independent director. Directors that were employees were not paid any fees for their role as director.

 

Involvement on Certain Material Legal Proceedings During the Last Five Years

 

No director, officer, significant employee or consultant has been convicted in a criminal proceeding, exclusive of traffic violations.

 

No bankruptcy petitions have been filed by or against any business or property of any director, officer, significant employee or consultant of the Company nor has any bankruptcy petition been filed against a partnership or business association where these persons were general partners or executive officers.

 

No director, officer, significant employee or consultant has been permanently or temporarily enjoined, barred, suspended or otherwise limited from involvement in any type of business, securities or banking activities.

 

No director, officer or significant employee has been convicted of violating a federal or state securities or commodities law.

 

Directors' and Officers' Liability Insurance

 

The Company does not have directors' and officers' liability insurance insuring our directors and officers against liability for acts or omissions in their capacities as directors or officers.

 

Code of Ethics

 

We intend to adopt a code of ethics that applies to our officers, directors and employees, including our principal executive officer and principal accounting officer, but have not done so to date due to our relatively small size. We intend to adopt a written code of ethics in the near future.

 

Corporate Governance and Board Independence

 

Our Board of Directors consists of three directors and has not established a Nominating or Governance Committees as standing committees. The Board does not have an executive committee or any committees performing a similar function. We are not currently listed on a national securities exchange or in an inter-dealer quotation system that has requirements that a majority of the board of directors be independent.

 

Due to our lack of operations and size, and since we are not currently listed on a national securities exchange, we are not subject to any listing requirements mandating the establishment of any particular committees; all functions of a nominating/governance committee were performed by our whole board of directors. Our board of directors intends to appoint such persons and form such committees as are required to meet the corporate governance requirements imposed by the national securities exchanges as necessary. Our board of directors does not believe that it is necessary to have such committees at the early stage of the company's development, and our board of directors believes that the functions of such committees can be adequately performed by the members of our board of directors.

 

 
17

Table of Contents

 

We believe that our board of directors is capable of analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting. We believe that retaining an independent director who would qualify as an "audit committee financial expert" would be overly costly and burdensome and is not warranted in our circumstances given the early stages of our development and the fact that we have not generated any material revenues to date.

 

Board Leadership Structure and the Board's Role in Risk Oversight.

 

The Board of Directors is led by a Chairman and at this time, our Chairman is also our Chief Executive Officer. Although our sole officer is our sole director, the Board believes that the most effective leadership structure at this time is not to separate the roles of Chairman and Chief Executive Officer. A combined structure provides the Company with a single leader who represents the company to our stockholders, regulators, business partners and other stakeholders, among other reasons set forth below.

 

This structure creates efficiency in the preparation of the meeting agendas and related Board materials as the Company's Chief Executive Officer works directly with those individuals preparing the necessary Board materials and is more connected to the overall daily operations of the Company. Agendas are also prepared with the permitted input of the full Board of Directors allowing for any concerns or risks of any individual director to be discussed as deemed appropriate. The Board believes that the Company has benefited from this structure, and Mr. Perry's continuation in the combined role of the Chairman and Chief Executive Officer is in the best interest of the stockholders.

 

The Company believes that the combined structure is necessary and allows for efficient and effective oversight, given the Company's relatively small size, its corporate strategy and focus.

 

The Board of Directors does not have a specific role in risk oversight of the Company. The Chairman, President and Chief Executive Officer and other executive officers and employees of the Company provide the Board of Directors with information regarding the Company's risks.

 

 
18

Table of Contents

 

Item 11. Executive Compensation

 

The table below sets forth, for our last two fiscal years ending September 30, 2022 (“2022”) and December 31, 2021 (“2021”), the compensation earned by our executive officers and former executive officers.

 

 

 

 

 

 

 

 

 

 

 

 

Option

 

 

 

 

 

 

 

 

 

 

Deferred

 

 

 

 

 

 

and

 

 

All Other

 

 

 

Name and

 

 

 

 

Compen-

 

 

 

 

Stock

 

 

Warrant

 

 

Compen-

 

 

 

Principal Position

 

 

Salary

 

 

sation

 

 

Bonus

 

 

Awards

 

 

Awards

 

 

sation

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bradley White

 

2022

 

$112,500

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$112,500

 

Chief Executive Officer, Chief Financial Officer, and Director (1)

 

2021

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dr. Clayton Yates

 

2022

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

Chief Scientific Officer, Director (1)

 

2021

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dr. Jesse Jaynes

 

2022

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

Chief Research Officer, Director (1)

 

2021

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Robert Bubeck

 

2022

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

Former Chief Executive Officer, Former Chief Financial Officer, Former Director (2)

 

2021

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Margaret McLaughlin

 

2022

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

Former Secretary, Former Director (2)

 

2021

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

___________

(1)

Appointed on January 12, 2021.

(2)

Resigned on January 12, 2021.

  

There are no current employment agreements between the Company and its officers and directors, and no compensation was earned by or paid to our officers and directors during the fiscal years ending September 30, 2022 and December 31, 2021.

 

No retirement, pension, profit sharing, stock option or insurance programs or other similar programs have been adopted by us for the benefit of our officer or director or employees.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The following table sets forth certain information regarding beneficial ownership of our common stock as of March 17, 2023, by (i) each person known by us to be the beneficial owner of more than 5% of any class of our voting equity, (ii) each director and each of our named executive officers and (iii) all executive officers and directors as a group.

 

The number of shares of stock beneficially owned by each person is determined under the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares as to which such person has sole or shared voting power or investment power and also any shares which the individual has the right to acquire within 60 days after the date hereof, through the exercise of any stock option, warrant or other right. Unless otherwise indicated, each person has sole investment and voting power (or shares such power with his or her spouse) with respect to the shares set forth in the following table. The inclusion herein of any shares deemed beneficially owned does not constitute an admission of beneficial ownership of those shares.

 

 
19

Table of Contents

 

The information reflected in the following table was, unless otherwise specified, the address of each of the persons set forth below, or is in care of the Company at the Company’s address.

 

Title of Class

 

Name & Address of

Beneficial Owners

 

Amount & Nature

of Beneficial Ownership (1)

 

 

Percent of

Class (2)

 

 

 

 

 

 

 

 

 

 

Common Stock

 

Bradley White (3)

 

 

5,025,120(4)

 

21.7

%

Common Stock

 

Dr. Clayton Yates (5)

 

 

7,312,620(6)

 

27.2

%

Common Stock

 

Dr. Jesse Jaynes (7)

 

 

6,767,620(8)

 

21.7

Common Stock

 

All Officers and Directors as a Group

 

 

19,105,360

 

 

51.3

%

Common Stock

 

John Coutris

 

 

1,500,000(9)

 

7.6

%

Common Stock

 

Judy Miller

 

 

1,106,170(10)

 

6.1

%

 

 

 

 

 

 

 

 

 

 

Common Stock

 

All Officers and Directors as a Group

 

 

71,938,459

 

 

62.67

%

Series B Preferred Stock

 

Bradley White

 

 

502,512

 

 

 

24.4%

Series B Preferred Stock

 

Dr. Clayton Yates

 

 

731,262

 

 

35.5

%

Series B Preferred Stock

 

Dr. Jesse Jaynes

 

 

676,762

 

 

32.8

%

Series B Preferred Stock

 

All Officers and Directors as a Group

 

 

1,910,536

 

 

92.7

%

Series B Preferred Stock

 

John Coutris

 

 

150,000

 

 

7.3

%

_______________  

 

(1)

Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Each of the beneficial owners listed above has direct ownership of and sole voting power and investment power with respect to the shares of the Company’s common stock unless otherwise stated herein.

 

 

 

 

(2)

As of March 24, 2023, a total of 18,122,821 shares of the Company’s common stock, and 2,060,536 shares of Series B Preferred Stock are considered to be outstanding pursuant to SEC Rule 13d-3(d)(1). For each beneficial owner above, any shares of common stock issuable upon conversion of Series B Preferred Stock within 60 days have been included for purposes of calculating the relevant percentage ownership. Each share of Series B Preferred Stock converts into 10 shares of common stock at the election of the holder.

 

 

 

 

(3)

Chief Executive Officer & Director.

 

 

 

 

(4)

122,500 shares of Series B Preferred Stock are held in the name of Mr. White, 380,012 shares of Series B Preferred Stock are held in the name of the LASB Family Trust, which may be deemed to be beneficially owned by Mr. White, and such shares of preferred stock are convertible into 5,025,120 shares of common stock.

 

 

 

 

(5)

Chief Science Officer & Director.

 

 

 

 

(6)

731,262 shares of Series B Preferred Stock are held in the name of ACT Holdings LLC, which may be deemed to be beneficially owned by Dr. Yates, and such shares of preferred stock are convertible into 7,312,620 shares of common stock.

 

 

 

 

(7)

Chief Research Officer & Director.

 

 

 

 

(8)

476,762 shares of Series B Preferred Stock are held jointly in the name of Dr. Jaynes and his spouse, 200,000 shares of Series B Preferred Stock held in the name of the Jaynes Investment LLC, which may be deemed to be beneficially owned by Dr. Jaynes, and such shares of preferred stock are convertible into 6,767,620 shares of common stock.

 

 

 

 

(9)

150,000 shares of Series B Preferred Stock are held in the name of PJ Advisory Group, which may be deemed to be beneficially owned by Mr. Coutris, and such shares of preferred stock are convertible into 1,500,000 shares of common stock. Upon belief, the address of PJ Advisory Group is 7227 Centenery Ave., Dallas, Texas, 75225.

 

 

 

 

(10)

1,106,170 shares of Common Stock are held in the name of Good Works Funding Inc., which may be deemed to be beneficially owned by Ms. Miller. Upon belief, the address of Good Works Funding Inc. is 201 S. Elliott Rd., #550, Chapel Hill, North Carolina, 27514.

 

 
20

Table of Contents

 

Item 13. Certain Relationships and Related Transactions

 

Transactions with Related Persons

 

None

 

The Company does not own or rent property. The office space is provided by an officer at no charge.

 

Director Independence

 

We currently do not have any independent directors, as the term "independent" is defined in Section 803A of the NYSE American Company Guide. The Board has made its determination as to director independence based on the definition of "independence" as defined under the rules of the New York Stock Exchange ("NYSE") and NYSE American.

 

Item 14. Principal Accounting Fees and Services.

 

The following table sets forth the fees billed by our principal independent accountants for the years ended September 30, 2022 and 2021, for the categories of services indicated.

 

 

 

For the Nine

 

 

For the Year

 

 

 

Months Ended

 

 

Ended

 

 

 

September 30,

 

 

December 31,

 

Category

 

2022

 

 

2021

 

Audit fees

 

$42,000

 

 

$20,000

 

Audit related fees

 

 

-

 

 

 

-

 

Tax fees

 

 

-

 

 

 

-

 

All other fees

 

 

-

 

 

 

-

 

Total

 

$42,000

 

 

$20,000

 

 

On December 16, 2020, we notified Adeptus Partners LLC (“Adeptus”) of their dismissal as our independent registered public accounting firm. On December 16, 2020, we engaged Turner, Stone & Company, L.L.P. (“Turner”) of Dallas, Texas, as our new independent registered public accounting firm.

 

Audit fees. Consists of fees billed for the audit of our annual financial statements and review of our interim financial information and services that are normally provided by the accountant in connection with year-end and quarter-end statutory and regulatory filings or engagements.

 

Audit-related fees. Consists of fees billed for services relating to review of other regulatory filings including registration statements, periodic reports and audit related consulting.

 

Tax fees. Consists of professional services rendered by our principal accountant for tax compliance, tax advice and tax planning.

 

Other fees. Other services provided by our accountants.

 

 
21

Table of Contents

 

Item 15. Exhibits, Financial Statement Schedules

 

Exhibit

 

Description

 

 

 

3.1

 

Florida Articles of Incorporation (incorporated by reference to Exhibit 3.A to our Registration Statement on Form S-1, filed on May 4, 2020)

 

 

 

3.2

 

Nevada Articles of Incorporation (incorporated by reference to Exhibit 3.2 to our Quarterly Report on Form 10-Q, filed on July 20, 2021)

 

 

 

3.3

 

Certificate of Correction to Nevada Articles of Incorporation (incorporated by reference to Exhibit 3.3 to our Quarterly Report on Form 10-Q, filed on July 20, 2021)

 

 

 

3.4

 

Bylaws (incorporated by reference to Exhibit 3.B to our Registration Statement on Form S-1, filed on May 4, 2020)

 

 

 

10.1*

 

Exchange Agreement, by and between the Company and Genvor Inc. (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on February 1, 2021)

 

 

 

10.2*

 

Agreement and Plan of Merger, by and between the Company, Genvor Inc., and Genvor Acquisition Corp. (incorporated by reference to Exhibit 10.2 to our Annual Report on Form 10-K filed on March 21, 2022)

 

 

 

31.1**

 

Certification of CEO required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

31.2**

 

Certification of CFO required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

32.1**

 

Certification of CEO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

 

 

 

32.2**

 

Certification of CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

 

 

 

101.INS***

 

Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).

 

 

 

101.SCH***

 

Inline XBRL Taxonomy Extension Schema Document.

 

 

 

101.CAL***

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

 

 

 

101.DEF***

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.

 

 

 

101.LAB***

 

Inline XBRL Taxonomy Extension Labels Linkbase Document.

 

 

 

101.PRE***

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

 

 

 

104

 

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

____________

* Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or Exhibit so furnished.

** Filed herewith.

*** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

 
22

Table of Contents

 

SIGNATURES

  

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

/s/ Bradley White

 

March 28, 2023

 

Chief Executive Officer and

 

Date

 

Chief Financial Officer

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

/s/ Bradley White

 

March 28, 2023

 

Chief Executive Officer, Chief Financial Officer & Director

 

Date

 

 

 

 

 

/s/ Dr. Clayton Yates

 

March 28, 2023

 

Director

 

Date

 

 

 

 

 

/s/ Bradley White

 

March 28, 2023

 

Director

 

Date

 

 

 

23

 

 

 

 

 

EX-31.1 2 genvor_ex311.htm CERTIFICATION genvor_ex311.htm

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

REQUIRED BY RULE 13A-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 AS AMENDED,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Bradley White, certify that:

 

1.

I have reviewed this annual report on Form 10-K of Genvor Incorporated;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)

disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: March 28, 2023

By:

/s/ Bradley White

Chief Executive Officer,

EX-31.2 3 genvor_ex312.htm CERTIFICATION genvor_ex312.htm

EXHIBIT 31.2

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

REQUIRED BY RULE 13A-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 AS AMENDED,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Bradley White, certify that:

 

1.

I have reviewed this annual report on Form 10-K of Genvor Incorporated;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)

disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: March 28, 2023

By:

/s/ Bradley White

Chief Financial Officer

EX-32.2 4 genvor_ex321.htm CERTIFICATION genvor_ex321.htm

EXHIBIT 32.1

 

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Bradley White, Chief Executive Officer of Genvor Incorporated (the "Company"), certify, pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

 

(1)

the Annual Report on Form 10-K of the Company for the year ended September 30, 2022 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

 

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 28, 2023

By:

/s/ Bradley White

Chief Executive Officer,

EX-32.2 5 genvor_ex322.htm CERTIFICATION genvor_ex322.htm

EXHIBIT 32.2

 

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Bradley White, Chief Financial Officer of Genvor Incorporated (the "Company"), certify, pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

 

(1)

the Annual Report on Form 10-K of the Company for the year ended September 30, 2022 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

 

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 28, 2023

By:

/s/ Bradley White

Chief Financial Officer

EX-101.SCH 6 genvor-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - BORROWINGS link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - STOCKHOLDERS DEFICIT link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - FEDERAL INCOME TAX link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - MERGER WITH OLD GENVOR link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - INTELLECTUAL PROPERTIES link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - BORROWINGS (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - FEDERAL INCOME TAX (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - SUBSEQUENT EVENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - BORROWINGS (Details) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - BORROWINGS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - BORROWINGS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - STOCKHOLDERS DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - FEDERAL INCOME TAX (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - FEDERAL INCOME TAX (Details 1) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - FEDERAL INCOME TAX (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - MERGER WITH OLD GENVOR (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 genvor-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Voluntary Filers Current Fiscal Year End Date Entity Well Known Seasoned Issuer Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Ex Transition Period Entity Common Stock Shares Outstanding Entity Public Float Document Annual Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Interactive Data Current Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Auditor Firm Id Auditor Name Auditor Location CONSOLIDATED BALANCE SHEETS ASSETS Current assets: Cash Prepaid expenses Prepaid costs for reverse capitalization Other current assets Total current assets [Assets, Current] Fixed assets, net Receivables from related parties Total assets [Assets] LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Notes payable Accounts payable and accrued expenses Due to related party SBA loan USDA CRADA liability Total current liabilities [Liabilities, Current] Non-current liabilities: Convertible notes payable, net of discounts Notes payable, net of discounts Total non-current liabilities [Liabilities, Noncurrent] Total liabilities [Liabilities] Commitments and contingencies (Note 6) Stockholders' deficit: Preferred stock, $0.001 par value, 20,000,000 shares authorized, 10 and 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively Common stock, $0.001 par value, 300,000,000 shares authorized, 38,678,155 and 26,025,020 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficit [Stockholders' Equity Attributable to Parent] Total liabilities and stockholders' deficit [Liabilities and Equity] Preferred Stock, Shares Par Value Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Shares Par Value Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding CONSOLIDATED STATEMENTS OF OPERATIONS Revenue Operating expenses Professional fees Payroll related expenses Research and development Stock-based compensation Depreciation expense Other general and administrative expenses Total operating expenses [Operating Expenses] Operating loss [Operating Income (Loss)] Other income (expense) Interest expense Penalties Beneficial conversion feature Loss on Agromed acuisition failure Loss on settlement of liabilities Total other income (expense) [Other Noncash Income Tax Expense] Net loss [Net Income (Loss) Available to Common Stockholders, Basic] Basic and diluted net loss per common share Basic and diluted weighted average common shares outstanding CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Additional Paid-in Capital Retained Earnings (Accumulated Deficit) Series A, Preferred Stock [Member] Balance, shares [Shares, Issued] Balance, amount Recapitalization / RTO impact Allure Balance, Amount Allure Balance, Shares Common stock issued for services, shares Common stock issued for services, amount Exercise of options, shares Exercise of options, amount Common stock issued for cash, shares Common stock issued for cash, amount Common stock options issued for services Net loss [Net Income (Loss) Attributable to Parent] Common stock issued for debt conversion, shares Common stock issued for debt conversion, amount Founder shares issued, shares Founder shares issued, amount Payment for reverse capitalization Issuance of common stock to prior S-1 investors, shares Issuance of common stock to prior S-1 investors, amount Issuance of common stock for note receivable, shares Issuance of common stock for note receivable, amount Issuance of common stock for 2021 SPA, shares Issuance of common stock for 2021 SPA, amount Issuance of common stock for settlements, shares Issuance of common stock for settlements, amount Beneficial conversion feature [Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature] fund raising services, shares fund raising services, amount Issuance of preferred stock, shares Issuance of preferred stock, amount Balance, shares Balance, amount CONSOLIDATED STATEMENTS OF CASH FLOWS Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Interest expense capitalized into notes payable Late fee capitalized into notes payable Loss on Agromed acquisition failure [Loss on Agromed acquisition failure] Stock-based compensation Beneficial conversion feature amortization [Beneficial conversion feature amortization] Amortization of debt discount Loss on settlement of liabilities [Gain (Loss) Related to Litigation Settlement] Changes in assets and liabilities: Prepaid expenses [Increase (Decrease) in Prepaid Expense] Prepaid costs for reverse capitalization [Prepaid costs for reverse capitalization] Other current assets [Increase (Decrease) in Other Current Assets] Receivables from related parties [Increase (Decrease) in Due from Related Parties] Accounts payable and accrued expenses [Securities Borrowed, Increase] Due to related party [Increase (Decrease) in Due to Related Parties] USDA CRADA liability [USDA CRADA liability] Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] Cash flows from financing activities: Proceeds from notes payable Payments of notes payable [Repayments of Notes Payable] Payments of receivable from related parties [Payments of receivable from related parties] Proceeds from sale of common stock Repayments of advances payable from related parties Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] Net increase (decrease) in cash [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect] Cash at beginning of period [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] Cash at end of period Cash paid for interest Cash paid for taxes Non-cash investing and financing activities: Discount on notes payable Right of use, lease asset and liability Issuance of common stock for debt conversion Fundraising services Issuance of common stock for debt settlement Prepaid costs for reverse capitalization recognized in additional paid-in capital ORGANIZATION AND BASIS OF PRESENTATION ORGANIZATION AND BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] BORROWINGS BORROWINGS Subordinated Borrowings Disclosure [Text Block] STOCKHOLDERS DEFICIT STOCKHOLDERS' DEFICIT FEDERAL INCOME TAX FEDERAL INCOME TAX Income Tax Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] MERGER WITH OLD GENVOR MERGER WITH OLD GENVOR [MERGER WITH OLD GENVOR] INTELLECTUAL PROPERTIES INTELLECTUAL PROPERTIES [INTELLECTUAL PROPERTIES] SUBSEQUENT EVENTS SUBSEQUENT EVENTS Subsequent Events [Text Block] Use of Estimates Cash Flow Reporting Cash Cash and Cash Equivalents, Policy [Policy Text Block] Fixed Assets Stock-Based Compensation Fair Value of Financial Instruments Long-lived Assets Research and Development Patents Income Taxes Stock-Based Compensation2 (Loss) Income Per Share of Common Stock Recently Issued Accounting Standards Schedule of Convertible Notes Payable Schedule of Future Maturities of the Notes Payable Schedule of loss before taxes for fiscal year Schedule of Deferred Tax Assets Schedule of converted shares of common stock of the Company into shares Accumulated deficit Net loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Net cash used in opearting activitites Research and development expenses Potential additional dilutive securities outstanding Amount in excess of FDIC insured limit Debt Instrument Axis Noteholder A [Member] Noteholder B [Member] Noteholder C [Member] Noteholder D [Member] Noteholder E [Member] Noteholder F [Member] Noteholder G [Member] Noteholder H [Member] Number of shares the notesis convertible into shares Loan Balance Debt discount [Debt Instrument, Unamortized Discount] Total loan Origination Maturity date Interest rate 2023 2024 Plan Name Axis Business Acquisition Axis Finite Lived Intangible Assets By Major Class Axis Paycheck Protection Program [Member] Agromed LLC [Member] Patent [Member] Principal amount Interest amount Debt conversion common shares Loss on debt settelment Interest expense [Interest Expense, Debt] Late fees Interest rate Consideration amount Stock issued for acquisition Stock issued for acquisition, value Loss on fail to acquisition Cost of intangible asset Note payable written off Penalty amount receive each month Financial Instrument [Axis] Class of Stock [Axis] Range [Axis] Related Party [Axis] Title of Individual [Axis] Share Issue For Services [Member] Stock Options And Warrants [Member] Series B Preferred Stock [Member] Series A, Preferred Stock Stock Issued for Cash [Member] Maximum [Member] Minimum [Member] Investor [Member] Bradley White [Member] Clayton Yates [Member] Jesse Jaynes [Member] Transfer And Agreement [Member] Nexion Contractor [Member] Designation authorized shares Conversion share description Number of votes Common stock, shares authorized Common stock, shares par value Exercise price Proceed from common stock issue Common stock share issued to individual Common stock share issued price to individual Common stock share issued value to individual Number of common stock cancel Number of common stock return Stock value price Common stock share issued Common stock value Shares issued to a debt Interest expense capitalized into notes payable [Interest Expense] Stock compensation Common stock price Consulting agreement description Risk-free interest rate Expected volatility Preferred stock, shares authorized Preferred stock, shares issue Preferred stock, shares outstanding Preferred stock, shares par value Tax expense (benefit) at the statutory rate [Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount] State income taxes, net of federal income tax benefit [Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount] Change in valuation allowance Total [Income Tax Expense (Benefit)] Net operating loss carryforwards Total gross deferred tax assets Valuation allowance [Deferred Tax Assets, Valuation Allowance] Deferred tax asset Federal tax statutory rate Net operating loss carry forwards Valuation allowance for net deferred tax assets Related Party Transaction Axis Research And Development Arrangement Contract To Perform For Others By Type Axis Consulting Agreements [Member] CEO [Member] Consulting Agreements One [Member] Consulting Agreements Two [Member] Consultant [Member] Investor [Member] Research And Development Agreement Fund [Member] Assets held in trust Rent expense Share issued for compensation Related party payable Annual salary Accrued payroll Monthly compensation Amount paid to consultant Share issued to consultant Share issued to consultant, value Common stock share issued Fund Amount CEO [Member] [CEO [Member]] Receivables from Related Parties Former CEO Board of Directors Due To Related Party Advanced recived Repaid To Related Party Expenses paid Paid of accrued expenses Common Stock, Shares Par Value [Common Stock, No Par Value] Total of shares issued Common Stock, value Investment, Name [Axis] Genvor Inc [Member] Common Stock, Shares Outstanding Cash Payment For Acquisation Ownership Of Shareholders, Percentage Additional paid-in capital Subsequent Event Type [Axis] Jaynes Investment LLC [Member] Subsequent Event [Member] ACT Holdings LLC [Member] LASB Family Trust [Member] Jesse Michael Jaynes [Member] Bradley White [Member] PJ Advisory Group [Member] Common share exchange Series B issued Subsequent Event [Member] Designation authorized shares [Common Unit, Authorized] Description of voting rights EX-101.CAL 8 genvor-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 genvor-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 genvor-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 11 genvor_10kimg3.jpg begin 644 genvor_10kimg3.jpg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end GRAPHIC 12 genvor_10kimg1.jpg begin 644 genvor_10kimg1.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
9 Months Ended
Sep. 30, 2022
Mar. 24, 2023
Mar. 31, 2022
Cover [Abstract]      
Entity Registrant Name GENVOR INCORPORATED    
Entity Central Index Key 0001792941    
Document Type 10-K    
Amendment Flag false    
Entity Voluntary Filers Yes    
Current Fiscal Year End Date --09-30    
Entity Well Known Seasoned Issuer No    
Entity Small Business true    
Entity Shell Company false    
Entity Emerging Growth Company true    
Entity Current Reporting Status No    
Document Period End Date Sep. 30, 2022    
Entity Filer Category Non-accelerated Filer    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Entity Ex Transition Period false    
Entity Common Stock Shares Outstanding   18,122,821  
Entity Public Float     $ 0
Document Annual Report true    
Document Transition Report false    
Entity File Number 333-234815    
Entity Incorporation State Country Code NV    
Entity Tax Identification Number 83-2054746    
Entity Interactive Data Current Yes    
Entity Address Address Line 1 13155 Noel Road    
Entity Address Address Line 2 Suite 900    
Entity Address City Or Town Dallas    
Entity Address State Or Province TX    
Entity Address Postal Zip Code 75240    
City Area Code 214    
Local Phone Number 427-1921    
Auditor Firm Id 76    
Auditor Name Turner, Stone & Company, L.L.P.    
Auditor Location Dallas, Texas    
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash $ 296,385 $ 384,621
Prepaid expenses 0 1,331
Prepaid costs for reverse capitalization 0 150,000
Other current assets 2,000 0
Total current assets 298,385 535,952
Fixed assets, net 17,565 18,939
Receivables from related parties 0 2,053
Total assets 315,951 556,944
Current liabilities:    
Notes payable 1,052,000 1,632,250
Accounts payable and accrued expenses 516,658 571,158
Due to related party 3,846 0
SBA loan 48,750 0
USDA CRADA liability 246,400 246,400
Total current liabilities 1,867,654 2,449,808
Non-current liabilities:    
Convertible notes payable, net of discounts 89,221 0
Notes payable, net of discounts 0 344,167
Total non-current liabilities 89,221 344,167
Total liabilities 1,956,875 2,793,975
Commitments and contingencies (Note 6) 0 0
Stockholders' deficit:    
Preferred stock, $0.001 par value, 20,000,000 shares authorized, 10 and 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively 0 0
Common stock, $0.001 par value, 300,000,000 shares authorized, 38,678,155 and 26,025,020 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively 38,678 26,025
Additional paid-in capital 14,608,815 9,538,772
Accumulated deficit (16,288,417) (11,801,828)
Total stockholders' deficit (1,640,924) (2,237,031)
Total liabilities and stockholders' deficit $ 315,951 $ 556,944
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
CONSOLIDATED BALANCE SHEETS    
Preferred Stock, Shares Par Value $ 0.001 $ 0.001
Preferred Stock, Shares Authorized 20,000,000 20,000,000
Preferred Stock, Shares Issued 9 0
Preferred Stock, Shares Outstanding 9 0
Common Stock, Shares Par Value $ 0.001 $ 0.001
Common Stock, Shares Authorized 300,000,000 300,000,000
Common Stock, Shares, Issued 38,678,155 26,025,020
Common Stock, Shares, Outstanding 38,678,155 26,025,020
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenue $ 0 $ 0
Operating expenses    
Professional fees 233,153 89,640
Payroll related expenses 120,725 390,000
Research and development 246,480 226,448
Stock-based compensation 3,512,500 2,222,961
Depreciation expense 1,374 1,832
Other general and administrative expenses 196,129 171,023
Total operating expenses 4,310,361 3,101,904
Operating loss (4,310,361) (3,101,904)
Other income (expense)    
Interest expense (51,117) (102,792)
Penalties (90,000) (120,000)
Beneficial conversion feature (30,111) 0
Loss on Agromed acuisition failure 0 (114,828)
Loss on settlement of liabilities (5,000) 0
Total other income (expense) (176,228) (337,620)
Net loss $ (4,486,589) $ (3,439,524)
Basic and diluted net loss per common share $ (0.14) $ (0.15)
Basic and diluted weighted average common shares outstanding 32,437,505 22,493,382
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT - USD ($)
Total
Common Stock
Additional Paid-in Capital
Retained Earnings (Accumulated Deficit)
Series A, Preferred Stock [Member]
Balance, shares at Dec. 31, 2020   20,000,000      
Balance, amount at Dec. 31, 2020 $ (1,590,473) $ 20,000 $ 6,751,831 $ (8,362,304) $ 0
Recapitalization / RTO impact (32,872) 18,000 (21,846) (29,026) 0
Allure Balance, Amount (1,557,601) $ 2,000 6,773,677 (8,333,278) 0
Allure Balance, Shares   20,000,000      
Common stock issued for services, shares   3,150,000      
Common stock issued for services, amount 1,523,012 $ 3,150 1,519,863 0 0
Exercise of options, shares   1,400,000      
Exercise of options, amount 0 $ 1,400 (1,400)   0
Common stock issued for cash, shares   1,475,020      
Common stock issued for cash, amount 570,005 $ 1,475 568,530   0
Common stock options issued for services 699,948 0 699,948 0 0
Net loss (3,439,524) $ 0 0 (3,439,524) 0
Balance, shares at Dec. 31, 2021   26,025,020      
Balance, amount at Dec. 31, 2021 (2,237,031) $ 26,025 9,538,772 (11,801,828) 0
Common stock issued for services, shares   6,525,000      
Common stock issued for services, amount 3,512,500 $ 6,525 3,505,975 0 0
Common stock issued for cash, shares   305,000      
Common stock issued for cash, amount 165,275 $ 305 164,970 0 0
Net loss (4,486,589) $ 0 0 (4,486,589) 0
Common stock issued for debt conversion, shares   2,622,647      
Common stock issued for debt conversion, amount 1,235,555 $ 2,622 1,232,933 0 0
Founder shares issued, shares   1,855,888      
Founder shares issued, amount 0 $ 1,856 (1,856) 0 0
Payment for reverse capitalization (150,000) $ 0 (150,000) 0 0
Issuance of common stock to prior S-1 investors, shares   975,000      
Issuance of common stock to prior S-1 investors, amount 49,725 $ 975 48,750 0 0
Issuance of common stock for note receivable, shares   99,600      
Issuance of common stock for note receivable, amount 0 $ 100 (100) 0 0
Issuance of common stock for 2021 SPA, shares   50,000      
Issuance of common stock for 2021 SPA, amount 0 $ 50 (50) 0 0
Issuance of common stock for settlements, shares   50,000      
Issuance of common stock for settlements, amount 0 $ 50 (50) 0 0
Beneficial conversion feature 269,916 $ 0 269,916 0 0
fund raising services, shares   170,000      
fund raising services, amount   $ 170 (170)   $ 0
Issuance of preferred stock, shares         9
Issuance of preferred stock, amount 0 $ 0 0 0 $ 0
Balance, shares at Sep. 30, 2022   38,678,155     9
Balance, amount at Sep. 30, 2022 $ (1,640,924) $ 38,678 $ 14,608,815 $ (16,288,417) $ 0
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net loss $ (4,486,589) $ (3,439,524)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 1,374 1,832
Interest expense capitalized into notes payable 0 10,000
Late fee capitalized into notes payable 90,000 120,000
Loss on Agromed acquisition failure 0 114,828
Stock-based compensation 3,512,500 2,222,961
Beneficial conversion feature amortization 30,111 0
Amortization of debt discount 0 11,667
Loss on settlement of liabilities 5,000 0
Changes in assets and liabilities:    
Prepaid expenses 1,331 (1,331)
Prepaid costs for reverse capitalization 150,000 (100,000)
Other current assets (2,000) 0
Receivables from related parties 2,053 0
Accounts payable and accrued expenses 139,138 323,564
Due to related party (3,846) 0
USDA CRADA liability 0 72,800
Net cash used in operating activities (553,236) (663,203)
Cash flows from financing activities:    
Proceeds from notes payable 300,000 365,000
Payments of notes payable 0 (6,000)
Payments of receivable from related parties 0 (25,579)
Proceeds from sale of common stock 165,000 570,005
Repayments of advances payable from related parties 0 (3,575)
Net cash provided by financing activities 465,000 899,851
Net increase (decrease) in cash (88,236) 236,648
Cash at beginning of period 384,621 147,973
Cash at end of period 296,385 384,621
Cash paid for interest 0 0
Cash paid for taxes 0 0
Non-cash investing and financing activities:    
Discount on notes payable 269,916 35,000
Right of use, lease asset and liability 0 13,480
Issuance of common stock for debt conversion 1,235,555 0
Fundraising services 170,000 0
Issuance of common stock for debt settlement 49,725 0
Prepaid costs for reverse capitalization recognized in additional paid-in capital $ 150,000 $ 0
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND BASIS OF PRESENTATION
9 Months Ended
Sep. 30, 2022
ORGANIZATION AND BASIS OF PRESENTATION  
ORGANIZATION AND BASIS OF PRESENTATION

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

 

Company Background

 

On May 27, 2022, Genvor Incorporated, formerly known as Allure Worldwide, Inc. (the “Company” or “Genvor” or “we”), a Nevada corporation, Genvor Acquisition, Corp., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Genvor Inc., a Delaware corporation (“Old Genvor”), completed their previously announced merger transaction pursuant to which the Company acquired Old Genvor (the “Acquisition”), and Old Genvor became a wholly-owned subsidiary of the Company. The Acquisition was completed pursuant to an Exchange Agreement, dated as of January 11, 2021 (the “Acquisition Agreement”), pursuant to which Old Genvor was to be acquired by the Company as its wholly owned subsidiary and each share of Old Genvor common stock would be exchanged for a share of the Company’s common stock, and a merger agreement, dated March 2, 2022 (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger, and each share of Old Genvor being converted into the right to receive a share of the Company (the “Merger”). After closing of the Merger, the Company was renamed “Genvor Incorporated”. Genvor develops plant-based defense technology designed to help farmers achieve global food security.

 

During May 2019, Old Genvor acquired Nexion Biosciences LLC (“NBLLC”) from a founder for nominal consideration as a wholly owned subsidiary. NBLLC was formed in the state of Delaware on December 28, 2018. The consolidated financial statements of the Company include the accounts of Genvor Incorporated, Old Genvor, and its wholly owned subsidiary NBLLC. Intercompany accounts and transactions have been eliminated upon consolidation.

 

Nature of Operations

 

The Company’s business plan is developing plant-based defense technology designed to help farmers achieve global food security. The Company’s technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike.

 

Basis of Presentation

 

The Company follows the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and has a year-end of September 30. The wholly owned subsidiary has a year-end of December 31. 

 

Due to the different fiscal year-ends, the consolidated financial statements will reflect the balance sheets and the statements of changes in stockholders’ deficit dates of September 30, 2022, and December 31, 2021, whereas the statements of operations and statements of cash flows are for the nine months ended September 30, 2022, and the year ended December 31, 2021.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in the consolidation. The consolidated financial statements included herein, presented in accordance with United States generally accepted accounting principles (“GAAP”) and stated in United States dollars, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission.

Liquidity and Going Concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At September 30, 2022, the Company had an accumulated deficit of $16,288,417. For the nine months ended September 30, 2022, the Company recognized a net loss of $4,486,589 and had net cash used in operating activities of $553,236, with no revenues earned, and limited operational history. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

While the Company is currently developing its products and technologies, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of additional public and/or private offerings of its stock. Management believes that the actions presently being taken to further implement its business plan, develop its products and technologies, and generate revenues should provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds in the future, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate cash flows from financing activities or operating activities. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash Flow Reporting

 

The Company follows Accounting Standards Codification (“ASC 230”), Statement of Cash Flows, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“indirect method”) as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.

 

Cash

 

Cash is comprised of cash balances. Cash is held at major financial institutions and is subject to credit risk to the extent that those balances exceed applicable Federal Deposit Insurance Corporation (“FDIC”) insurance amounts of $250,000. From time to time, the Company has certain cash balances, including restricted cash, that may exceed insured limits. The Company utilizes large banking institutions that are reputable therefore mitigating the risks.

 

The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. At September 30, 2022, $46,385 of the Company’s cash balances were in excess of federally insured limits.

 

Fixed Assets

 

Furniture and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately seven years. Expenditures for minor enhancements and maintenance are expensed as incurred.

Stock-Based Compensation

 

The Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, Compensation – Stock Compensation, and Certain Redeemable Financial Instruments. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.

 

Fair Value of Financial Instruments

 

The book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature of these instruments. The fair value hierarchy under GAAP distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).

 

The hierarchy consists of three levels

 

 

Level one — Quoted market prices in active markets for identical assets or liabilities;

 

Level two — Inputs other than level one inputs that are either directly or indirectly observable; and

 

Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

 

Determining which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures each quarter.

 

Long-lived Assets

 

The Company’s long-lived assets and other assets (consisting of furniture, equipment and a patent) are reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company had not experienced impairment losses on its long-lived assets.

 

Research and Development

 

The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional service costs associated with the development of the plant-based defense technology products.  For the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company had $246,480 and $226,448 in research and development expenses, respectively.

 

Patents

 

Any patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative expenses in the statement of operations.

 

Purchased patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements.

Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases.

 

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled.

 

The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of September 30, 2022. Interest and penalties in any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the nine months ended September 30, 2022.

 

Stock-Based Compensation

 

The Company measures compensation cost for all employee stock-based awards at their fair values on the date of grant. Stock-based awards issued to non-employees are measured at their fair values on the date of grant and are re-measured at each reporting period through their vesting dates, as applicable. The fair value of stock-based awards is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method.

 

Loss Per Share of Common Stock

 

Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (“EPS”) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. The Company had total potential additional dilutive securities outstanding at September 30, 2022 and December 31, 2021 of $300,000 and $0, respectively.

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options, which simplifies accounting for convertible instruments. The new guidance eliminates two of the three models in ASC 470-20 that require separating embedded conversion features from convertible instruments. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share calculation. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.

 

Recently Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.23.1
BORROWINGS
9 Months Ended
Sep. 30, 2022
BORROWINGS  
BORROWINGS

NOTE 3 – BORROWINGS

 

Commercial Loan

 

On April 9, 2020, the Company received a loan from the Small Business Administration pursuant to the Paycheck Protection Program (PPP) in the principal amount of $48,750. The note bears interest at a variable rate of approximately 1% and matured in April 2022; and it is currently in default. Forgiveness for the loan was applied for and is pending. The principal amount of the loan was based on the consulting agreement salary between Nexion Biosciences, Inc., organized in the state of Florida (NBFL) (a related party) and the CEO.

 

Payable for Patent

 

On August 22, 2020, the Company’s subsidiary, Genvor Inc., completed an acquisition of Agromed LLC (“Agromed”) in a transaction accounted for under the asset purchase method of accounting, whereby the assets acquired and the liabilities, if any assumed, are to be valued at fair value, and compared to the fair value of the consideration given to identify if there are any identifiable intangible assets to be recognized as a result of the transaction. Based on ASC 805, the Company first performed a screen test; determining that substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset. Agromed only held one patent and two applications for patents and had no sales, employees, or customers as of the acquisition date. Accordingly, the assets acquired are not considered a business and the recorded cost of the acquisition was based upon the fair value of the assets acquired. As consideration for Agromed, the Company was to pay $150,000 by March 31, 2021, and issue 230,000 shares of the Company’s common stock, which shares were issued and valued at $114,828. Accordingly, the patent was recorded at $264,828 on the date of acquisition. Subsequently, it was discovered that the patent had been transferred to another party prior to August 2020. Such transfer had not been recorded with the United States Patent and Trademark Office and therefore neither the Company nor the seller were aware of the seller at the time of the acquisition. As a result, the Company is no longer honoring the agreement to pay $150,000 but decided to let the seller retain the shares. The $150,000 note payable was written off along with the patent during the year ended December 31, 2021, resulting in a loss on the failed acquisition of $114,828 for the year ended December 31, 2021.

 

Notes Payable

 

From time to time, the Company’s subsidiary, Genvor Inc., enters into unsecured notes payable with individual investors. Only Noteholder E (below) has security in the form of a personal guarantee by the CEO and prior consultant (Note 6). The terms of these notes are listed below. Several of the notes are convertible into shares of the Company’s common stock as detailed in the following schedule.

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible

 

 

 

 

 

 

 

Interest

 

 

 Loan

 

 

into

 

Noteholder

 

Origination

 

Maturity

 

Rate

 

 

 Balance

 

 

Shares (c)

 

Noteholder A (a)

 

2019

 

12/31/2021

 

 

0%

 

$217,000

 

 

 

N/A

 

Noteholder B (a)

 

3/19/2019

 

4/29/2019

 

 

0%

 

 

450,000

 

 

 

N/A

 

Noteholder C (a)

 

3/1/2019

 

2/29/2020

 

 

18%

 

 

32,500

 

 

 

N/A

 

Noteholder D (d)

 

4/29/2019

 

unspecified

 

 

0%

 

 

300,000

 

 

 

30,000

 

Noteholder E (a)

 

8/1/2019

 

8/31/2019

 

 

0%

 

 

37,500

 

 

 

N/A

 

Noteholder F (a)(b)

 

2/27/2020

 

4/30/2020

 

 

0%

 

 

2,500

 

 

 

5,000

 

Noteholder G

 

8/3/2021

 

8/3/2023

 

 

10%

 

 

12,500

 

 

 

25,000

 

Noteholder H (e)

 

6/27/2022

 

6/27/2024

 

 

5%

 

 

300,000

 

 

 

1,000,000

 

 

 

 

 

 

 

 

 

 

 

 

1,352,000

 

 

 

1,060,000

 

(d) Debt discount

 

 

 

 

 

 

 

 

 

 

(210,779)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$1,141,221

 

 

 

 

 

(a) Past due at September 30, 2022

(b) Note is payable in a combination of $2,500 to $6,000 in cash and 5,000 to 15,000 share of common stock

(c) Convertible into common stock of the subsidiary, Genvor Inc.

(d) Debt discount

(e) Noteholder is a shareholder of the Company.

 

The notes do not have default provisions except Noteholder B receives a default penalty of $10,000 each month the note goes unpaid.

During the nine months ended September 30, 2022, $989,000 principal and $146,946 interest was converted into 2,316,147 common stock shares of the Company. One note holder had a change in settlement terms, resulting in the recognition of $5,000 loss on debt settlement in the accompanying statement of operations for the nine months ended September 30, 2022.

 

Future maturities of the notes payable are as follows:

 

2023

 

$12,500

 

 

 

 

 

 

2024

 

$300,000

 

 

Interest expense totaled $141,117 and $222,792, respectively, for the nine months ended September 30, 2022, and the year ended December 31, 2021, including default penalties. Late fees totaled $90,000 and $120,000, respectively, for the nine months ended September 30, 2022, and the year ended December 31, 2021.

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS DEFICIT
9 Months Ended
Sep. 30, 2022
STOCKHOLDERS DEFICIT  
STOCKHOLDERS' DEFICIT

NOTE 4 – STOCKHOLDERS’ DEFICIT

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 20,000,000 shares with a $0.001 par value.

 

On August 10, 2022, the Company designated 10 shares of its preferred stock as Series A Preferred Stock (“Series A”). Each share of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation. When and as any dividend or distribution is declared or paid by the Company on the common stock, the Series A holders are entitled to participate in such dividend or distribution. Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock. Upon any liquidation, dissolution, or winding-up of the Company, the Series A holders are entitled to receive out the assets of the Company, for each share of Series A, an amount equal to par value before any distribution or payment shall be made to the holder of any junior securities (including common stock and all other equity or equity equivalent securities of the Company).  

 

As of September 30, 2022, and December 31, 2021, there were 9 and 0 shares of preferred stock issued and outstanding, respectively.  The preferred stock was issued on August 16, 2022, as follows: Bradley White (Chief Executive Officer), 3 shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 7.

 

On October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B Preferred Stock (“Series B”).  The designation authorized 2,500,000 shares of Series B.  Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company. See Note 10.

 

Common Stock

 

The authorized common stock of the Company consists of 300,000,000 shares with a $0.001 par value. All common stock shares are non-assessable and have one vote per share.

 

On April 21, 2022, the Company issued 569 shares of common stock to an individual under a transfer and exchange agreement for a note receivable held in NBFL (see Note 3). At the transfer date, the latest sale of common stock was at $0.50, accordingly the shares were valued at $285, and the note was written off since NBFL has since dissolved.

 

In connection with the Merger (see Notes 1 and 8), the founding shareholders of the Company cancelled 18,144,112 shares of common stock, retaining 5%, or 1,855,888 shares of common stock, as of June 30, 2022. The cancellation is presented in the accompanying statements of changes in stockholders’ deficit within the line item “Retroactive application of recapitalization.”

During July 2022, the Company entered into a transfer and exchange agreement with an individual to issue 99,600 shares of common stock for the note receivable held in NBFL. Since NBFL has minimal assets and was dissolved during the year ended December 31, 2019, the note receivable was immediately written-off. Based on the latest SPA price per share, the stock was valued at $1.00 per share, or $99,600.

 

On September 8, 2022, the Company issued 100,000 shares of common stock to a prior Nexion contractor.  This was in regard to a claim against the predecessor management and the Company opted as a settlement to issue the common stock.

 

Shares Issued for Services

 

During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company issued 751,500 and 2,650,000 shares of common stock, respectively, for business advisory services received, valued at $325,750 and $1,325,323, respectively.

 

On February 18, 2022, the Company issued 20,000 shares of common stock, valued at $10,000 (based on the latest third-party sale of common stock) to an investor for stock compensation. Additionally, 5,000 shares were issued to a debt holder as incentive, valued at $2,500 (based on the latest third-party sale of common stock), recorded in interest expense in the accompanying consolidated statement of operations for the nine months ended September 30, 2022.

 

On March 8, 2022, the Company issued 2,000,000 shares of common stock to each of its three directors, for a total of 6,000,000 shares issued valued at $3,000,000 (based on the latest third-party sale of common stock). The issuances are recorded in stock compensation in the accompanying consolidated statement of operations.

 

During April 2022, the Company issued 5,000 shares of common stock to a consultant valued at $2,500 and recorded in stock compensation in the accompanying consolidated statement of operations.

 

On May 27, 2022, the Company issued 500,000 shares of common stock for consulting services. Based on the latest third-party sale of common stock, this resulted in $500,000 stock-based compensation.

 

On September 13, 2022, the Company issued 170,000 shares of common stock to Scott Gann for services.

 

Stock Issued for Cash

 

From October through December 2021, the Company entered into fourteen stock purchase agreements (“SPA”) for the issuance of a total of 1,475,020 shares of common stock at prices ranging from $0.40-$0.50. The proceeds received under these SPAs totaled $570,005.

 

During January and February 2022, the Company entered into six SPAs for the issuance of a total of 280,000 shares of common stock at $0.50. The proceeds received under these SPAs totaled $140,000.

 

On May 12, 2022, the Company entered into an SPA for the issuance of 25,000 shares of common stock for $25,000, or $1.00 per share.

 

During July 2022, the Company issued 975,000 common stock shares to the prior S-1 investors pursuant to their subscription agreements.

 

During July 2022, the Company issued 50,000 shares of common stock to a shareholder pursuant to a December 2021 SPA.

Stock Options and Warrants

 

During 2019, as an inducement for debt, the Company issued a stock option to Noteholder E for 10,000 shares of common stock at the time of the Company’s initial public offering (“IPO”). The cost of the option was $1.00 and provides for a 50% discount to the initial opening stock price. Since the IPO has yet to take place and the Company had minimal assets at the time of issuance, the option was valued at $0.

 

On January 4, 2021, the Company entered into a consulting agreement for product development and marketing services. As part of the agreement, 600,000 option shares were issued at signing. An additional 100,000 option shares are earned monthly through August 2021. Although the IPO is still pending, since the Company sold warrants at $.50 during 2020, these options were valued at $.50. On December 20, 2021, the consultant elected to convert all 1,400,000 option shares into 1,400,000 shares of common stock.

 

The Company estimated the fair value of the 2021 options based on weighted probabilities of assumptions used in the Black Scholes pricing model. At issuance, the fair value of the options was estimated using the following weighted-average inputs: the price of the Company’s common stock of $0.50; a risk-free interest rate of 0.10% and expected volatility of the Company’s common stock of 500%, an exercise price of $.0001, and terms under one year.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.23.1
FEDERAL INCOME TAX
9 Months Ended
Sep. 30, 2022
FEDERAL INCOME TAX  
FEDERAL INCOME TAX

NOTE 5 – FEDERAL INCOME TAX

 

As of September 30, 2022, and December 31, 2021, the Company has net operating loss carry forwards of $2,572,885 and $2,343,000, respectively, which may be available to reduce future years’ taxable income through 2042. The Company’s net operating loss carry forwards may be subject to annual limitations, which could reduce or defer the utilization of the losses as a result of an ownership change as defined in Section 382 of the Internal Revenue Code.

 

The Company’s tax expense differs from the “expected” tax expense for Federal income tax purposes (computed by applying the United States Federal tax rate of 21% to loss before taxes for fiscal year 2022 and 2021), as follows:

 

 

 

 September 30,

 

 

 December 31,

 

 

 

 2022

 

 

 2021

 

Tax expense (benefit) at the statutory rate

 

$(204,559 )

 

$(255,478 )

State income taxes, net of federal income tax benefit

 

 

(25,326 )

 

 

(31,631 )

Change in valuation allowance

 

 

229,885

 

 

 

287,109

 

Total

 

$-

 

 

$-

 

 

The tax effects of the temporary differences between reportable financial statement income and taxable income are recognized as deferred tax assets and liabilities.

 

The tax years 2022 and 2021 remains open for examination by federal agencies and other jurisdictions in which it operates.

 

The tax effect of significant components of the Company’s deferred tax assets and liabilities at September 30, 2022 and December 31, 2021, are as follows:

 

 

 

 September 30,

 

 

 December 31,

 

 

 

 2022

 

 

 2021

 

Net operating loss carryforward

 

$2,572,885

 

 

$2,343,000

 

Total gross deferred tax assets

 

 

2,572,885

 

 

 

2,343,000

 

Less: Deferred tax asset valuation allowance

 

 

(2,572,885 )

 

 

(2,343,000 )

Total net deferred taxes

 

$-

 

 

$-

 

 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

 

Because of the historical earnings history of the Company, the net deferred tax assets for 2022 and 2021 were fully offset by a 100% valuation allowance. The valuation allowance for the remaining net deferred tax assets was $2,572,885 and $2,343,000 as of December 31, 2022, and 2021, respectively.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
9 Months Ended
Sep. 30, 2022
COMMITMENTS AND CONTINGENCIES  
COMMITMENTS AND CONTINGENCIES

NOTE 6 – COMMITMENTS AND CONTINGENCIES

 

From time to time, the Company may be involved in litigation in the ordinary course of business. The Company is not currently involved in any litigation that we believe could have a material adverse effect on its financial condition or results of operations.

 

Subscription Agreement and Cash Held in Escrow

 

On February 20, 2019, the Company entered into a subscription escrow agreement (the “Trust Agreement”) with Branch Banking and Trust Company (“BB&T”). This Trust Agreement was established for the subscription agreement proceeds raised and escrowed pursuant to the Company’s prior Rule 419 S-1 offering. The balance held in trust at September 30, 2022 and December 31, 2021, totaled $19,705.

 

Upon completion of the Merger (see Notes 1 and 8), the Company issued 975,000 common stock shares to the investors in that prior S-1 offering during July 2022 and were released to the Company.

 

Consulting Agreements

 

During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company paid the CEO $103,605 and $39,966, respectively, pursuant to a consulting agreement carried over from related party NBFL. The agreement provides for an annual salary of $150,000 which increases based on certain capital raise thresholds. At September 30, 2022 and December 31, 2021, accrued payroll owed to the CEO totaled $188,484 and $186,034, respectively, as presented in the accompanying consolidated balance sheets.

 

On July 24, 2020, the Company entered into a consulting agreement for business development activities, networking, negotiations, and strategic planning. The compensation pursuant to the agreement was $20,000 monthly. During the nine months ended September 30, 2022, and the year ended December 31, 2021, $144,975 and $47,500, respectively, was paid to the consultant. Additionally, during the year ended December 31, 2021, the Company issued 500,000 shares of common stock to the consultant, valued at $250,000. During the nine months ended September 30, 2022, the Company issued 751,500 shares of common stock, valued at $325,750, to settle the amounts owed to the consultant (Note 4).  Accordingly, at September 30, 2022 and December 31, 2021, $0 and $202,500, respectively, accrued payroll remained outstanding which is presented in the accompanying consolidated balance sheets.

 

On January 14, 2021, the Company entered into two consulting agreements for strategic advisory services to be provided through December 31, 2021. The compensation per the two agreements provided for the issuance of 1,700,000 and 450,000 shares of common stock. The stock compensation to these two advisors totaled $1,073,388.

 

Office Lease

 

The Company entered into a sublease agreement with the above consultant (providing business development assistance from 2019-2020) effective August 1, 2019, subject to the terms and conditions of the office lease held by the consultant at 15540 Quorum Drive #2624, Addison, Texas. On January 1, 2019, the Company adopted ASC 842 requiring this lease to be recorded as an asset and corresponding liability on its balance sheet. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms of the underlying lease. A discount rate was not used in the determination of the right of use asset and liability since its effect would not be significant. The lease moved to a month-to-month basis beginning in September 2021 at $2,810 per month in addition to common area maintenance charges. During the nine months ended September 30, 2022, and the year ended December 31, 2021, we incurred $30,240 and $20,094, respectively, in office rental expense.

 

Research and Development Agreement

 

During September 2020, the Company assumed a Cooperative Research And Development Agreement (CRADA) with the United States Department of Agriculture (USDA), Agricultural Research Service (ARS). Under this agreement, the Company committed to funding the remaining amount due. As of September 30, 2022, and December 31, 2021, $246,400 and $243,400, respectively, remained outstanding and is presented in the accompanying consolidated balance sheets as USDA CRADA liability.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS
9 Months Ended
Sep. 30, 2022
RELATED PARTY TRANSACTIONS  
RELATED PARTY TRANSACTIONS

NOTE 7 – RELATED PARTY TRANSACTIONS

 

Share Issuances to the Board of Directors

 

During December 2020, the Board of Directors allocated 11,137,833 shares of common stock among the three founders. These issuances were valued at $.50 per share based on a third-party sale of common stock (see Note 4), totaling $5,560,567.

 

On March 8, 2022, the Company issued 2,000,000 shares of common stock to each of its three directors, for a total of 6,000,000 shares issued valued at $3,000,000 (based on the latest third-party sale of common stock). The issuances are recorded in stock compensation in the accompanying consolidated statement of operations.

 

The Company issued Series B preferred stock on August 16, 2022, as follows: Bradley White (Chief Executive Officer), 3 shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 4.

 

Services from Related Parties

 

The daughter of the CEO and Board member was paid $21,900 and $16,925, respectively, for clerical services provided during the nine months ended September 30, 2022 and the year ended December 31, 2021.

 

Advance payable from CEO and Director

 

During the year ended December 31, 2019, the Company’s CEO advanced $5,000 to the Company. During the year ended December 31, 2021, the CEO was advanced $991 and was repaid the full amount by December 31, 2021. The advance was non-interest bearing and due upon demand.

 

Receivables from Related Parties

 

During the year ended December 31, 2020, one of the Company’s directors advanced the Company $3,000. Later that year, $5,000 was repaid leaving a total $2,000 receivable from the director at September 30, 2022 and 2021, respectively.

 

During 2018, Robert Bubeck, former CEO, paid $3,846 of expenses on behalf of the Company. The amount due to related party at both September 30, 2022 and 2021 is $3,846 and is due on demand and non-interest bearing.

 

During the nine months ended September 30, 2021, Robert Bubeck, former CEO, paid $13,500 of accrued expenses on behalf of the Company. Since the amount due to the shareholder is not expected to be repaid, it has been accounted for as additional paid-in capital in the accompanying consolidated financial statements.

 

During January 2021, in connection with the acquisition (see Note 8), Robert Bubeck resigned as CEO and Bradley White was appointed to serve as CEO.

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.23.1
MERGER WITH OLD GENVOR
9 Months Ended
Sep. 30, 2022
MERGER WITH OLD GENVOR  
MERGER WITH OLD GENVOR

NOTE 8 – MERGER WITH OLD GENVOR

 

On May 27, 2022, the Company, formerly known as Allure Worldwide, Inc., Merger Sub, and Old Genvor completed the Acquisition and Merger transaction (Note 1). The transaction was completed pursuant to the Merger Agreement, pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation in the Merger. Immediately upon completion of the Merger, the former stockholders of Old Genvor stockholders held a majority of the common stock and voting interest of the combined company.

 

In the Merger, the Company issued shares of its common stock to Old Genvor stockholders at an exchange ratio of 1:1 (with each share of Old Genvor common stock automatically converted in the merger into the right to receive a share of Company common stock, and a total of 35,261,871 shares of Company common stock issued to Old Genvor’s pre-merger stockholders). Pursuant to the original Acquisition agreement and Merger, the Company’s founding shareholders retained 5% of the Company’s outstanding shares of common stock, or 1,855,888 shares (Note 4). After closing the Acquisition and for a period of two years following commencement of trading of the Company’s common stock, the Company and Old Genvor agreed that the Company will make additional issuances of the Company’s common stock to the founding shareholders to ensure that in the aggregate they maintain their 5% ownership of the Company’s outstanding common stock.

 

Pursuant to business combination accounting for reverse acquisitions, the Company accounted for the Merger as a capital transaction (reverse recapitalization) rather than a business combination (or asset acquisition). Since the Company was formerly a special purpose acquisition company (SPAC) with no assets and only expenses related to maintaining its public shell company status, and Old Genvor has cash, other assets, a contract with the USDA (Note 6), and has raised funds from investors, Old Genvor was determined to be the accounting acquirer. Because a reverse recapitalization is equivalent to the issuance of shares by the private operating company for the net monetary assets of the public shell company, the transaction costs incurred by Old Genvor to effect the recapitalization were recognized as a reduction in additional paid-in capital rather than expensed as incurred. The assets and liabilities of Old Genvor were consolidated with the Company at their book value, the equity accounts were retroactively adjusted to reflect the equity of the Company, with a balancing adjustment through the additional paid-in capital account.

 

During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company paid $140,000 and $10,000, respectively, in anticipation of closing the Acquisition. The total $150,000 was recognized in additional paid-in capital as of the date of the Merger.

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.23.1
INTELLECTUAL PROPERTIES
9 Months Ended
Sep. 30, 2022
INTELLECTUAL PROPERTIES  
INTELLECTUAL PROPERTIES

NOTE 9 – INTELLECTUAL PROPERTIES

 

The Company was granted a patent (#11083775) on August 10, 2021 by the United States Patent and Trademark Office. The patent was assigned by the inventors to the Company and The United States of America, as represented by the Secretary of Agriculture.

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2022
SUBSEQUENT EVENTS  
SUBSEQUENT EVENTS

NOTE 10 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from the balance sheet through the date of this filing and determined there were no events to disclose except the following.

 

On October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B.  The designation authorized 2,500,000 shares of Series B.  Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company. See Note 4.

 

On October 19, 2022, the following shareholders converted shares of common stock of the Company into shares of Series B, as follows:

 

Name

 

Common Shares Exchanged

 

 

Series B

Issued

 

Jaynes Investment LLC

 

 

2,000,000

 

 

 

200,000

 

ACT Holdings LLC

 

 

7,312,612

 

 

 

731,262

 

LASB Family Trust

 

 

3,800,112

 

 

 

380,012

 

Jesse Michael Jaynes

 

 

4,767,611

 

 

 

476,762

 

Bradley White

 

 

1,225,000

 

 

 

122,500

 

 PJ Advisory Group 

 

 

1,500,000

 

 

 

150,000

 

 Total   

 

 

20,605,334

 

 

 

2,060,536

 

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Sep. 30, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash Flow Reporting

The Company follows Accounting Standards Codification (“ASC 230”), Statement of Cash Flows, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“indirect method”) as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.

Cash

Cash is comprised of cash balances. Cash is held at major financial institutions and is subject to credit risk to the extent that those balances exceed applicable Federal Deposit Insurance Corporation (“FDIC”) insurance amounts of $250,000. From time to time, the Company has certain cash balances, including restricted cash, that may exceed insured limits. The Company utilizes large banking institutions that are reputable therefore mitigating the risks.

 

The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. At September 30, 2022, $46,385 of the Company’s cash balances were in excess of federally insured limits.

Fixed Assets

Furniture and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately seven years. Expenditures for minor enhancements and maintenance are expensed as incurred.

Stock-Based Compensation

The Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, Compensation – Stock Compensation, and Certain Redeemable Financial Instruments. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.

Fair Value of Financial Instruments

The book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature of these instruments. The fair value hierarchy under GAAP distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).

 

The hierarchy consists of three levels

 

 

Level one — Quoted market prices in active markets for identical assets or liabilities;

 

Level two — Inputs other than level one inputs that are either directly or indirectly observable; and

 

Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

 

Determining which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures each quarter.

Long-lived Assets

The Company’s long-lived assets and other assets (consisting of furniture, equipment and a patent) are reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company had not experienced impairment losses on its long-lived assets.

Research and Development

The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional service costs associated with the development of the plant-based defense technology products.  For the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company had $246,480 and $226,448 in research and development expenses, respectively.

Patents

Any patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative expenses in the statement of operations.

 

Purchased patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements.

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases.

 

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled.

 

The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of September 30, 2022. Interest and penalties in any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the nine months ended September 30, 2022.

Stock-Based Compensation2

The Company measures compensation cost for all employee stock-based awards at their fair values on the date of grant. Stock-based awards issued to non-employees are measured at their fair values on the date of grant and are re-measured at each reporting period through their vesting dates, as applicable. The fair value of stock-based awards is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method.

(Loss) Income Per Share of Common Stock

Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (“EPS”) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. The Company had total potential additional dilutive securities outstanding at September 30, 2022 and December 31, 2021 of $300,000 and $0, respectively.

Recently Issued Accounting Standards

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options, which simplifies accounting for convertible instruments. The new guidance eliminates two of the three models in ASC 470-20 that require separating embedded conversion features from convertible instruments. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share calculation. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.

 

Recently Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.23.1
BORROWINGS (Tables)
9 Months Ended
Sep. 30, 2022
BORROWINGS  
Schedule of Convertible Notes Payable

 

 

 

 

 

 

 

 

 

 

 

 

Balance

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible

 

 

 

 

 

 

 

Interest

 

 

 Loan

 

 

into

 

Noteholder

 

Origination

 

Maturity

 

Rate

 

 

 Balance

 

 

Shares (c)

 

Noteholder A (a)

 

2019

 

12/31/2021

 

 

0%

 

$217,000

 

 

 

N/A

 

Noteholder B (a)

 

3/19/2019

 

4/29/2019

 

 

0%

 

 

450,000

 

 

 

N/A

 

Noteholder C (a)

 

3/1/2019

 

2/29/2020

 

 

18%

 

 

32,500

 

 

 

N/A

 

Noteholder D (d)

 

4/29/2019

 

unspecified

 

 

0%

 

 

300,000

 

 

 

30,000

 

Noteholder E (a)

 

8/1/2019

 

8/31/2019

 

 

0%

 

 

37,500

 

 

 

N/A

 

Noteholder F (a)(b)

 

2/27/2020

 

4/30/2020

 

 

0%

 

 

2,500

 

 

 

5,000

 

Noteholder G

 

8/3/2021

 

8/3/2023

 

 

10%

 

 

12,500

 

 

 

25,000

 

Noteholder H (e)

 

6/27/2022

 

6/27/2024

 

 

5%

 

 

300,000

 

 

 

1,000,000

 

 

 

 

 

 

 

 

 

 

 

 

1,352,000

 

 

 

1,060,000

 

(d) Debt discount

 

 

 

 

 

 

 

 

 

 

(210,779)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$1,141,221

 

 

 

 

 

(a) Past due at September 30, 2022

(b) Note is payable in a combination of $2,500 to $6,000 in cash and 5,000 to 15,000 share of common stock

(c) Convertible into common stock of the subsidiary, Genvor Inc.

(d) Debt discount

(e) Noteholder is a shareholder of the Company.

Schedule of Future Maturities of the Notes Payable

2023

 

$12,500

 

 

 

 

 

 

2024

 

$300,000

 

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.23.1
FEDERAL INCOME TAX (Tables)
9 Months Ended
Sep. 30, 2022
FEDERAL INCOME TAX  
Schedule of loss before taxes for fiscal year

 

 

 September 30,

 

 

 December 31,

 

 

 

 2022

 

 

 2021

 

Tax expense (benefit) at the statutory rate

 

$(204,559 )

 

$(255,478 )

State income taxes, net of federal income tax benefit

 

 

(25,326 )

 

 

(31,631 )

Change in valuation allowance

 

 

229,885

 

 

 

287,109

 

Total

 

$-

 

 

$-

 

Schedule of Deferred Tax Assets

 

 

 September 30,

 

 

 December 31,

 

 

 

 2022

 

 

 2021

 

Net operating loss carryforward

 

$2,572,885

 

 

$2,343,000

 

Total gross deferred tax assets

 

 

2,572,885

 

 

 

2,343,000

 

Less: Deferred tax asset valuation allowance

 

 

(2,572,885 )

 

 

(2,343,000 )

Total net deferred taxes

 

$-

 

 

$-

 

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS (Tables)
9 Months Ended
Sep. 30, 2022
SUBSEQUENT EVENTS  
Schedule of converted shares of common stock of the Company into shares

Name

 

Common Shares Exchanged

 

 

Series B

Issued

 

Jaynes Investment LLC

 

 

2,000,000

 

 

 

200,000

 

ACT Holdings LLC

 

 

7,312,612

 

 

 

731,262

 

LASB Family Trust

 

 

3,800,112

 

 

 

380,012

 

Jesse Michael Jaynes

 

 

4,767,611

 

 

 

476,762

 

Bradley White

 

 

1,225,000

 

 

 

122,500

 

 PJ Advisory Group 

 

 

1,500,000

 

 

 

150,000

 

 Total   

 

 

20,605,334

 

 

 

2,060,536

 

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
ORGANIZATION AND BASIS OF PRESENTATION    
Accumulated deficit $ (16,288,417) $ (11,801,828)
Net loss (4,486,589)  
Net cash used in opearting activitites $ (553,236) $ (663,203)
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES    
Research and development expenses $ 246,480 $ 226,448
Potential additional dilutive securities outstanding 300,000 $ 0
Amount in excess of FDIC insured limit $ 46,385  
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.23.1
BORROWINGS (Details)
9 Months Ended
Sep. 30, 2022
USD ($)
shares
Number of shares the notesis convertible into shares | shares 1,060,000
Loan Balance $ 1,352,000
Debt discount (210,779)
Total loan $ 1,141,221
Noteholder A [Member]  
Number of shares the notesis convertible into shares | shares 0
Loan Balance $ 217,000
Origination 2019
Maturity date Dec. 31, 2021
Interest rate 0.00%
Noteholder B [Member]  
Number of shares the notesis convertible into shares | shares 0
Loan Balance $ 450,000
Origination 3/19/2019
Maturity date Apr. 29, 2019
Interest rate 0.00%
Noteholder C [Member]  
Number of shares the notesis convertible into shares | shares 0
Loan Balance $ 32,500
Origination 3/1/2019
Maturity date Feb. 29, 2020
Interest rate 18.00%
Noteholder D [Member]  
Number of shares the notesis convertible into shares | shares 30,000
Loan Balance $ 300,000
Origination 4/29/2019
Interest rate 0.00%
Noteholder E [Member]  
Number of shares the notesis convertible into shares | shares 0
Loan Balance $ 37,500
Origination 8/1/2019
Maturity date Aug. 31, 2019
Interest rate 0.00%
Noteholder F [Member]  
Number of shares the notesis convertible into shares | shares 5,000
Loan Balance $ 2,500
Origination 2/27/2020
Maturity date Apr. 30, 2020
Interest rate 0.00%
Noteholder G [Member]  
Number of shares the notesis convertible into shares | shares 25,000
Loan Balance $ 12,500
Origination 8/3/2021
Maturity date Aug. 03, 2023
Interest rate 10.00%
Noteholder H [Member]  
Number of shares the notesis convertible into shares | shares 1,000,000
Loan Balance $ 300,000
Origination 6/27/2022
Maturity date Jun. 27, 2024
Interest rate 5.00%
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.23.1
BORROWINGS (Details 1)
Sep. 30, 2022
USD ($)
BORROWINGS  
2023 $ 12,500
2024 $ 300,000
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.23.1
BORROWINGS (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
Apr. 09, 2020
Aug. 22, 2020
Sep. 30, 2022
Dec. 31, 2021
Principal amount     $ 989,000  
Interest amount     $ 146,946  
Debt conversion common shares     2,316,147  
Loss on debt settelment     $ 5,000  
Interest expense     141,117 $ 222,792
Late fees     $ 90,000 120,000
Patent [Member]        
Cost of intangible asset   $ 264,828    
Note payable written off       150,000
Agromed LLC [Member]        
Consideration amount   $ 150,000    
Stock issued for acquisition   230,000    
Stock issued for acquisition, value   $ 114,828    
Loss on fail to acquisition       $ 114,828
Paycheck Protection Program [Member]        
Principal amount $ 48,750      
Interest rate 1.00%      
Noteholder B [Member]        
Interest rate     0.00%  
Penalty amount receive each month     $ 10,000  
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 08, 2022
Aug. 10, 2022
May 12, 2022
Jan. 14, 2021
Jan. 04, 2021
Oct. 19, 2022
Jul. 31, 2022
May 27, 2022
Apr. 21, 2022
Feb. 28, 2022
Dec. 31, 2021
Sep. 30, 2022
Dec. 31, 2021
Sep. 13, 2022
Aug. 16, 2022
Jun. 30, 2022
Apr. 30, 2022
Mar. 08, 2022
Feb. 18, 2022
Dec. 31, 2019
Common stock, shares authorized                     300,000,000 300,000,000 300,000,000              
Common stock, shares par value                     $ 0.001 $ 0.001 $ 0.001              
Common stock share issued to individual                 569                      
Common stock share issued price to individual                 $ 0.50                      
Common stock share issued value to individual                 $ 285                      
Number of common stock cancel                 18,144,112                      
Number of common stock return                               1,855,888        
Common stock share issued                     26,025,020 38,678,155 26,025,020              
Common stock value                     $ 26,025 $ 38,678 $ 26,025              
Stock compensation       $ 1,073,388               $ 3,512,500 $ 2,222,961              
Preferred stock, shares authorized                     20,000,000 20,000,000 20,000,000              
Preferred stock, shares issue                     0 9 0              
Preferred stock, shares outstanding                     0 9 0              
Preferred stock, shares par value                     $ 0.001 $ 0.001 $ 0.001              
Bradley White [Member]                                        
Preferred stock, shares issue                             3          
Clayton Yates [Member]                                        
Preferred stock, shares issue                             3          
Jesse Jaynes [Member]                                        
Preferred stock, shares issue                             3          
Investor [Member]                                        
Common stock share issued                       975,000                
Nexion Contractor [Member]                                        
Common stock share issued to individual 100,000                                      
Series B Preferred Stock [Member]                                        
Designation authorized shares           2,500,000                            
Conversion share description           Each share of Series B is convertible into 10 shares of common stock of the Company                            
Number of votes           Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company                            
Series A, Preferred Stock                                        
Designation authorized shares   10                                    
Conversion share description   Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock                                    
Number of votes   Each share of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation                                    
Stock Issued for Cash [Member]                                        
Proceed from common stock issue     $ 25,000             $ 140,000 $ 570,005                  
Common stock share issued     25,000       50,000     280,000 1,475,020   1,475,020              
Common stock price     $ 1.00             $ 0.50                    
Stock Issued for Cash [Member] | Investor [Member]                                        
Common stock share issued             975,000                          
Stock Issued for Cash [Member] | Maximum [Member]                                        
Common stock price                     $ 0.50   $ 0.50              
Stock Issued for Cash [Member] | Minimum [Member]                                        
Common stock price                     $ 0.40   $ 0.40              
Stock Options And Warrants [Member]                                        
Exercise price         $ 0.0001                              
Common stock share issued                                       10,000
Common stock price         $ 0.50                             $ 1.00
Consulting agreement description         As part of the agreement, 600,000 option shares were issued at signing. An additional 100,000 option shares are earned monthly through August 2021. Although the IPO is still pending, since the Company sold warrants at $.50 during 2020, these options were valued at $.50. On December 20, 2021, the consultant elected to convert all 1,400,000 option shares into 1,400,000 shares of common stock                              
Risk-free interest rate         0.10%                              
Expected volatility         500.00%                              
Share Issue For Services [Member]                                        
Common stock share issued               500,000     2,650,000 751,500 2,650,000 170,000     5,000 6,000,000 20,000  
Common stock value                     $ 1,325,323 $ 325,750 $ 1,325,323         $ 3,000,000 $ 10,000  
Shares issued to a debt                                     5,000  
Interest expense capitalized into notes payable                       2,500                
Stock compensation               $ 500,000       2,500                
Transfer And Agreement [Member]                                        
Common stock share issued to individual             99,600                          
Stock value price                       $ 99,600                
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.23.1
FEDERAL INCOME TAX (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
FEDERAL INCOME TAX    
Tax expense (benefit) at the statutory rate $ (204,559) $ (255,478)
State income taxes, net of federal income tax benefit (25,326) (31,631)
Change in valuation allowance 229,885 287,109
Total $ 0 $ 0
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.23.1
FEDERAL INCOME TAX (Details 1) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
FEDERAL INCOME TAX    
Net operating loss carryforwards $ 2,572,885 $ 2,343,000
Total gross deferred tax assets 2,572,885 2,343,000
Valuation allowance (2,572,885) (2,343,000)
Deferred tax asset $ 0 $ 0
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.23.1
FEDERAL INCOME TAX (Details Narrative) - USD ($)
9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
FEDERAL INCOME TAX    
Federal tax statutory rate 21.00%  
Net operating loss carry forwards $ 2,572,885 $ 2,343,000
Valuation allowance for net deferred tax assets $ 2,572,885 $ 2,343,000
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
Jan. 14, 2021
Jul. 24, 2020
Sep. 30, 2022
Dec. 31, 2021
Sep. 30, 2021
Assets held in trust     $ 19,705 $ 19,705  
Rent expense     30,240 20,094 $ 2,810
Stock compensation $ 1,073,388   $ 3,512,500 $ 2,222,961  
Common stock share issued     38,678,155 26,025,020  
Research And Development Agreement Fund [Member]          
Fund Amount     $ 246,400 $ 243,400  
Investor [Member]          
Common stock share issued     975,000    
Consulting Agreements [Member] | Consultant [Member]          
Accrued payroll     $ 0 202,500  
Monthly compensation   $ 20,000      
Amount paid to consultant     $ 144,975 $ 47,500  
Share issued to consultant     751,500 500,000  
Share issued to consultant, value     $ 325,750 $ 250,000  
Consulting Agreements [Member] | CEO [Member]          
Related party payable     103,605 39,966  
Annual salary     150,000    
Accrued payroll     $ 188,484 $ 186,034  
Consulting Agreements One [Member]          
Share issued for compensation 1,700,000        
Consulting Agreements Two [Member]          
Share issued for compensation 450,000        
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Mar. 08, 2022
Due To Related Party $ 3,846 $ 0        
Common stock share issued 38,678,155 26,025,020        
Common Stock, value $ 38,678 $ 26,025        
Board of Directors            
Common Stock, Shares Par Value     $ 0.50      
Common stock share issued     11,137,833     2,000,000
Total of shares issued           6,000,000
Common Stock, value     $ 5,560,567     $ 3,000,000
CEO [Member]            
Due To Related Party 21,900 16,925        
Advanced recived       $ 5,000    
Repaid To Related Party   991        
Receivables from Related Parties            
Advanced recived     3,000      
Repaid To Related Party 2,000 2,000 $ 5,000      
Receivables from Related Parties | Former CEO            
Due To Related Party $ 3,846 0        
Expenses paid         $ 3,846  
Paid of accrued expenses   $ 13,500        
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.23.1
MERGER WITH OLD GENVOR (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Common Stock, Shares Outstanding 38,678,155 26,025,020
Common stock share issued 38,678,155 26,025,020
Additional paid-in capital $ 14,608,815 $ 9,538,772
Genvor Inc [Member]    
Common Stock, Shares Outstanding 1,855,888  
Common stock share issued 35,261,871  
Cash Payment For Acquisation $ 140,000 $ 10,000
Ownership Of Shareholders, Percentage 5.00%  
Additional paid-in capital $ 150,000  
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS (Details) - shares
1 Months Ended 9 Months Ended
Oct. 19, 2022
Sep. 30, 2022
Common share exchange   2,316,147
Subsequent Event [Member]    
Common share exchange 20,605,334  
Series B issued 2,060,536  
Jaynes Investment LLC [Member] | Subsequent Event [Member]    
Common share exchange 2,000,000  
Series B issued 200,000  
ACT Holdings LLC [Member] | Subsequent Event [Member]    
Common share exchange 7,312,612  
Series B issued 731,262  
LASB Family Trust [Member] | Subsequent Event [Member]    
Common share exchange 3,800,112  
Series B issued 380,012  
Jesse Michael Jaynes [Member] | Subsequent Event [Member]    
Common share exchange 4,767,611  
Series B issued 476,762  
Bradley White [Member] | Subsequent Event [Member]    
Common share exchange 1,225,000  
Series B issued 122,500  
PJ Advisory Group [Member] | Subsequent Event [Member]    
Common share exchange 1,500,000  
Series B issued 150,000  
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]
1 Months Ended
Oct. 19, 2022
shares
Designation authorized shares 2,500,000
Description of voting rights Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company
XML 47 genvor_10k_htm.xml IDEA: XBRL DOCUMENT 0001792941 2022-01-01 2022-09-30 0001792941 us-gaap:SubsequentEventMember 2022-10-19 0001792941 genvor:PJAdvisoryGroupMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-19 0001792941 genvor:BradleyWhiteMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-19 0001792941 genvor:JesseMichaelJaynesMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-19 0001792941 genvor:LASBFamilyTrustMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-19 0001792941 genvor:ACTHoldingsLLCMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-19 0001792941 genvor:JaynesInvestmentLLCMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-19 0001792941 us-gaap:SubsequentEventMember 2022-10-01 2022-10-19 0001792941 genvor:GenvorIncMember 2022-01-01 2022-09-30 0001792941 genvor:GenvorIncMember 2021-01-01 2021-12-31 0001792941 genvor:GenvorIncMember 2022-09-30 0001792941 srt:DirectorMember 2022-03-08 0001792941 srt:DirectorMember 2020-12-31 0001792941 genvor:ReceivablesFromRelatedPartiesMember genvor:FormerCEOMember 2021-01-01 2021-12-31 0001792941 genvor:ReceivablesFromRelatedPartiesMember genvor:FormerCEOMember 2018-01-01 2018-12-31 0001792941 genvor:ReceivablesFromRelatedPartiesMember 2022-01-01 2022-09-30 0001792941 genvor:ReceivablesFromRelatedPartiesMember 2021-01-01 2021-12-31 0001792941 genvor:CeoMember 2021-01-01 2021-12-31 0001792941 genvor:ReceivablesFromRelatedPartiesMember 2020-01-01 2020-12-31 0001792941 genvor:CeoMember 2019-01-01 2019-12-31 0001792941 genvor:ReceivablesFromRelatedPartiesMember genvor:FormerCEOMember 2021-12-31 0001792941 genvor:ReceivablesFromRelatedPartiesMember genvor:FormerCEOMember 2022-09-30 0001792941 genvor:CeoMember 2021-12-31 0001792941 genvor:CeoMember 2022-09-30 0001792941 genvor:ResearchAndDevelopmentAgreementFundMember 2021-12-31 0001792941 genvor:ResearchAndDevelopmentAgreementFundMember 2022-09-30 0001792941 us-gaap:InvestorMember 2022-09-30 0001792941 genvor:ConsultingAgreementsMember genvor:ConsultantMember 2021-01-01 2021-12-31 0001792941 genvor:ConsultingAgreementsMember genvor:ConsultantMember 2022-01-01 2022-09-30 0001792941 genvor:ConsultingAgreementsMember genvor:ConsultantMember 2020-07-01 2020-07-24 0001792941 genvor:ConsultingAgreementsMember genvor:ConsultantMember 2021-12-31 0001792941 genvor:ConsultingAgreementsMember genvor:ConsultantMember 2022-09-30 0001792941 genvor:ConsultingAgreementsMember srt:ChiefExecutiveOfficerMember 2021-12-31 0001792941 genvor:ConsultingAgreementsMember srt:ChiefExecutiveOfficerMember 2022-09-30 0001792941 genvor:ConsultingAgreementsMember srt:ChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0001792941 genvor:ConsultingAgreementsMember srt:ChiefExecutiveOfficerMember 2022-01-01 2022-09-30 0001792941 genvor:ConsultingAgreementsOneMember 2021-01-01 2021-01-14 0001792941 genvor:ConsultingAgreementsTwoMember 2021-01-01 2021-01-14 0001792941 2021-01-01 2021-01-14 0001792941 2020-10-01 2021-09-30 0001792941 us-gaap:InvestorMember genvor:StockIssueForCashMember 2022-07-31 0001792941 genvor:JesseJaynesMember 2022-08-16 0001792941 genvor:ClaytonYatesMember 2022-08-16 0001792941 genvor:BradleyWhiteMember 2022-08-16 0001792941 genvor:StockOptionsAndWarrantsMember 2021-01-01 2021-01-04 0001792941 genvor:StockOptionsAndWarrantsMember 2019-12-31 0001792941 srt:MinimumMember genvor:StockIssueForCashMember 2021-12-31 0001792941 genvor:StockIssueForCashMember 2022-07-31 0001792941 genvor:StockIssueForCashMember 2022-05-01 2022-05-12 0001792941 genvor:StockIssueForCashMember 2022-05-12 0001792941 genvor:StockIssueForCashMember 2022-01-01 2022-02-28 0001792941 genvor:StockIssueForCashMember 2022-02-28 0001792941 srt:MaximumMember genvor:StockIssueForCashMember 2021-12-31 0001792941 genvor:StockIssueForCashMember 2021-12-31 0001792941 genvor:ShareIssueForServicesMember 2022-09-13 0001792941 genvor:ShareIssueForServicesMember 2022-05-01 2022-05-27 0001792941 genvor:ShareIssueForServicesMember 2022-05-27 0001792941 genvor:ShareIssueForServicesMember 2022-04-30 0001792941 genvor:ShareIssueForServicesMember 2022-03-08 0001792941 genvor:ShareIssueForServicesMember 2022-01-01 2022-09-30 0001792941 genvor:ShareIssueForServicesMember 2022-02-18 0001792941 genvor:ShareIssueForServicesMember 2021-12-31 0001792941 genvor:ShareIssueForServicesMember 2022-09-30 0001792941 genvor:NexionContractorMember 2022-09-01 2022-09-08 0001792941 genvor:TransferAndAgreementMember 2022-01-01 2022-09-30 0001792941 genvor:TransferAndAgreementMember 2022-07-01 2022-07-31 0001792941 2022-06-30 0001792941 2022-04-21 0001792941 2022-04-01 2022-04-21 0001792941 genvor:StockIssueForCashMember 2021-10-01 2021-12-31 0001792941 genvor:StockOptionsAndWarrantsMember 2021-01-04 0001792941 us-gaap:SeriesBPreferredStockMember 2022-10-01 2022-10-19 0001792941 us-gaap:SeriesAPreferredStockMember 2022-08-10 0001792941 us-gaap:SeriesAPreferredStockMember 2022-08-02 2022-08-10 0001792941 us-gaap:SeriesBPreferredStockMember 2022-10-19 0001792941 us-gaap:PatentsMember 2021-01-01 2021-12-31 0001792941 us-gaap:PatentsMember 2020-08-22 0001792941 genvor:AgromedLCMember 2021-01-01 2021-12-31 0001792941 genvor:AgromedLCMember 2020-08-01 2020-08-22 0001792941 genvor:AgromedLCMember 2020-08-22 0001792941 genvor:PaycheckProtectionProgramMember 2020-04-01 2020-04-09 0001792941 genvor:PaycheckProtectionProgramMember 2020-04-09 0001792941 genvor:NoteholderHMember 2022-01-01 2022-09-30 0001792941 genvor:NoteholderHMember 2022-09-30 0001792941 genvor:NoteholderGMember 2022-01-01 2022-09-30 0001792941 genvor:NoteholderGMember 2022-09-30 0001792941 genvor:NoteholderFMember 2022-01-01 2022-09-30 0001792941 genvor:NoteholderFMember 2022-09-30 0001792941 genvor:NoteholderEMember 2022-01-01 2022-09-30 0001792941 genvor:NoteholderEMember 2022-09-30 0001792941 genvor:NoteholderDMember 2022-01-01 2022-09-30 0001792941 genvor:NoteholderDMember 2022-09-30 0001792941 genvor:NoteholderCMember 2022-01-01 2022-09-30 0001792941 genvor:NoteholderCMember 2022-09-30 0001792941 genvor:NoteholderBMember 2022-01-01 2022-09-30 0001792941 genvor:NoteholderBMember 2022-09-30 0001792941 genvor:NoteholderAMember 2022-01-01 2022-09-30 0001792941 genvor:NoteholderAMember 2022-09-30 0001792941 us-gaap:RetainedEarningsMember 2022-09-30 0001792941 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001792941 us-gaap:CommonStockMember 2022-09-30 0001792941 genvor:PreferredStockSeriesAMember 2022-09-30 0001792941 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001792941 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001792941 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001792941 genvor:PreferredStockSeriesAMember 2022-01-01 2022-09-30 0001792941 us-gaap:RetainedEarningsMember 2021-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001792941 us-gaap:CommonStockMember 2021-12-31 0001792941 genvor:PreferredStockSeriesAMember 2021-12-31 0001792941 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001792941 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001792941 genvor:PreferredStockSeriesAMember 2021-01-01 2021-12-31 0001792941 2020-12-31 0001792941 us-gaap:RetainedEarningsMember 2020-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001792941 us-gaap:CommonStockMember 2020-12-31 0001792941 genvor:PreferredStockSeriesAMember 2020-12-31 0001792941 2021-01-01 2021-12-31 0001792941 2021-12-31 0001792941 2022-09-30 0001792941 2023-03-24 0001792941 2022-03-31 iso4217:USD shares iso4217:USD shares pure 0001792941 false --09-30 FY 2022 0 0.001 20000000 0 9 0.001 300000000 38678155 26025020 0 0 0 0 0.0001 19705 0 0 2000 0.50 10-K true 2022-09-30 false 333-234815 GENVOR INCORPORATED NV 83-2054746 13155 Noel Road Suite 900 Dallas TX 75240 214 427-1921 No Yes No Yes Non-accelerated Filer true true false false 18122821 76 Turner, Stone & Company, L.L.P. Dallas, Texas 296385 384621 0 1331 0 150000 2000 0 298385 535952 17565 18939 0 2053 315951 556944 1052000 1632250 516658 571158 3846 0 48750 0 246400 246400 1867654 2449808 89221 0 0 344167 89221 344167 1956875 2793975 0 0 0.001 20000000 9 0 0 0 0.001 300000000 38678155 26025020 38678 26025 14608815 9538772 -16288417 -11801828 -1640924 -2237031 315951 556944 0 0 233153 89640 120725 390000 246480 226448 3512500 2222961 1374 1832 196129 171023 4310361 3101904 -4310361 -3101904 -51117 -102792 -90000 -120000 -30111 0 0 -114828 -5000 0 176228 337620 -4486589 -3439524 -0.14 -0.15 32437505 22493382 0 20000000 2000 6773677 -8333278 -1557601 0 18000 -21846 -29026 -32872 0 20000000 20000 6751831 -8362304 -1590473 0 3150000 3150 1519863 0 1523012 0 1400000 1400 -1400 0 0 1475020 1475 568530 570005 0 0 699948 0 699948 0 0 0 -3439524 -3439524 0 26025020 26025 9538772 -11801828 -2237031 0 6525000 6525 3505975 0 3512500 0 305000 305 164970 0 165275 0 2622647 2622 1232933 0 1235555 0 1855888 1856 -1856 0 0 0 0 -150000 0 -150000 0 975000 975 48750 0 49725 0 99600 100 -100 0 0 0 50000 50 -50 0 0 0 50000 50 -50 0 0 0 0 269916 0 269916 0 170000 170 -170 9 0 0 0 0 0 0 0 0 -4486589 -4486589 9 0 38678155 38678 14608815 -16288417 -1640924 -4486589 -3439524 1374 1832 0 10000 90000 120000 0 -114828 3512500 2222961 -30111 0 0 11667 -5000 0 -1331 1331 150000 -100000 2000 0 -2053 0 139138 323564 -3846 0 0 72800 -553236 -663203 300000 365000 0 6000 0 25579 165000 570005 0 -3575 465000 899851 -88236 236648 384621 147973 296385 384621 0 0 0 0 269916 35000 0 13480 1235555 0 49725 0 170000 0 150000 0 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Company Background</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 27, 2022, Genvor Incorporated, formerly known as Allure Worldwide, Inc. (the “Company” or “Genvor” or “we”), a Nevada corporation, Genvor Acquisition, Corp., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Genvor Inc., a Delaware corporation (“Old Genvor”), completed their previously announced merger transaction pursuant to which the Company acquired Old Genvor (the “Acquisition”), and Old Genvor became a wholly-owned subsidiary of the Company. The Acquisition was completed pursuant to an Exchange Agreement, dated as of January 11, 2021 (the “Acquisition Agreement”), pursuant to which Old Genvor was to be acquired by the Company as its wholly owned subsidiary and each share of Old Genvor common stock would be exchanged for a share of the Company’s common stock, and a merger agreement, dated March 2, 2022 (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger, and each share of Old Genvor being converted into the right to receive a share of the Company (the “Merger”). After closing of the Merger, the Company was renamed “Genvor Incorporated”. Genvor develops plant-based defense technology designed to help farmers achieve global food security.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During May 2019, Old Genvor acquired Nexion Biosciences LLC (“NBLLC”) from a founder for nominal consideration as a wholly owned subsidiary. NBLLC was formed in the state of Delaware on December 28, 2018. The consolidated financial statements of the Company include the accounts of Genvor Incorporated, Old Genvor, and its wholly owned subsidiary NBLLC. Intercompany accounts and transactions have been eliminated upon consolidation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Nature of Operations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s business plan is developing plant-based defense technology designed to help farmers achieve global food security. The Company’s technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Basis of Presentation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and has a year-end of September 30. The wholly owned subsidiary has a year-end of December 31.  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Due to the different fiscal year-ends, the consolidated financial statements will reflect the balance sheets and the statements of changes in stockholders’ deficit dates of September 30, 2022, and December 31, 2021, whereas the statements of operations and statements of cash flows are for the nine months ended September 30, 2022, and the year ended December 31, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Principles of Consolidation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in the consolidation. The consolidated financial statements included herein, presented in accordance with United States generally accepted accounting principles (“GAAP”) and stated in United States dollars, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Liquidity and Going Concern</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At September 30, 2022, the Company had an accumulated deficit of $16,288,417. For the nine months ended September 30, 2022, the Company recognized a net loss of $4,486,589 and had net cash used in operating activities of $553,236, with no revenues earned, and limited operational history. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">While the Company is currently developing its products and technologies, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of additional public and/or private offerings of its stock. Management believes that the actions presently being taken to further implement its business plan, develop its products and technologies, and generate revenues should provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds in the future, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate cash flows from financing activities or operating activities. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> -16288417 -4486589 -553236 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Use of Estimates</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cash Flow Reporting</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows Accounting Standards Codification (“ASC 230”), <em>Statement of Cash Flows</em>, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“indirect method”) as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cash </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash is comprised of cash balances. Cash is held at major financial institutions and is subject to credit risk to the extent that those balances exceed applicable Federal Deposit Insurance Corporation (“FDIC”) insurance amounts of $250,000. From time to time, the Company has certain cash balances, including restricted cash, that may exceed insured limits. The Company utilizes large banking institutions that are reputable therefore mitigating the risks.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. At September 30, 2022, $46,385 of the Company’s cash balances were in excess of federally insured limits.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Fixed Assets</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Furniture and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately seven years. Expenditures for minor enhancements and maintenance are expensed as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Stock-Based Compensation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, <em>Compensation – Stock Compensation, and Certain Redeemable Financial Instruments</em>. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Fair Value of Financial Instruments</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature of these instruments. The fair value hierarchy under GAAP distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>The hierarchy consists of three levels</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">●</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level one — Quoted market prices in active markets for identical assets or liabilities;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">●</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level two — Inputs other than level one inputs that are either directly or indirectly observable; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">●</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Determining which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures each quarter.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Long-lived Assets</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s long-lived assets and other assets (consisting of furniture, equipment and a patent) are reviewed for impairment in accordance with the guidance of the ASC 360, <em>Property, Plant, and Equipment</em>, and ASC 205, <em>Presentation of Financial Statements</em>. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company had not experienced impairment losses on its long-lived assets. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Research and Development</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional service costs associated with the development of the plant-based defense technology products.  For the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company had $246,480 and $226,448 in research and development expenses, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Patents</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Any patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative expenses in the statement of operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Purchased patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360, <em>Property, Plant, and Equipment</em>, and ASC 205, <em>Presentation of Financial Statements</em>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Income Taxes</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for income taxes in accordance with FASB ASC 740, <em>Income Taxes</em>. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of September 30, 2022. Interest and penalties in any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the nine months ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Stock-Based Compensation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company measures compensation cost for all employee stock-based awards at their fair values on the date of grant. Stock-based awards issued to non-employees are measured at their fair values on the date of grant and are re-measured at each reporting period through their vesting dates, as applicable. The fair value of stock-based awards is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Loss Per Share of Common Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (“EPS”) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. The Company had total potential additional dilutive securities outstanding at September 30, 2022 and December 31, 2021 of $300,000 and $0, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recent Accounting Pronouncements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2020, the FASB issued ASU 2020-06, <em>Debt with Conversion and Other Options</em>, which simplifies accounting for convertible instruments. The new guidance eliminates two of the three models in ASC 470-20 that require separating embedded conversion features from convertible instruments. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share calculation. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Recently Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows Accounting Standards Codification (“ASC 230”), <em>Statement of Cash Flows</em>, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“indirect method”) as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash is comprised of cash balances. Cash is held at major financial institutions and is subject to credit risk to the extent that those balances exceed applicable Federal Deposit Insurance Corporation (“FDIC”) insurance amounts of $250,000. From time to time, the Company has certain cash balances, including restricted cash, that may exceed insured limits. The Company utilizes large banking institutions that are reputable therefore mitigating the risks.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. At September 30, 2022, $46,385 of the Company’s cash balances were in excess of federally insured limits.</p> 46385 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Furniture and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately seven years. Expenditures for minor enhancements and maintenance are expensed as incurred.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, <em>Compensation – Stock Compensation, and Certain Redeemable Financial Instruments</em>. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature of these instruments. The fair value hierarchy under GAAP distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>The hierarchy consists of three levels</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">●</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level one — Quoted market prices in active markets for identical assets or liabilities;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">●</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level two — Inputs other than level one inputs that are either directly or indirectly observable; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">●</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Determining which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures each quarter.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s long-lived assets and other assets (consisting of furniture, equipment and a patent) are reviewed for impairment in accordance with the guidance of the ASC 360, <em>Property, Plant, and Equipment</em>, and ASC 205, <em>Presentation of Financial Statements</em>. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company had not experienced impairment losses on its long-lived assets. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional service costs associated with the development of the plant-based defense technology products.  For the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company had $246,480 and $226,448 in research and development expenses, respectively.</p> 246480 226448 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Any patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative expenses in the statement of operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Purchased patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360, <em>Property, Plant, and Equipment</em>, and ASC 205, <em>Presentation of Financial Statements</em>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for income taxes in accordance with FASB ASC 740, <em>Income Taxes</em>. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of September 30, 2022. Interest and penalties in any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the nine months ended September 30, 2022.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company measures compensation cost for all employee stock-based awards at their fair values on the date of grant. Stock-based awards issued to non-employees are measured at their fair values on the date of grant and are re-measured at each reporting period through their vesting dates, as applicable. The fair value of stock-based awards is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (“EPS”) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. The Company had total potential additional dilutive securities outstanding at September 30, 2022 and December 31, 2021 of $300,000 and $0, respectively.</p> 300000 0 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2020, the FASB issued ASU 2020-06, <em>Debt with Conversion and Other Options</em>, which simplifies accounting for convertible instruments. The new guidance eliminates two of the three models in ASC 470-20 that require separating embedded conversion features from convertible instruments. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share calculation. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Recently Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 3 – BORROWINGS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Commercial Loan</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 9, 2020, the Company received a loan from the Small Business Administration pursuant to the Paycheck Protection Program (PPP) in the principal amount of $48,750. The note bears interest at a variable rate of approximately 1% and matured in April 2022; and it is currently in default. Forgiveness for the loan was applied for and is pending. The principal amount of the loan was based on the consulting agreement salary between Nexion Biosciences, Inc., organized in the state of Florida (NBFL) (a related party) and the CEO. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Payable for Patent</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 22, 2020, the Company’s subsidiary, Genvor Inc., completed an acquisition of Agromed LLC (“Agromed”) in a transaction accounted for under the asset purchase method of accounting, whereby the assets acquired and the liabilities, if any assumed, are to be valued at fair value, and compared to the fair value of the consideration given to identify if there are any identifiable intangible assets to be recognized as a result of the transaction. Based on ASC 805, the Company first performed a screen test; determining that substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset. Agromed only held one patent and two applications for patents and had no sales, employees, or customers as of the acquisition date. Accordingly, the assets acquired are not considered a business and the recorded cost of the acquisition was based upon the fair value of the assets acquired. As consideration for Agromed, the Company was to pay $150,000 by March 31, 2021, and issue 230,000 shares of the Company’s common stock, which shares were issued and valued at $114,828. Accordingly, the patent was recorded at $264,828 on the date of acquisition. Subsequently, it was discovered that the patent had been transferred to another party prior to August 2020. Such transfer had not been recorded with the United States Patent and Trademark Office and therefore neither the Company nor the seller were aware of the seller at the time of the acquisition. As a result, the Company is no longer honoring the agreement to pay $150,000 but decided to let the seller retain the shares. The $150,000 note payable was written off along with the patent during the year ended December 31, 2021, resulting in a loss on the failed acquisition of $114,828 for the year ended December 31, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Notes Payable</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time to time, the Company’s subsidiary, Genvor Inc., enters into unsecured notes payable with individual investors. Only Noteholder E (below) has security in the form of a personal guarantee by the CEO and prior consultant (Note 6). The terms of these notes are listed below. Several of the notes are convertible into shares of the Company’s common stock as detailed in the following schedule.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Balance</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Convertible</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Interest</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong> Loan </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>into</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Noteholder</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Origination</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Maturity</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Rate</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong> Balance </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares (c)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder A (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">12/31/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder B (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">3/19/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4/29/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder C (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">3/1/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2/29/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder D (d)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4/29/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">unspecified</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder E (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8/1/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8/31/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder F (a)(b)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2/27/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4/30/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder G</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8/3/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8/3/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder H (e)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">6/27/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">6/27/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,000,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,352,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,060,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(d) Debt discount</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(210,779</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,141,221</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="17" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(a) Past due at September 30, 2022</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="17" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(b) Note is payable in a combination of $2,500 to $6,000 in cash and 5,000 to 15,000 share of common stock</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="17" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(c) Convertible into common stock of the subsidiary, Genvor Inc.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="17" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(d) Debt discount</p></td></tr><tr style="height:15px"><td colspan="17"><p style="font-size:10pt;font-family:times new roman;margin:0px">(e) Noteholder is a shareholder of the Company.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The notes do not have default provisions except Noteholder B receives a default penalty of $10,000 each month the note goes unpaid.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2022, $989,000 principal and $146,946 interest was converted into 2,316,147 common stock shares of the Company. One note holder had a change in settlement terms, resulting in the recognition of $5,000 loss on debt settlement in the accompanying statement of operations for the nine months ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Future maturities of the notes payable are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Interest expense totaled $141,117 and $222,792, respectively, for the nine months ended September 30, 2022, and the year ended December 31, 2021, including default penalties. Late fees totaled $90,000 and $120,000, respectively, for the nine months ended September 30, 2022, and the year ended December 31, 2021.</p> 48750 0.01 150000 230000 114828 264828 150000 114828 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Balance</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Convertible</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Interest</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong> Loan </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>into</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Noteholder</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Origination</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Maturity</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Rate</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong> Balance </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares (c)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder A (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">12/31/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder B (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">3/19/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4/29/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder C (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">3/1/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2/29/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder D (d)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4/29/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">unspecified</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder E (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8/1/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8/31/2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder F (a)(b)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2/27/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4/30/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder G</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8/3/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8/3/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Noteholder H (e)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">6/27/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">6/27/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,000,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,352,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,060,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(d) Debt discount</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(210,779</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,141,221</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="17" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(a) Past due at September 30, 2022</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="17" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(b) Note is payable in a combination of $2,500 to $6,000 in cash and 5,000 to 15,000 share of common stock</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="17" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(c) Convertible into common stock of the subsidiary, Genvor Inc.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="17" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(d) Debt discount</p></td></tr><tr style="height:15px"><td colspan="17"><p style="font-size:10pt;font-family:times new roman;margin:0px">(e) Noteholder is a shareholder of the Company.</p></td></tr></tbody></table> 2019 2021-12-31 0 217000 3/19/2019 2019-04-29 0 450000 3/1/2019 2020-02-29 0.18 32500 4/29/2019 0 300000 30000 8/1/2019 2019-08-31 0 37500 2/27/2020 2020-04-30 0 2500 5000 8/3/2021 2023-08-03 0.10 12500 25000 6/27/2022 2024-06-27 0.05 300000 1000000 1352000 1060000 210779 1141221 10000 989000 146946 2316147 5000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 12500 300000 141117 222792 90000 120000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 4 – STOCKHOLDERS’ DEFICIT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Preferred Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The authorized preferred stock of the Company consists of 20,000,000 shares with a $0.001 par value. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 10, 2022, the Company designated 10 shares of its preferred stock as Series A Preferred Stock (“Series A”). Each share of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation. When and as any dividend or distribution is declared or paid by the Company on the common stock, the Series A holders are entitled to participate in such dividend or distribution. Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock. Upon any liquidation, dissolution, or winding-up of the Company, the Series A holders are entitled to receive out the assets of the Company, for each share of Series A, an amount equal to par value before any distribution or payment shall be made to the holder of any junior securities (including common stock and all other equity or equity equivalent securities of the Company).  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2022, and December 31, 2021, there were 9 and 0 shares of preferred stock issued and outstanding, respectively.  The preferred stock was issued on August 16, 2022, as follows: Bradley White (Chief Executive Officer), 3 shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 7.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B Preferred Stock (“Series B”).  The designation authorized 2,500,000 shares of Series B.  Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company. See Note 10.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The authorized common stock of the Company consists of 300,000,000 shares with a $0.001 par value. All common stock shares are non-assessable and have one vote per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 21, 2022, the Company issued 569 shares of common stock to an individual under a transfer and exchange agreement for a note receivable held in NBFL (see Note 3). At the transfer date, the latest sale of common stock was at $0.50, accordingly the shares were valued at $285, and the note was written off since NBFL has since dissolved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the Merger (see Notes 1 and 8), the founding shareholders of the Company cancelled 18,144,112 shares of common stock, retaining 5%, or 1,855,888 shares of common stock, as of June 30, 2022. The cancellation is presented in the accompanying statements of changes in stockholders’ deficit within the line item “Retroactive application of recapitalization.” </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During July 2022, the Company entered into a transfer and exchange agreement with an individual to issue 99,600 shares of common stock for the note receivable held in NBFL. Since NBFL has minimal assets and was dissolved during the year ended December 31, 2019, the note receivable was immediately written-off. Based on the latest SPA price per share, the stock was valued at $1.00 per share, or $99,600.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 8, 2022, the Company issued 100,000 shares of common stock to a prior Nexion contractor.  This was in regard to a claim against the predecessor management and the Company opted as a settlement to issue the common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Shares Issued for Services</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company issued 751,500 and 2,650,000 shares of common stock, respectively, for business advisory services received, valued at $325,750 and $1,325,323, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 18, 2022, the Company issued 20,000 shares of common stock, valued at $10,000 (based on the latest third-party sale of common stock) to an investor for stock compensation. Additionally, 5,000 shares were issued to a debt holder as incentive, valued at $2,500 (based on the latest third-party sale of common stock), recorded in interest expense in the accompanying consolidated statement of operations for the nine months ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 8, 2022, the Company issued 2,000,000 shares of common stock to each of its three directors, for a total of 6,000,000 shares issued valued at $3,000,000 (based on the latest third-party sale of common stock). The issuances are recorded in stock compensation in the accompanying consolidated statement of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During April 2022, the Company issued 5,000 shares of common stock to a consultant valued at $2,500 and recorded in stock compensation in the accompanying consolidated statement of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 27, 2022, the Company issued 500,000 shares of common stock for consulting services. Based on the latest third-party sale of common stock, this resulted in $500,000 stock-based compensation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 13, 2022, the Company issued 170,000 shares of common stock to Scott Gann for services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Stock Issued for Cash</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From October through December 2021, the Company entered into fourteen stock purchase agreements (“SPA”) for the issuance of a total of 1,475,020 shares of common stock at prices ranging from $0.40-$0.50. The proceeds received under these SPAs totaled $570,005.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During January and February 2022, the Company entered into six SPAs for the issuance of a total of 280,000 shares of common stock at $0.50. The proceeds received under these SPAs totaled $140,000.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 12, 2022, the Company entered into an SPA for the issuance of 25,000 shares of common stock for $25,000, or $1.00 per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During July 2022, the Company issued 975,000 common stock shares to the prior S-1 investors pursuant to their subscription agreements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During July 2022, the Company issued 50,000 shares of common stock to a shareholder pursuant to a December 2021 SPA. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Stock Options and Warrants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During 2019, as an inducement for debt, the Company issued a stock option to Noteholder E for 10,000 shares of common stock at the time of the Company’s initial public offering (“IPO”). The cost of the option was $1.00 and provides for a 50% discount to the initial opening stock price. Since the IPO has yet to take place and the Company had minimal assets at the time of issuance, the option was valued at $0.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 4, 2021, the Company entered into a consulting agreement for product development and marketing services. As part of the agreement, 600,000 option shares were issued at signing. An additional 100,000 option shares are earned monthly through August 2021. Although the IPO is still pending, since the Company sold warrants at $.50 during 2020, these options were valued at $.50. On December 20, 2021, the consultant elected to convert all 1,400,000 option shares into 1,400,000 shares of common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company estimated the fair value of the 2021 options based on weighted probabilities of assumptions used in the Black Scholes pricing model. At issuance, the fair value of the options was estimated using the following weighted-average inputs: the price of the Company’s common stock of $0.50; a risk-free interest rate of 0.10% and expected volatility of the Company’s common stock of 500%, an exercise price of $.0001, and terms under one year.</p> 20000000 0.001 10 Each share of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock 9 0 3 3 3 2500000 Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company Each share of Series B is convertible into 10 shares of common stock of the Company 300000000 0.001 569 0.50 285 18144112 1855888 99600 99600 100000 751500 2650000 325750 1325323 20000 10000 5000 2500 6000000 3000000 5000 2500 500000 500000 170000 1475020 0.40 0.50 570005 280000 0.50 140000 25000 25000 1.00 975000 50000 10000 1.00 As part of the agreement, 600,000 option shares were issued at signing. An additional 100,000 option shares are earned monthly through August 2021. Although the IPO is still pending, since the Company sold warrants at $.50 during 2020, these options were valued at $.50. On December 20, 2021, the consultant elected to convert all 1,400,000 option shares into 1,400,000 shares of common stock 0.50 0.0010 5 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 5 – FEDERAL INCOME TAX </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2022, and December 31, 2021, the Company has net operating loss carry forwards of $2,572,885 and $2,343,000, respectively, which may be available to reduce future years’ taxable income through 2042. The Company’s net operating loss carry forwards may be subject to annual limitations, which could reduce or defer the utilization of the losses as a result of an ownership change as defined in Section 382 of the Internal Revenue Code.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s tax expense differs from the “expected” tax expense for Federal income tax purposes (computed by applying the United States Federal tax rate of 21% to loss before taxes for fiscal year 2022 and 2021), as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> September 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2022 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2021 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Tax expense (benefit) at the statutory rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(204,559 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(255,478 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State income taxes, net of federal income tax benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(25,326 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(31,631 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">229,885</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">287,109</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The tax effects of the temporary differences between reportable financial statement income and taxable income are recognized as deferred tax assets and liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The tax years 2022 and 2021 remains open for examination by federal agencies and other jurisdictions in which it operates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The tax effect of significant components of the Company’s deferred tax assets and liabilities at September 30, 2022 and December 31, 2021, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> September 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net operating loss carryforward</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,572,885</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,343,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total gross deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,572,885</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,343,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Deferred tax asset valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,572,885 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,343,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total net deferred taxes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Because of the historical earnings history of the Company, the net deferred tax assets for 2022 and 2021 were fully offset by a 100% valuation allowance. The valuation allowance for the remaining net deferred tax assets was $2,572,885 and $2,343,000 as of December 31, 2022, and 2021, respectively. </p> 2572885 2343000 0.21 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> September 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2022 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2021 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Tax expense (benefit) at the statutory rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(204,559 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(255,478 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State income taxes, net of federal income tax benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(25,326 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(31,631 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">229,885</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">287,109</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 204559 255478 25326 31631 229885 287109 0 0 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> September 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net operating loss carryforward</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,572,885</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,343,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total gross deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,572,885</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,343,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Deferred tax asset valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,572,885 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,343,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total net deferred taxes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 2572885 2343000 2572885 2343000 2572885 2343000 0 0 2572885 2343000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 6 – COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time to time, the Company may be involved in litigation in the ordinary course of business. The Company is not currently involved in any litigation that we believe could have a material adverse effect on its financial condition or results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Subscription Agreement and Cash Held in Escrow</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 20, 2019, the Company entered into a subscription escrow agreement (the “Trust Agreement”) with Branch Banking and Trust Company (“BB&amp;T”). This Trust Agreement was established for the subscription agreement proceeds raised and escrowed pursuant to the Company’s prior Rule 419 S-1 offering. The balance held in trust at September 30, 2022 and December 31, 2021, totaled $19,705.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Upon completion of the Merger (see Notes 1 and 8), the Company issued 975,000 common stock shares to the investors in that prior S-1 offering during July 2022 and were released to the Company. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Consulting Agreements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company paid the CEO $103,605 and $39,966, respectively, pursuant to a consulting agreement carried over from related party NBFL. The agreement provides for an annual salary of $150,000 which increases based on certain capital raise thresholds. At September 30, 2022 and December 31, 2021, accrued payroll owed to the CEO totaled $188,484 and $186,034, respectively, as presented in the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 24, 2020, the Company entered into a consulting agreement for business development activities, networking, negotiations, and strategic planning. The compensation pursuant to the agreement was $20,000 monthly. During the nine months ended September 30, 2022, and the year ended December 31, 2021, $144,975 and $47,500, respectively, was paid to the consultant. Additionally, during the year ended December 31, 2021, the Company issued 500,000 shares of common stock to the consultant, valued at $250,000. During the nine months ended September 30, 2022, the Company issued 751,500 shares of common stock, valued at $325,750, to settle the amounts owed to the consultant (Note 4).  Accordingly, at September 30, 2022 and December 31, 2021, $0 and $202,500, respectively, accrued payroll remained outstanding which is presented in the accompanying consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 14, 2021, the Company entered into two consulting agreements for strategic advisory services to be provided through December 31, 2021. The compensation per the two agreements provided for the issuance of 1,700,000 and 450,000 shares of common stock. The stock compensation to these two advisors totaled $1,073,388.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Office Lease</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company entered into a sublease agreement with the above consultant (providing business development assistance from 2019-2020) effective August 1, 2019, subject to the terms and conditions of the office lease held by the consultant at 15540 Quorum Drive #2624, Addison, Texas. On January 1, 2019, the Company adopted ASC 842 requiring this lease to be recorded as an asset and corresponding liability on its balance sheet. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms of the underlying lease. A discount rate was not used in the determination of the right of use asset and liability since its effect would not be significant. The lease moved to a month-to-month basis beginning in September 2021 at $2,810 per month in addition to common area maintenance charges. During the nine months ended September 30, 2022, and the year ended December 31, 2021, we incurred $30,240 and $20,094, respectively, in office rental expense. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Research and Development Agreement</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During September 2020, the Company assumed a Cooperative Research And Development Agreement (CRADA) with the United States Department of Agriculture (USDA), Agricultural Research Service (ARS). Under this agreement, the Company committed to funding the remaining amount due. As of September 30, 2022, and December 31, 2021, $246,400 and $243,400, respectively, remained outstanding and is presented in the accompanying consolidated balance sheets as USDA CRADA liability.</p> 19705 975000 103605 39966 150000 188484 186034 20000 144975 47500 500000 250000 751500 325750 202500 1700000 450000 1073388 2810 30240 20094 246400 243400 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 7 – RELATED PARTY TRANSACTIONS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Share Issuances to the Board of Directors</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During December 2020, the Board of Directors allocated 11,137,833 shares of common stock among the three founders. These issuances were valued at $.50 per share based on a third-party sale of common stock (see Note 4), totaling $5,560,567.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 8, 2022, the Company issued 2,000,000 shares of common stock to each of its three directors, for a total of 6,000,000 shares issued valued at $3,000,000 (based on the latest third-party sale of common stock). The issuances are recorded in stock compensation in the accompanying consolidated statement of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued Series B preferred stock on August 16, 2022, as follows: Bradley White (Chief Executive Officer), 3 shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 4.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Services from Related Parties</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The daughter of the CEO and Board member was paid $21,900 and $16,925, respectively, for clerical services provided during the nine months ended September 30, 2022 and the year ended December 31, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Advance payable from CEO and Director</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2019, the Company’s CEO advanced $5,000 to the Company. During the year ended December 31, 2021, the CEO was advanced $991 and was repaid the full amount by December 31, 2021. The advance was non-interest bearing and due upon demand.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Receivables from Related Parties</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2020, one of the Company’s directors advanced the Company $3,000. Later that year, $5,000 was repaid leaving a total $2,000 receivable from the director at September 30, 2022 and 2021, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During 2018, Robert Bubeck, former CEO, paid $3,846 of expenses on behalf of the Company. The amount due to related party at both September 30, 2022 and 2021 is $3,846 and is due on demand and non-interest bearing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2021, Robert Bubeck, former CEO, paid $13,500 of accrued expenses on behalf of the Company. Since the amount due to the shareholder is not expected to be repaid, it has been accounted for as additional paid-in capital in the accompanying consolidated financial statements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During January 2021, in connection with the acquisition (see Note 8), Robert Bubeck resigned as CEO and Bradley White was appointed to serve as CEO.</p> 11137833 5560567 2000000 6000000 3000000 21900 16925 5000 991 3000 5000 2000 3846 3846 13500 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 8 – MERGER WITH OLD GENVOR</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 27, 2022, the Company, formerly known as Allure Worldwide, Inc., Merger Sub, and Old Genvor completed the Acquisition and Merger transaction (Note 1). The transaction was completed pursuant to the Merger Agreement, pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation in the Merger. Immediately upon completion of the Merger, the former stockholders of Old Genvor stockholders held a majority of the common stock and voting interest of the combined company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the Merger, the Company issued shares of its common stock to Old Genvor stockholders at an exchange ratio of 1:1 (with each share of Old Genvor common stock automatically converted in the merger into the right to receive a share of Company common stock, and a total of 35,261,871 shares of Company common stock issued to Old Genvor’s pre-merger stockholders). Pursuant to the original Acquisition agreement and Merger, the Company’s founding shareholders retained 5% of the Company’s outstanding shares of common stock, or 1,855,888 shares (Note 4). After closing the Acquisition and for a period of two years following commencement of trading of the Company’s common stock, the Company and Old Genvor agreed that the Company will make additional issuances of the Company’s common stock to the founding shareholders to ensure that in the aggregate they maintain their 5% ownership of the Company’s outstanding common stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to business combination accounting for reverse acquisitions, the Company accounted for the Merger as a capital transaction (reverse recapitalization) rather than a business combination (or asset acquisition). Since the Company was formerly a special purpose acquisition company (SPAC) with no assets and only expenses related to maintaining its public shell company status, and Old Genvor has cash, other assets, a contract with the USDA (Note 6), and has raised funds from investors, Old Genvor was determined to be the accounting acquirer. Because a reverse recapitalization is equivalent to the issuance of shares by the private operating company for the net monetary assets of the public shell company, the transaction costs incurred by Old Genvor to effect the recapitalization were recognized as a reduction in additional paid-in capital rather than expensed as incurred. The assets and liabilities of Old Genvor were consolidated with the Company at their book value, the equity accounts were retroactively adjusted to reflect the equity of the Company, with a balancing adjustment through the additional paid-in capital account.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company paid $140,000 and $10,000, respectively, in anticipation of closing the Acquisition. The total $150,000 was recognized in additional paid-in capital as of the date of the Merger.</p> 35261871 0.05 1855888 140000 10000 150000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 9 – INTELLECTUAL PROPERTIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company was granted a patent (#11083775) on August 10, 2021 by the United States Patent and Trademark Office. The patent was assigned by the inventors to the Company and The United States of America, as represented by the Secretary of Agriculture.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 10 – SUBSEQUENT EVENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has evaluated subsequent events from the balance sheet through the date of this filing and determined there were no events to disclose except the following.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B.  The designation authorized 2,500,000 shares of Series B.  Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company. See Note 4.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 19, 2022, the following shareholders converted shares of common stock of the Company into shares of Series B, as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Name</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Shares Exchanged</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series B</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Issued</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Jaynes Investment LLC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ACT Holdings LLC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,312,612</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">731,262</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">LASB Family Trust</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,800,112</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">380,012</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Jesse Michael Jaynes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,767,611</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">476,762</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bradley White</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,225,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">122,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> PJ Advisory Group </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,500,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Total   </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">20,605,334</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,060,536</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 2500000 Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Name</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Shares Exchanged</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series B</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Issued</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Jaynes Investment LLC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ACT Holdings LLC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,312,612</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">731,262</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">LASB Family Trust</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,800,112</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">380,012</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Jesse Michael Jaynes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,767,611</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">476,762</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bradley White</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,225,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">122,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> PJ Advisory Group </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,500,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Total   </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">20,605,334</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,060,536</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 2000000 200000 7312612 731262 3800112 380012 4767611 476762 1225000 122500 1500000 150000 20605334 2060536 EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 125 245 1 false 46 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://genvor.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://genvor.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://genvor.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://genvor.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT Sheet http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT Statements 5 false false R6.htm 000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://genvor.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 000007 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION Sheet http://genvor.com/role/OrganizationAndBasisOfPresentation ORGANIZATION AND BASIS OF PRESENTATION Notes 7 false false R8.htm 000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://genvor.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 000009 - Disclosure - BORROWINGS Sheet http://genvor.com/role/BORROWINGS BORROWINGS Notes 9 false false R10.htm 000010 - Disclosure - STOCKHOLDERS DEFICIT Sheet http://genvor.com/role/StockholdersDeficit STOCKHOLDERS DEFICIT Notes 10 false false R11.htm 000011 - Disclosure - FEDERAL INCOME TAX Sheet http://genvor.com/role/FederalIncomeTax FEDERAL INCOME TAX Notes 11 false false R12.htm 000012 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://genvor.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 000013 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://genvor.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 13 false false R14.htm 000014 - Disclosure - MERGER WITH OLD GENVOR Sheet http://genvor.com/role/MergerWithOldGenvor MERGER WITH OLD GENVOR Notes 14 false false R15.htm 000015 - Disclosure - INTELLECTUAL PROPERTIES Sheet http://genvor.com/role/IntellectualProperties INTELLECTUAL PROPERTIES Notes 15 false false R16.htm 000016 - Disclosure - SUBSEQUENT EVENTS Sheet http://genvor.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 000018 - Disclosure - BORROWINGS (Tables) Sheet http://genvor.com/role/BorrowingsTables BORROWINGS (Tables) Tables http://genvor.com/role/BORROWINGS 18 false false R19.htm 000019 - Disclosure - FEDERAL INCOME TAX (Tables) Sheet http://genvor.com/role/FederalIncomeTaxTables FEDERAL INCOME TAX (Tables) Tables http://genvor.com/role/FederalIncomeTax 19 false false R20.htm 000020 - Disclosure - SUBSEQUENT EVENTS (Tables) Sheet http://genvor.com/role/SubsequentEventsTables SUBSEQUENT EVENTS (Tables) Tables http://genvor.com/role/SubsequentEvents 20 false false R21.htm 000021 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) Sheet http://genvor.com/role/OrganizationAndBasisOfPresentationDetailsNarrative ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) Details http://genvor.com/role/OrganizationAndBasisOfPresentation 21 false false R22.htm 000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://genvor.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies 22 false false R23.htm 000023 - Disclosure - BORROWINGS (Details) Sheet http://genvor.com/role/BorrowingsDetails BORROWINGS (Details) Details http://genvor.com/role/BorrowingsTables 23 false false R24.htm 000024 - Disclosure - BORROWINGS (Details 1) Sheet http://genvor.com/role/BorrowingsDetails1 BORROWINGS (Details 1) Details http://genvor.com/role/BorrowingsTables 24 false false R25.htm 000025 - Disclosure - BORROWINGS (Details Narrative) Sheet http://genvor.com/role/BorrowingsDetailsNarrative BORROWINGS (Details Narrative) Details http://genvor.com/role/BorrowingsTables 25 false false R26.htm 000026 - Disclosure - STOCKHOLDERS DEFICIT (Details Narrative) Sheet http://genvor.com/role/StockholdersDeficitDetailsNarrative STOCKHOLDERS DEFICIT (Details Narrative) Details http://genvor.com/role/StockholdersDeficit 26 false false R27.htm 000027 - Disclosure - FEDERAL INCOME TAX (Details) Sheet http://genvor.com/role/FederalIncomeTaxDetails FEDERAL INCOME TAX (Details) Details http://genvor.com/role/FederalIncomeTaxTables 27 false false R28.htm 000028 - Disclosure - FEDERAL INCOME TAX (Details 1) Sheet http://genvor.com/role/FederalIncomeTaxDetails1 FEDERAL INCOME TAX (Details 1) Details http://genvor.com/role/FederalIncomeTaxTables 28 false false R29.htm 000029 - Disclosure - FEDERAL INCOME TAX (Details Narrative) Sheet http://genvor.com/role/FederalIncomeTaxDetailsNarrative FEDERAL INCOME TAX (Details Narrative) Details http://genvor.com/role/FederalIncomeTaxTables 29 false false R30.htm 000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://genvor.com/role/CommitmentsAndContingencies 30 false false R31.htm 000031 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://genvor.com/role/RelatedPartyTransactions 31 false false R32.htm 000032 - Disclosure - MERGER WITH OLD GENVOR (Details Narrative) Sheet http://genvor.com/role/MergerWithOldGenvorDetailsNarrative MERGER WITH OLD GENVOR (Details Narrative) Details http://genvor.com/role/MergerWithOldGenvor 32 false false R33.htm 000033 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://genvor.com/role/SubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://genvor.com/role/SubsequentEventsTables 33 false false R34.htm 000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://genvor.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://genvor.com/role/SubsequentEventsTables 34 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 6 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. genvor_10k.htm 1 [dq-0542-Deprecated-Concept] Concept NotesReceivableRelatedParties in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. genvor_10k.htm 1 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 20 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityPublicFloat, genvor:RepaidToRelatedParty, us-gaap:AccruedPayrollTaxesCurrent, us-gaap:AssetsHeldInTrust, us-gaap:CommonStockNoParValue, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesOutstanding, us-gaap:DebtConversionConvertedInstrumentSharesIssued1, us-gaap:DueToRelatedPartiesCurrent, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesOutstanding, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice - genvor_10k.htm 1 genvor_10k.htm genvor-20220930.xsd genvor-20220930_cal.xml genvor-20220930_def.xml genvor-20220930_lab.xml genvor-20220930_pre.xml genvor_ex311.htm genvor_ex312.htm genvor_ex321.htm genvor_ex322.htm genvor_10kimg1.jpg genvor_10kimg3.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 54 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "genvor_10k.htm": { "axisCustom": 0, "axisStandard": 14, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 352, "http://xbrl.sec.gov/dei/2022": 34 }, "contextCount": 125, "dts": { "calculationLink": { "local": [ "genvor-20220930_cal.xml" ] }, "definitionLink": { "local": [ "genvor-20220930_def.xml" ] }, "inline": { "local": [ "genvor_10k.htm" ] }, "labelLink": { "local": [ "genvor-20220930_lab.xml" ] }, "presentationLink": { "local": [ "genvor-20220930_pre.xml" ] }, "schema": { "local": [ "genvor-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 348, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 17, "http://genvor.com/20220930": 1, "http://xbrl.sec.gov/dei/2022": 6, "total": 24 }, "keyCustom": 80, "keyStandard": 165, "memberCustom": 33, "memberStandard": 12, "nsprefix": "genvor", "nsuri": "http://genvor.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://genvor.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - STOCKHOLDERS DEFICIT", "menuCat": "Notes", "order": "10", "role": "http://genvor.com/role/StockholdersDeficit", "shortName": "STOCKHOLDERS DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - FEDERAL INCOME TAX", "menuCat": "Notes", "order": "11", "role": "http://genvor.com/role/FederalIncomeTax", "shortName": "FEDERAL INCOME TAX", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "12", "role": "http://genvor.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "13", "role": "http://genvor.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "genvor:MergerWithOldGenvordisclosuretextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - MERGER WITH OLD GENVOR", "menuCat": "Notes", "order": "14", "role": "http://genvor.com/role/MergerWithOldGenvor", "shortName": "MERGER WITH OLD GENVOR", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "genvor:MergerWithOldGenvordisclosuretextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "genvor:IntellectualPropertiesdisclosuretextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - INTELLECTUAL PROPERTIES", "menuCat": "Notes", "order": "15", "role": "http://genvor.com/role/IntellectualProperties", "shortName": "INTELLECTUAL PROPERTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "genvor:IntellectualPropertiesdisclosuretextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "16", "role": "http://genvor.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "17", "role": "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - BORROWINGS (Tables)", "menuCat": "Tables", "order": "18", "role": "http://genvor.com/role/BorrowingsTables", "shortName": "BORROWINGS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "genvor:ScheduleOfLossBeforeTaxesForFiscalYeartabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - FEDERAL INCOME TAX (Tables)", "menuCat": "Tables", "order": "19", "role": "http://genvor.com/role/FederalIncomeTaxTables", "shortName": "FEDERAL INCOME TAX (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "genvor:ScheduleOfLossBeforeTaxesForFiscalYeartabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://genvor.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "genvor:ScheduleOfConvertedSharesOfCommonStockOfTheCompanyIntoSharestabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - SUBSEQUENT EVENTS (Tables)", "menuCat": "Tables", "order": "20", "role": "http://genvor.com/role/SubsequentEventsTables", "shortName": "SUBSEQUENT EVENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "genvor:ScheduleOfConvertedSharesOfCommonStockOfTheCompanyIntoSharestabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative)", "menuCat": "Details", "order": "21", "role": "http://genvor.com/role/OrganizationAndBasisOfPresentationDetailsNarrative", "shortName": "ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "22", "role": "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "lang": null, "name": "us-gaap:DilutiveSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - BORROWINGS (Details)", "menuCat": "Details", "order": "23", "role": "http://genvor.com/role/BorrowingsDetails", "shortName": "BORROWINGS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "genvor:ScheduleOfFutureMaturitiesOfTheNotesPayabletabletextblock", "ix:continuation", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "genvor:FutureMaturitiesOfNotesPayableYearOne", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - BORROWINGS (Details 1)", "menuCat": "Details", "order": "24", "role": "http://genvor.com/role/BorrowingsDetails1", "shortName": "BORROWINGS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "genvor:ScheduleOfFutureMaturitiesOfTheNotesPayabletabletextblock", "ix:continuation", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "genvor:FutureMaturitiesOfNotesPayableYearOne", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - BORROWINGS (Details Narrative)", "menuCat": "Details", "order": "25", "role": "http://genvor.com/role/BorrowingsDetailsNarrative", "shortName": "BORROWINGS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - STOCKHOLDERS DEFICIT (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://genvor.com/role/StockholdersDeficitDetailsNarrative", "shortName": "STOCKHOLDERS DEFICIT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-04-01to2022-04-21", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesOther", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "genvor:ScheduleOfLossBeforeTaxesForFiscalYeartabletextblock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - FEDERAL INCOME TAX (Details)", "menuCat": "Details", "order": "27", "role": "http://genvor.com/role/FederalIncomeTaxDetails", "shortName": "FEDERAL INCOME TAX (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "genvor:ScheduleOfLossBeforeTaxesForFiscalYeartabletextblock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - FEDERAL INCOME TAX (Details 1)", "menuCat": "Details", "order": "28", "role": "http://genvor.com/role/FederalIncomeTaxDetails1", "shortName": "FEDERAL INCOME TAX (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - FEDERAL INCOME TAX (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://genvor.com/role/FederalIncomeTaxDetailsNarrative", "shortName": "FEDERAL INCOME TAX (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://genvor.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrust", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrust", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "31", "role": "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2020-12-31_srt_DirectorMember", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - MERGER WITH OLD GENVOR (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://genvor.com/role/MergerWithOldGenvorDetailsNarrative", "shortName": "MERGER WITH OLD GENVOR (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "genvor:MergerWithOldGenvordisclosuretextblock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-09-30_genvor_GenvorIncMember", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConversionOfStockSharesConverted1", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - SUBSEQUENT EVENTS (Details)", "menuCat": "Details", "order": "33", "role": "http://genvor.com/role/SubsequentEventsDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "genvor:ScheduleOfConvertedSharesOfCommonStockOfTheCompanyIntoSharestabletextblock", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-10-01to2022-10-19_us-gaap_SubsequentEventMember", "decimals": "0", "lang": null, "name": "us-gaap:ConversionOfStockSharesConverted1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-10-19_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonUnitAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://genvor.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2022-10-19_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonUnitAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://genvor.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT", "menuCat": "Statements", "order": "5", "role": "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://genvor.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "lang": null, "name": "genvor:InterestExpenseCapitalizedIntoNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION", "menuCat": "Notes", "order": "7", "role": "http://genvor.com/role/OrganizationAndBasisOfPresentation", "shortName": "ORGANIZATION AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://genvor.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - BORROWINGS", "menuCat": "Notes", "order": "9", "role": "http://genvor.com/role/BORROWINGS", "shortName": "BORROWINGS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "genvor_10k.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 46, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r391", "r392", "r393" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r391", "r392", "r393" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r391", "r392", "r393" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r391", "r392", "r393" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "genvor_ACTHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACT Holdings LLC [Member]" } } }, "localname": "ACTHoldingsLLCMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "genvor_AdjustedBalanceBeginningOfPeriodAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Allure Balance, Amount" } } }, "localname": "AdjustedBalanceBeginningOfPeriodAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_AdjustedBalanceBeginningOfPeriodShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Allure Balance, Shares" } } }, "localname": "AdjustedBalanceBeginningOfPeriodShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "genvor_AgromedLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agromed LLC [Member]" } } }, "localname": "AgromedLCMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_AmountPaidToConsultant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Amount paid to consultant" } } }, "localname": "AmountPaidToConsultant", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "genvor_BalanceSheetsUnauditedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "localname": "BalanceSheetsUnauditedAbstract", "nsuri": "http://genvor.com/20220930", "xbrltype": "stringItemType" }, "genvor_BasicAndDilutedNetLossPerCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted net loss per common share" } } }, "localname": "BasicAndDilutedNetLossPerCommonShare", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "genvor_BasicAndDilutedWeightedAverageCommonSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted weighted average common shares outstanding" } } }, "localname": "BasicAndDilutedWeightedAverageCommonSharesOutstanding", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "genvor_BeneficialConversionFeature": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 12.0, "parentTag": "us-gaap_OtherNoncashIncomeTaxExpense", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Beneficial conversion feature" } } }, "localname": "BeneficialConversionFeature", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "genvor_BeneficialConversionFeatureAmortization": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Beneficial conversion feature amortization]", "negatedLabel": "Beneficial conversion feature amortization" } } }, "localname": "BeneficialConversionFeatureAmortization", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "genvor_BradleyWhiteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bradley White [Member]", "verboseLabel": "Bradley White [Member]" } } }, "localname": "BradleyWhiteMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative", "http://genvor.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "genvor_CashFlowReportingpolicytextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Reporting" } } }, "localname": "CashFlowReportingpolicytextblock", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "genvor_CeoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[CEO [Member]]", "verboseLabel": "CEO [Member]" } } }, "localname": "CeoMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_ClaytonYatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Clayton Yates [Member]" } } }, "localname": "ClaytonYatesMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_CommonStockCancel": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of common stock cancel" } } }, "localname": "CommonStockCancel", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "genvor_CommonStockIssuedForCashAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for cash, amount" } } }, "localname": "CommonStockIssuedForCashAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_CommonStockIssuedForCashShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for cash, shares" } } }, "localname": "CommonStockIssuedForCashShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "genvor_CommonStockIssuedForDebtConversionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for debt conversion, amount" } } }, "localname": "CommonStockIssuedForDebtConversionAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_CommonStockIssuedForDebtConversionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for debt conversion, shares" } } }, "localname": "CommonStockIssuedForDebtConversionShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "genvor_CommonStockIssuedForServicesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for services, amount" } } }, "localname": "CommonStockIssuedForServicesAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_CommonStockIssuedForServicesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for services, shares" } } }, "localname": "CommonStockIssuedForServicesShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "genvor_CommonStockOptionsIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock options issued for services" } } }, "localname": "CommonStockOptionsIssuedForServices", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_CommonStockReturn": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of common stock return" } } }, "localname": "CommonStockReturn", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "genvor_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_ConsultingAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting agreement description" } } }, "localname": "ConsultingAgreementDescription", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "genvor_ConsultingAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreements [Member]" } } }, "localname": "ConsultingAgreementsMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_ConsultingAgreementsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreements One [Member]" } } }, "localname": "ConsultingAgreementsOneMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_ConsultingAgreementsTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreements Two [Member]" } } }, "localname": "ConsultingAgreementsTwoMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_ConversionShareDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion share description" } } }, "localname": "ConversionShareDescription", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "genvor_ConvertibleNotesPayableNetOfDiscounts": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible notes payable, net of discounts" } } }, "localname": "ConvertibleNotesPayableNetOfDiscounts", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "genvor_DescriptionOfVotingRights": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of voting rights" } } }, "localname": "DescriptionOfVotingRights", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "genvor_DesignationAuthorizedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Designation authorized shares" } } }, "localname": "DesignationAuthorizedShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "genvor_DiscountOnNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Discount on notes payable" } } }, "localname": "DiscountOnNotesPayable", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "genvor_DueToRelatedPartiesCurrentF9": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Advanced recived" } } }, "localname": "DueToRelatedPartiesCurrentF9", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "genvor_ExerciseOfOptionsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Exercise of options, amount" } } }, "localname": "ExerciseOfOptionsAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_ExerciseOfOptionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise of options, shares" } } }, "localname": "ExerciseOfOptionsShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "genvor_FixedAssetspolicytextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fixed Assets" } } }, "localname": "FixedAssetspolicytextblock", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "genvor_FormerCEOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Former CEO" } } }, "localname": "FormerCEOMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_FounderSharesIssuedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Founder shares issued, amount" } } }, "localname": "FounderSharesIssuedAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_FounderSharesIssuedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Founder shares issued, shares" } } }, "localname": "FounderSharesIssuedShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "genvor_FundAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fund Amount" } } }, "localname": "FundAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "genvor_FundRaisingServicesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "fund raising services, amount" } } }, "localname": "FundRaisingServicesAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_FundRaisingServicesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "fund raising services, shares" } } }, "localname": "FundRaisingServicesShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "genvor_FundraisingServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fundraising services" } } }, "localname": "FundraisingServices", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "genvor_FutureMaturitiesOfNotesPayableYearOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "2023" } } }, "localname": "FutureMaturitiesOfNotesPayableYearOne", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetails1" ], "xbrltype": "monetaryItemType" }, "genvor_FutureMaturitiesOfNotesPayableYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "2024" } } }, "localname": "FutureMaturitiesOfNotesPayableYearTwo", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetails1" ], "xbrltype": "monetaryItemType" }, "genvor_GenvorIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Genvor Inc [Member]" } } }, "localname": "GenvorIncMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/MergerWithOldGenvorDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_IncreaseDecreaseInUsdaCradaLiability": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[USDA CRADA liability]", "verboseLabel": "USDA CRADA liability" } } }, "localname": "IncreaseDecreaseInUsdaCradaLiability", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "genvor_IntellectualPropertiesdisclosuretextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[INTELLECTUAL PROPERTIES]", "verboseLabel": "INTELLECTUAL PROPERTIES" } } }, "localname": "IntellectualPropertiesdisclosuretextblock", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/IntellectualProperties" ], "xbrltype": "textBlockItemType" }, "genvor_InterestExpenseCapitalizedIntoNotesPayable": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest expense capitalized into notes payable" } } }, "localname": "InterestExpenseCapitalizedIntoNotesPayable", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "genvor_IssuanceOfCommonStockFor2021SpaAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for 2021 SPA, amount" } } }, "localname": "IssuanceOfCommonStockFor2021SpaAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_IssuanceOfCommonStockFor2021SpaShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for 2021 SPA, shares" } } }, "localname": "IssuanceOfCommonStockFor2021SpaShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "genvor_IssuanceOfCommonStockForDebtConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for debt conversion" } } }, "localname": "IssuanceOfCommonStockForDebtConversion", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "genvor_IssuanceOfCommonStockForNoteReceivableAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for note receivable, amount" } } }, "localname": "IssuanceOfCommonStockForNoteReceivableAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_IssuanceOfCommonStockForNoteReceivableShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for note receivable, shares" } } }, "localname": "IssuanceOfCommonStockForNoteReceivableShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "genvor_IssuanceOfCommonStockForSettlementsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for settlements, amount" } } }, "localname": "IssuanceOfCommonStockForSettlementsAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_IssuanceOfCommonStockForSettlementsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for settlements, shares" } } }, "localname": "IssuanceOfCommonStockForSettlementsShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "genvor_IssuanceOfCommonStockToPriorS1InvestorsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock to prior S-1 investors, amount" } } }, "localname": "IssuanceOfCommonStockToPriorS1InvestorsAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_IssuanceOfCommonStockToPriorS1InvestorsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock to prior S-1 investors, shares" } } }, "localname": "IssuanceOfCommonStockToPriorS1InvestorsShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "genvor_IssuanceOfPreferredStockAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of preferred stock, amount" } } }, "localname": "IssuanceOfPreferredStockAmount", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_IssuanceOfPreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of preferred stock, shares" } } }, "localname": "IssuanceOfPreferredStockShares", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "genvor_JaynesInvestmentLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jaynes Investment LLC [Member]" } } }, "localname": "JaynesInvestmentLLCMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "genvor_JesseJaynesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jesse Jaynes [Member]" } } }, "localname": "JesseJaynesMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_JesseMichaelJaynesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jesse Michael Jaynes [Member]" } } }, "localname": "JesseMichaelJaynesMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "genvor_LASBFamilyTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LASB Family Trust [Member]" } } }, "localname": "LASBFamilyTrustMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "genvor_LateFeeCapitalizedIntoNotesPayable": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Late fee capitalized into notes payable" } } }, "localname": "LateFeeCapitalizedIntoNotesPayable", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "genvor_LateFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Late fees" } } }, "localname": "LateFees", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "genvor_LossOnAgromedAcquisitionFailure": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Loss on Agromed acquisition failure]", "negatedLabel": "Loss on Agromed acquisition failure" } } }, "localname": "LossOnAgromedAcquisitionFailure", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "genvor_LossOnAgromedAcuisitionFailure": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 13.0, "parentTag": "us-gaap_OtherNoncashIncomeTaxExpense", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loss on Agromed acuisition failure" } } }, "localname": "LossOnAgromedAcuisitionFailure", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "genvor_LossOnDebtSettelment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loss on debt settelment" } } }, "localname": "LossOnDebtSettelment", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "genvor_LossOnFailToAcquisition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loss on fail to acquisition" } } }, "localname": "LossOnFailToAcquisition", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "genvor_LossOnSettlementOfLiabilities": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 14.0, "parentTag": "us-gaap_OtherNoncashIncomeTaxExpense", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loss on settlement of liabilities" } } }, "localname": "LossOnSettlementOfLiabilities", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "genvor_MergerWithOldGenvordisclosuretextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[MERGER WITH OLD GENVOR]", "verboseLabel": "MERGER WITH OLD GENVOR" } } }, "localname": "MergerWithOldGenvordisclosuretextblock", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/MergerWithOldGenvor" ], "xbrltype": "textBlockItemType" }, "genvor_NexionContractorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nexion Contractor [Member]" } } }, "localname": "NexionContractorMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_NotePayableWrittenOff": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Note payable written off" } } }, "localname": "NotePayableWrittenOff", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "genvor_NoteholderAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noteholder A [Member]" } } }, "localname": "NoteholderAMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "domainItemType" }, "genvor_NoteholderBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noteholder B [Member]" } } }, "localname": "NoteholderBMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetails", "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_NoteholderCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noteholder C [Member]" } } }, "localname": "NoteholderCMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "domainItemType" }, "genvor_NoteholderDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noteholder D [Member]" } } }, "localname": "NoteholderDMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "domainItemType" }, "genvor_NoteholderEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noteholder E [Member]" } } }, "localname": "NoteholderEMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "domainItemType" }, "genvor_NoteholderFMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noteholder F [Member]" } } }, "localname": "NoteholderFMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "domainItemType" }, "genvor_NoteholderGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noteholder G [Member]" } } }, "localname": "NoteholderGMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "domainItemType" }, "genvor_NoteholderHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noteholder H [Member]" } } }, "localname": "NoteholderHMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "domainItemType" }, "genvor_Origination": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Origination" } } }, "localname": "Origination", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "stringItemType" }, "genvor_PJAdvisoryGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PJ Advisory Group [Member]" } } }, "localname": "PJAdvisoryGroupMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "genvor_PaidOfAccruedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Paid of accrued expenses" } } }, "localname": "PaidOfAccruedExpenses", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "genvor_PatentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patents" } } }, "localname": "PatentsPolicyTextBlock", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "genvor_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Paycheck Protection Program [Member]" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_PaymentForReversesCapitalization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payment for reverse capitalization" } } }, "localname": "PaymentForReversesCapitalization", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_Penalties": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 11.0, "parentTag": "us-gaap_OtherNoncashIncomeTaxExpense", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Penalties" } } }, "localname": "Penalties", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "genvor_PenaltyAmountReceive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Penalty amount receive each month" } } }, "localname": "PenaltyAmountReceive", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "genvor_PreferredStockSeriesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A, Preferred Stock [Member]" } } }, "localname": "PreferredStockSeriesAMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "genvor_PrepaidCostForReverseCapitalization": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid costs for reverse capitalization" } } }, "localname": "PrepaidCostForReverseCapitalization", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "genvor_PrepaidCostsForReverseCapitalization": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Prepaid costs for reverse capitalization]", "verboseLabel": "Prepaid costs for reverse capitalization" } } }, "localname": "PrepaidCostsForReverseCapitalization", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "genvor_PrepaidCostsForReverseCapitalizationRecognizedInAdditionalPaidInCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid costs for reverse capitalization recognized in additional paid-in capital" } } }, "localname": "PrepaidCostsForReverseCapitalizationRecognizedInAdditionalPaidInCapital", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "genvor_RecapitalizationRtoImpact": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Recapitalization / RTO impact" } } }, "localname": "RecapitalizationRtoImpact", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "genvor_ReceivablesFromRelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables from Related Parties" } } }, "localname": "ReceivablesFromRelatedPartiesMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_RelatedPartyPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Related party payable" } } }, "localname": "RelatedPartyPayable", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "genvor_RepaidToRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Repaid To Related Party" } } }, "localname": "RepaidToRelatedParty", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "genvor_RepaymentOfReceivableFromRelatedParties": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Payments of receivable from related parties]", "negatedLabel": "Payments of receivable from related parties" } } }, "localname": "RepaymentOfReceivableFromRelatedParties", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "genvor_ResearchAndDevelopmentAgreementFundMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research And Development Agreement Fund [Member]" } } }, "localname": "ResearchAndDevelopmentAgreementFundMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_SbaLoanCurrent": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "SBA loan" } } }, "localname": "SbaLoanCurrent", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "genvor_ScheduleOfConvertedSharesOfCommonStockOfTheCompanyIntoSharestabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of converted shares of common stock of the Company into shares" } } }, "localname": "ScheduleOfConvertedSharesOfCommonStockOfTheCompanyIntoSharestabletextblock", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/SubsequentEventsTables" ], "xbrltype": "textBlockItemType" }, "genvor_ScheduleOfFutureMaturitiesOfTheNotesPayabletabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Future Maturities of the Notes Payable" } } }, "localname": "ScheduleOfFutureMaturitiesOfTheNotesPayabletabletextblock", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "genvor_ScheduleOfLossBeforeTaxesForFiscalYeartabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of loss before taxes for fiscal year" } } }, "localname": "ScheduleOfLossBeforeTaxesForFiscalYeartabletextblock", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/FederalIncomeTaxTables" ], "xbrltype": "textBlockItemType" }, "genvor_ShareIssueForServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Issue For Services [Member]" } } }, "localname": "ShareIssueForServicesMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_SharesIssuedToADebt": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued to a debt" } } }, "localname": "SharesIssuedToADebt", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "genvor_StockBasedCompensation2policytextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation2" } } }, "localname": "StockBasedCompensation2policytextblock", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "genvor_StockIssueForCashMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Issued for Cash [Member]" } } }, "localname": "StockIssueForCashMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_StockOptionsAndWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options And Warrants [Member]" } } }, "localname": "StockOptionsAndWarrantsMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_TransferAndAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Transfer And Agreement [Member]" } } }, "localname": "TransferAndAgreementMember", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "genvor_UsdaCradaLiability": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "USDA CRADA liability" } } }, "localname": "UsdaCradaLiability", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "genvor_ValuationAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in valuation allowance" } } }, "localname": "ValuationAllowance", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "genvor_VotingRightsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of votes" } } }, "localname": "VotingRightsDescription", "nsuri": "http://genvor.com/20220930", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "label": "CEO [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "label": "Board of Directors" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://genvor.com/role/MergerWithOldGenvorDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r200", "r201", "r202", "r203", "r244", "r337", "r359", "r368", "r369", "r381", "r384", "r389", "r426", "r467", "r468", "r469", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r200", "r201", "r202", "r203", "r244", "r337", "r359", "r368", "r369", "r381", "r384", "r389", "r426", "r467", "r468", "r469", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r200", "r201", "r202", "r203", "r242", "r244", "r245", "r246", "r247", "r313", "r337", "r359", "r368", "r369", "r381", "r384", "r389", "r421", "r426", "r468", "r469", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r200", "r201", "r202", "r203", "r242", "r244", "r245", "r246", "r247", "r313", "r337", "r359", "r368", "r369", "r381", "r384", "r389", "r421", "r426", "r468", "r469", "r470", "r471", "r472" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://genvor.com/role/MergerWithOldGenvorDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r416", "r463" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15", "r388" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued payroll" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r10", "r388" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets", "http://genvor.com/role/MergerWithOldGenvorDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r248", "r249", "r250", "r412", "r413", "r414", "r458" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r62", "r63", "r263" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "[Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature]", "verboseLabel": "Beneficial conversion feature" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r27", "r37", "r79", "r230" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r84", "r94", "r111", "r131", "r166", "r169", "r173", "r181", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r277", "r281", "r286", "r388", "r424", "r425", "r465" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r109", "r118", "r131", "r181", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r277", "r281", "r286", "r388", "r424", "r425", "r465" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrust": { "auth_ref": [ "r407" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.", "label": "Assets held in trust" } } }, "localname": "AssetsHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r274", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r73", "r74", "r274", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition Axis" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Consideration amount" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MERGER WITH OLD GENVOR" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r0", "r46", "r53" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "verboseLabel": "ORGANIZATION AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/OrganizationAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r365", "r366", "r388", "r399" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r33", "r39", "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r33", "r78" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Amount in excess of FDIC insured limit" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r112", "r113", "r114", "r131", "r149", "r150", "r153", "r154", "r156", "r157", "r181", "r204", "r207", "r208", "r209", "r213", "r214", "r235", "r236", "r237", "r238", "r240", "r286", "r370", "r398", "r408", "r415" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r22", "r88", "r99" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r61", "r198", "r199", "r367", "r423" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r412", "r413", "r458" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "[Common Stock, No Par Value]", "verboseLabel": "Common Stock, Shares Par Value" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Shares Par Value", "verboseLabel": "Common stock, shares par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheetsParenthetical", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheetsParenthetical", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock share issued", "verboseLabel": "Common stock share issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/ConsolidatedBalanceSheetsParenthetical", "http://genvor.com/role/MergerWithOldGenvorDetailsNarrative", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r9", "r62" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common Stock, Shares Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheetsParenthetical", "http://genvor.com/role/MergerWithOldGenvorDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r9", "r388" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value, 300,000,000 shares authorized, 38,678,155 and 26,025,020 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively", "terseLabel": "Common Stock, value", "verboseLabel": "Common stock value" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of common units of ownership permitted to be issued by a limited liability company (LLC).", "label": "[Common Unit, Authorized]", "verboseLabel": "Designation authorized shares" } } }, "localname": "CommonUnitAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r42", "r43", "r44" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion common shares", "verboseLabel": "Common share exchange" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative", "http://genvor.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r42", "r43", "r44" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Series B issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Schedule of Convertible Notes Payable" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r42", "r44" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Number of shares the notesis convertible into shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BORROWINGS" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r4", "r5", "r6", "r85", "r86", "r93", "r134", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r295", "r376", "r377", "r378", "r379", "r380", "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument Axis" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetails", "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r6", "r86", "r93", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Principal amount" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r80", "r82", "r215", "r295", "r377", "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Loan Balance" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r20", "r80", "r227" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate", "verboseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetails", "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r119", "r376", "r459" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r21", "r134", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r295", "r376", "r377", "r378", "r379", "r380", "r409" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetails", "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r79", "r82", "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "[Debt Instrument, Unamortized Discount]", "negatedLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Total gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r456" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred tax asset" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r72", "r457" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r259" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "[Deferred Tax Assets, Valuation Allowance]", "negatedLabel": "Valuation allowance", "verboseLabel": "Valuation allowance for net deferred tax assets" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetails1", "http://genvor.com/role/FederalIncomeTaxDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r37", "r59" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation expense", "verboseLabel": "Depreciation expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows", "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DilutiveSecurities": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.", "label": "Potential additional dilutive securities outstanding" } } }, "localname": "DilutiveSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r15", "r206", "r207", "r208", "r212", "r213", "r214", "r301", "r411" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to related party", "verboseLabel": "Due To Related Party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r47", "r49" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "(Loss) Income Per Share of Common Stock" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r132", "r254", "r268" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal tax statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r62", "r107", "r123", "r124", "r125", "r135", "r136", "r137", "r139", "r144", "r146", "r155", "r182", "r241", "r248", "r249", "r250", "r264", "r265", "r284", "r287", "r288", "r289", "r290", "r291", "r292", "r297", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Ownership Of Shareholders, Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/MergerWithOldGenvorDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r178", "r179", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r231", "r239", "r283", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r375", "r417", "r418", "r419", "r474", "r475", "r476", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r194", "r195", "r196", "r197", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite Lived Intangible Assets By Major Class Axis" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r56", "r57" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r58", "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Cost of intangible asset" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r422" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "[Gain (Loss) Related to Litigation Settlement]", "negatedLabel": "Loss on settlement of liabilities" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FEDERAL INCOME TAX" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r132", "r255", "r256", "r261", "r266", "r269", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "FEDERAL INCOME TAX" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/FederalIncomeTax" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r133", "r145", "r146", "r165", "r253", "r267", "r270", "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "[Income Tax Expense (Benefit)]", "verboseLabel": "Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r122", "r251", "r252", "r256", "r257", "r260", "r262" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r254" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "[Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount]", "negatedLabel": "Tax expense (benefit) at the statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "[Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount]", "negatedLabel": "State income taxes, net of federal income tax benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r34", "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueFromRelatedParties": { "auth_ref": [ "r36" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.", "label": "[Increase (Decrease) in Due from Related Parties]", "negatedLabel": "Receivables from related parties" } } }, "localname": "IncreaseDecreaseInDueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r36" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "[Increase (Decrease) in Due to Related Parties]", "verboseLabel": "Due to related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r405" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "[Increase (Decrease) in Other Current Assets]", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r36" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "[Increase (Decrease) in Prepaid Expense]", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r57", "r338", "r339", "r340", "r342", "r372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Long-lived Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r81", "r91", "r126", "r164", "r294" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "verboseLabel": "Interest expense capitalized into notes payable" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r27", "r228", "r234", "r379", "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "[Interest Expense, Debt]", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r90" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 10.0, "parentTag": "us-gaap_OtherNoncashIncomeTaxExpense", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r406" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Cash paid for interest" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest amount" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]", "verboseLabel": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LaborAndRelatedExpense": { "auth_ref": [ "r404" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.", "label": "Payroll related expenses" } } }, "localname": "LaborAndRelatedExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r17", "r131", "r181", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r278", "r281", "r282", "r286", "r373", "r424", "r465", "r466" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r14", "r87", "r97", "r388", "r410", "r420", "r460" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Total liabilities and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r19", "r110", "r131", "r181", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r278", "r281", "r282", "r286", "r388", "r424", "r465", "r466" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r1", "r2", "r3", "r6", "r7", "r131", "r181", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r278", "r281", "r282", "r286", "r424", "r465", "r466" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "[Liabilities, Noncurrent]", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r6", "r86", "r95", "r222", "r233", "r377", "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Total loan" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r129" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r33", "r35", "r38" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities", "verboseLabel": "Net cash used in opearting activitites" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows", "http://genvor.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r24", "r38", "r89", "r101", "r108", "r120", "r121", "r125", "r131", "r138", "r140", "r141", "r142", "r143", "r145", "r146", "r151", "r166", "r168", "r172", "r174", "r181", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r285", "r286", "r374", "r424" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows", "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r140", "r141", "r142", "r143", "r147", "r148", "r152", "r154", "r166", "r168", "r172", "r174", "r374" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "[Net Income (Loss) Available to Common Stockholders, Basic]", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r6", "r86", "r95" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes payable, net of discounts" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableRelatedParties": { "auth_ref": [ "r83", "r100", "r115", "r411" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.", "label": "Receivables from related parties" } } }, "localname": "NotesReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r166", "r168", "r172", "r174", "r374" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 15.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss carry forwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r117", "r388" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r26", "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Expenses paid" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r25" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "Other general and administrative expenses" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashIncomeTaxExpense": { "auth_ref": [ "r38" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 16.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities.", "label": "[Other Noncash Income Tax Expense]", "negatedTotalLabel": "Total other income (expense)" } } }, "localname": "OtherNoncashIncomeTaxExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patent [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Issuance of common stock for debt settlement" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r28", "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Cash Payment For Acquisation" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/MergerWithOldGenvorDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name Axis" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative", "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative", "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r8", "r235" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Shares Par Value", "verboseLabel": "Preferred stock, shares par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheetsParenthetical", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheetsParenthetical", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r8", "r235" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issue" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheetsParenthetical", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheetsParenthetical", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r8", "r388" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.001 par value, 20,000,000 shares authorized, 10 and 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r116", "r192", "r193", "r371" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceed from common stock issue" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r29" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r30" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Repayments of advances payable from related parties" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r103", "r104" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r108", "r120", "r121", "r128", "r131", "r138", "r145", "r146", "r166", "r168", "r172", "r174", "r181", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r276", "r279", "r280", "r285", "r286", "r356", "r374", "r385", "r386", "r402", "r424" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r60", "r98", "r357", "r388" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INTELLECTUAL PROPERTIES" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r243", "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative", "http://genvor.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r106", "r300", "r301", "r464" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction Axis" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r243", "r300", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r464" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative", "http://genvor.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r298", "r299", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r31" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "[Repayments of Notes Payable]", "negatedLabel": "Payments of notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r68", "r69" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research And Development Arrangement Contract To Perform For Others By Type Axis" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r68", "r69" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r67", "r105", "r473" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations", "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r11", "r63", "r96", "r363", "r364", "r388" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets", "http://genvor.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r107", "r135", "r136", "r137", "r139", "r144", "r146", "r182", "r248", "r249", "r250", "r264", "r265", "r284", "r360", "r362" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r127", "r131", "r162", "r163", "r167", "r170", "r171", "r175", "r176", "r177", "r181", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r286", "r356", "r424" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r296", "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right of use, lease asset and liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Annual salary" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesWagesAndOfficersCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Monthly compensation" } } }, "localname": "SalariesWagesAndOfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/FederalIncomeTaxTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuritiesBorrowedIncrease": { "auth_ref": [ "r183" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in security borrowed from entering into new transaction.", "label": "[Securities Borrowed, Increase]", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "SecuritiesBorrowedIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r400", "r401", "r428" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A, Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r400", "r401", "r428" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r36" ], "calculation": { "http://genvor.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://genvor.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation", "terseLabel": "Stock compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/ConsolidatedStatementsOfCashFlows", "http://genvor.com/role/ConsolidatedStatementsOfOperations", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Common stock price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r64", "r66" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "STOCKHOLDERS' DEFICIT" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares", "verboseLabel": "Total of shares issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Common stock share issued price to individual" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r46", "r130" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r112", "r113", "r114", "r131", "r149", "r150", "r153", "r154", "r156", "r157", "r181", "r204", "r207", "r208", "r209", "r213", "r214", "r235", "r236", "r237", "r238", "r240", "r286", "r370", "r398", "r408", "r415" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r23", "r62", "r107", "r123", "r124", "r125", "r135", "r136", "r137", "r139", "r144", "r146", "r155", "r182", "r241", "r248", "r249", "r250", "r264", "r265", "r284", "r287", "r288", "r289", "r290", "r291", "r292", "r297", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetails", "http://genvor.com/role/BorrowingsDetailsNarrative", "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit", "http://genvor.com/role/MergerWithOldGenvorDetailsNarrative", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative", "http://genvor.com/role/SubsequentEventsDetails", "http://genvor.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r135", "r136", "r137", "r155", "r341" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetails", "http://genvor.com/role/BorrowingsDetailsNarrative", "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit", "http://genvor.com/role/MergerWithOldGenvorDetailsNarrative", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative", "http://genvor.com/role/SubsequentEventsDetails", "http://genvor.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r8", "r9", "r63" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock issued for acquisition" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r8", "r9", "r62", "r63" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Share issued to consultant" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Common stock share issued to individual" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r8", "r9", "r62", "r63" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Share issued for compensation" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r23", "r62", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock issued for acquisition, value" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r8", "r9", "r62", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock value price", "verboseLabel": "Share issued to consultant, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "auth_ref": [ "r23", "r62", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued to shareholders as a dividend during the period.", "label": "Common stock share issued value to individual" } } }, "localname": "StockIssuedDuringPeriodValueStockDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r9", "r12", "r13", "r54", "r388", "r410", "r420", "r460" ], "calculation": { "http://genvor.com/role/ConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets", "http://genvor.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS DEFICIT" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubordinatedBorrowingsDisclosureTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for borrowings under subordinated debt agreements that qualify as available in computing net capital under SEC's uniform net capital rule, including restrictive covenants, collateral, interest rates and due dates, amounts due by date and amount owed in total.", "label": "Subordinated Borrowings Disclosure [Text Block]", "verboseLabel": "BORROWINGS" } } }, "localname": "SubordinatedBorrowingsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/BORROWINGS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r293", "r305" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "verboseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SubsequentEventsDetails", "http://genvor.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r293", "r305" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SubsequentEventsDetails", "http://genvor.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r293", "r305" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SubsequentEventsDetails", "http://genvor.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r304", "r306" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r178", "r179", "r231", "r239", "r283", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r417", "r418", "r419", "r474", "r475", "r476", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r50", "r51", "r52", "r158", "r159", "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e34017-109320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r391": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r392": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r393": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r394": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r395": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r396": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r397": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r423": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6479118&loc=d3e64650-112822", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 55 0001477932-23-001798-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-23-001798-xbrl.zip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end